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Abstract 
Transcription factors (TFs), the key players in transcriptional regulation, have attracted great 
experimental attention, yet the functions of most human TFs remain poorly understood. Recent 
capabilities in genome-wide protein binding profiling have stimulated systematic studies of the 
hierarchical organization of human gene regulatory network and DNA-binding specificity of TFs, 
shedding light on combinatorial gene regulation. We show here that these data also enable a 
systematic annotation of the biological functions and functional diversity of TFs. We compiled a 
human gene regulatory network for 384 TFs covering the 146,096 TF-target gene relationships, 
extracted from over 850 ChIP-seq experiments as well as the literature. By integrating this 
network of TF-TF and TF-target gene relationships with 3,715 functional concepts from six 
sources of gene function annotations, we obtained over 9,000 confident functional annotations for 
279 TFs. We observe extensive connectivity between transcription factors and Mendelian 
diseases, GWAS phenotypes, and pharmacogenetic pathways. Further, we show that transcription 
factors link apparently unrelated functions, even when the two functions do not share common 
genes. Finally, we analyze the pleiotropic functions of TFs and suggest that increased number of 
upstream regulators contributes to the functional pleiotropy of TFs. Our computational approach 
is complementary to focused experimental studies on TF functions, and the resulting knowledge 
can guide experimental design for discovering the unknown roles of TFs in human disease and 
drug response. 
 
Introduction 
Regulation of gene expression is essential for the realization of cell type specific phenotypes 
(Whyte et al. 2013) during normal development (Reik 2007) and the adaptation of cellular 
organisms to their environment (López-Maury et al. 2008). To a large degree, transcriptional 
regulation occurs through the interaction of protein factors with the genomic DNA (Lenhard et al. 
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2012). Multiple proteins, including the chromatin remodelers, transcription factors, cofactors and 
other transcription initiation factors (Perissi and Rosenfeld 2005) work in coordination to regulate 
the spatial-temporal details of gene expression. Transcription factors (TFs) bind DNA in a 
sequence specific manner and mediate the integrations of other proteins with specific target genes 
for fine-granular expression control (Maniatis et al. 1987).  
 
The pivotal role of TFs in development and cell identity determination is highlighted by the 
induced pluripotent stem cell (iPSC) technology (Takahashi and Yamanaka 2006; Park et al. 2008) 
and trans-induction techniques (Lee and Young 2013; Jopling et al. 2011), in which the 
introduction of just a few specific transcription factors is sufficient for converting fibroblast cell 
into pluripotent stem cell, or converting one differentiated cell type, e.g. pancreatic exocrine cell, 
directly into another differentiated cell type, e.g. β-cell. In addition, transcription factors are key 
players controlling diverse physiological functions ranging from metabolism (Yamashita et al. 
2001; Wang et al. 2011), chemical and  mechanical stress responses (Kaspar et al. 2009; Tothova 
et al. 2007; Kumar and Boriek 2003; Mendez and Janmey 2012), song-learning (Whitney et al. 
2014; Pfenning et al. 2012), to longevity and aging (Greer and Brunet 2005; Salih and Brunet 
2008; Tilstra et al. 2012). Many TFs are directly involved in diseases, such as cancer, diabetes, 
and neural developmental disorders (Lee and Young 2013).  
 
Transcription factors have attracted intense research attention (Yusuf et al. 2012); yet the 
biological functions of most TFs are still poorly understood. The number of human TFs is 
estimated to be around 1500-2000 based on DNA-binding domain evidence (Vaquerizas et al. 
2009; Ravasi et al. 2010; Ashburner et al. 2000; Kummerfeld and Teichmann 2006). In total, the 
sequence-specific DNA-binding activities of only 564 TFs are confirmed by experimental 
evidence and the existence of an additional 490 is supported indirectly by phylogenetic evidence 
or author claims (The Gene Ontology Consortium 2015). Limited knowledge is available on the 
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biological functions of most TFs, with a small number of “famous” TFs such as TP53 attracting 
much attention (Vaquerizas et al. 2009). However, recent development of high-throughput 
technology such as ChIP-seq and DNase-seq (Furey 2012) provide an unprecedented amount of 
data on gene regulation, with binding profiles for over 100 transcription factors from ENCODE 
alone (Gerstein et al. 2012). This has spurred systematic data-driven studies on transcriptional 
regulation, such as the discovery of cis-regulatory motifs (Kheradpour and Kellis 2014; Jolma et 
al. 2013), the mapping of the hierarchical architecture of human gene regulatory network, and the 
modeling of combinatorial regulation (Gerstein et al. 2012; Cheng et al. 2011b; Neph et al. 2012; 
Bernstein et al. 2012; Jiang and Singh 2014). At the same time, analytics tools have been 
developed for annotating ChIP-seq data (Ji et al. 2011; Zhang et al. 2008; Spyrou et al. 2009), 
some allowing analysis of gene ontology term enrichment for the binding sites (Zhu et al. 2010; 
McLean et al. 2010; Welch et al. 2014). 
 
In this study, we integrate the existing knowledge about functions and phenotypes of human 
genes with the transcriptional regulatory network to study the functions of human transcription 
factors. We define the “target functions” of a TF as the statistical overrepresented functions 
among its target genes, and provide a systematic annotation of TF functions, ranging from 
metabolic pathways to disease phenotypes. In parallel, we define the functional similarity of two-
TFs based on their target gene overlaps, independent of the availability of gene function 
annotations, and annotate each TF by functionally similar TFs (Fig. 1). We study the pleiotropic 
functions of individual TFs and show that multifunctionality is associated with the number of 
upstream regulators of the TFs. With these analyses, we demonstrate a computational approach 
for achieving systematic understanding of transcription factor functions.  
 
Results 
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The Compendium of Human Transcription Factor Target Genes 
We compiled a Transcription Factor-Target Gene (TFTG) data compendium covering the direct 
transcriptional regulation targets of 384 unique transcription factors (TFs) extracted from over 
850 ChIP-seq experiments as well as the literature with low throughput experimental evidence. 
Low throughput experiments, ENCODE ChIP-seq, and other sources of ChIP-seq data are 
complementary in their TF coverage. 149 (39%) TFs are covered only by high-throughput 
experiments, among which 52 (35%) are covered by the ENCODE consortium (Gerstein et al. 
2012; Bernstein et al. 2012), 107 are covered by individual research labs (based on data published 
by October 2013). Meanwhile 122 (32%) TFs are only from low throughput experiments, and 113 
(29%) TFs are from both low and high throughput experiments (Fig. S1A). 
 
There are in total 16,967 unique target genes (TGs) of TFs, including both transcription factors 
and non-transcription factors. We filtered the target genes identified in high-throughput 
experiments to achieve an estimated false discovery rate of 0.01. Combining all sources, 146,096 
TF-TG relationships are obtained. Each gene is regulated by 8.6 TFs on average, while each TF 
regulates 380.5 genes (see Fig. S1B). 63% of target genes are each regulated by 5 or more TFs, 
while 18% are each regulated by a single TF. Most TFs also have regulators within the 
compendium, with the exception of 14 TFs that appear to be master regulators, including BCOR, 
GLI2, HLF, HNF4G, MAZ, NELFE, NFATC1, NOTCH1, PHOX2A, RXRA, STAT4, SOX10, 
TEAD2 and THRA, although RXRA and SOX10 are self-regulated.  
 
Defining the Target Functions of Transcription Factors 
Transcription factors perform their functions by i) interacting with proteins and cis-regulatory 
elements and ii) consequently regulating the expression of downstream target genes. There are 
hence two aspects of functions for a TF, the molecular functions of a TF that enables its 
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regulation of the target genes, and the biological functions exerted by the genes that are under 
control of the TF. Formally, we define the target functions (e.g. target diseases, target signaling 
pathways) of a transcription factor as the consensus functions of the target genes, and we identify 
the target functions of a TF by detecting the enrichment of functional terms in the target genes. 
The target genes as a whole precisely define the biological functions regulated by a TF, while the 
target functions summarize the functional impacts upon perturbation of a transcription factor. 
 
We first compiled 3715 functional concepts covering molecular to organism level functions 
(Table S1), including Mendelian diseases from OMIM, disease and phenotype associations from 
dbGAP genome wide association studies (GWAS), pharmacokinetic (PK) and pharmacodynamics 
(PD) pathways from PharmGKB, signaling and metabolic pathways from Reactome, and 
molecular functions and biological processes from Gene Ontology (GO). There are significant 
overlaps among the genes annotated in the six sources, yet each source has some unique genes 
(Fig. S2.)  
 
We then confirmed the presence of functional signals in the TFTG compendium, i.e., TFs are not 
randomly targeting functionally unrelated genes, and the TFTG compendium contains significant 
number of true target genes. We compared the TF-Function associations obtained using real 
TFTG compendium against that obtained using a randomized compendium, where we constructed 
the fake TFs to have the same number of random target genes as the corresponding real TFs. We 
observed 237,566 TF-Function pairs with p-values for real TFs smaller than the corresponding p-
values for the fake TFs, compared to 155,801 pairs showing the opposite relationship (Fig. 2). To 
estimate the total number of true associations present for the real TFs, we assume i) true 
associations for real TFs are all in the upper triangle, i.e. having p-values from real compendium 
less than corresponding p-values from randomized compendium; ii) false associations for real 
TFs equally distribute in the upper and lower triangle, i.e. having similar p-values from the real 
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and fake TFs. This leads to an estimated 81,765 true target function annotations for the real TFs. 
The ratio between the true and false associations is larger at the smaller p-value regions (Fig. 2 
inset). At p-value cutoff of 0.001, there are 16,158 associations for real TFs and 999 for fake TFs, 
corresponding to an FDR of 6.18%; while at p-value cutoff of 0.0001, there are 9,132 
associations for real TFs but only 130 for fake TFs, corresponding to an FDR of 1.42%.  
 
Gene Universe Impacts the Detection of Target Functions 
The target functions of a transcription factor are detected by identifying statistically significant 
enrichment of functional terms among the target genes of the TF. A critical step for obtaining 
proper statistics for enrichment analysis is the choice of gene universe, which is the “allowed” set 
of genes that restrict the target genes of a TF as well as the member genes of a functional term to 
be used in determining statistical associations. In Fig. S3, we show the example of TF SP1 and 
functional term “immune system”. The choice of gene universe affects not only the significance 
(p-value) but also the direction of TF-target function association. In general, an overly large gene 
universe inflates the strength of positive association, i.e. enrichment of functional terms, while an 
overly restrictive gene universe inflates the strength of negative association, i.e. depletion of 
functional terms.  
 
We suggest that the gene universe must be chosen based on the implicit limitations of each type 
of functional annotations stemming from how the annotation was obtained, thus generally 
providing a smaller and hence more conservative universe.  For manual curation, such as OMIM 
and PharmGKB, the function annotations are limited by the available literature. We hence 
constructed a conservative “Literature Rich” gene universe that includes protein-coding genes 
annotated by one or more sources from OMIM, PharmGKB, GO BP, GO MF, Reactome, KEGG, 
and Biocarta. For machine annotations coming from high throughput experiments followed by 
computational filtering, such as the GWAS phenotype annotations, we use the “Coding Genes” as 
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a conservative universe (see Methods for more details). We disregard non-coding genes as they 
are generally poorly annotated. We used the Literature Rich gene universe to detect target 
Mendelian diseases, pharmacogenomic pathways, signaling/metabolic pathways, molecular 
functions, and biological processes, and used the Coding gene universe to detect target 
phenotypes studied in GWAS.  
 
Transcription Factor-Target Function Network  
At false discovery rate of 0.05, we identified 9,747  significant TF-target function relationships 
using the conservative gene universes (Fig. 3A). The TF-target function associations form a 
scale-free network (Barabási 1999), with power law distributions for both the number of target 
functions per TF and the number of TFs per target function (Fig. 3B and Fig. S4A). Overall, 279 
(73%) transcription factors are annotated by at least one functional term (Supplemental Material 
Section 1.1). The lack of the annotations of the remaining TFs is likely due to small sample size, 
i.e. number of target genes. The un-annotated TFs have 26.3 target genes on average, compared to 
519.0 target genes on average for annotated TFs (Fig. S4B). An average TF is positively 
associated with 0.47 Mendelian diseases, 0.052 GWAS phenotypes or diseases, 0.26 
pharmacogenomic pathways, 11.2 signaling and metabolic pathways, 7.9 biological processes, 
and 1.4 molecular functions (Table S2). Extensive regulator sharing is observed among different 
types of gene functions (Fig. S5A), while we also observed biases of 62 TFs towards specific 
types of functions (Fig. S5B and Supplemental Material Section 1.2).  
 
Target Functions Predict Known Functions of Transcription Factors 
We globally validate the TF-target function relationships by comparing them against the known 
functions of these transcription factors. Of course, our TF-target function relationships do not 
necessarily map to a TF-function relationship that is covered by existing gene annotation 
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databases. For example, AHR targets molecular function “oxygen binding”, indicating that AHR 
regulates proteins that bind oxygen and likely catalyze oxidation reactions, but this does not mean 
oxygen binding is a molecular function of AHR protein itself. HNF1A targets many 
pharmacokinetic pathways (Fig. 3G), but HNF1A is naturally not an annotated member of these 
pharmacokinetic (PK) pathways, as the PK pathways in PharmGKB focus on the metabolic 
enzymes and transporters of drugs. Despite that, we find that the TF-target function associations 
can predict the known TF-target function relationships for all six types of functions. An overall 
area under the ROC curve (AUC) of 0.80 is achieved by using the p-value from Fisher’s exact 
test as the predictive score. For specific types of functions, AUC of 0.81 is achieved for 
Mendelian diseases, 0.74 for GWAS phenotypes, 0.85 for pharmacogenetic pathways, 0.76 for 
GO biological processes, 0.76 for Reactome signaling and metabolic pathways, and 0.72 for GO 
molecular functions (see Fig. S6). The true performance is likely higher, given the function-target 
function mapping issue. 
 
Not only are target functions of TFs predictive of their known functions, the numbers of target 
functions (i.e. multi-functionality) are also predictive of the numbers of known functions (Wald t 
statistic 6.07, p-value 3.1 × 10-9; or Wald t statistic 5.07, p-value 6.3 × 10-7 after controlling for 
the number of target genes per TF).  
 
We manually validated the TF-target function relationships for Mendelian diseases, GWAS 
phenotypes, and pharmacogenetic pathways, for which solid genetic evidence such as direct 
mutation of the TF in patients are available. 
 
Mendelian Diseases Targeted by Transcription Factors 
We identified the target Mendelian diseases of a TF based on the enrichment of disease causing 
genes (Hamosh et al. 2005) in the target genes of the TF. In total 181 TF - target Mendelian 
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disease relationships were identified at false discovery rate of 0.05. The majority of the top 
twenty TF-Mendelian disease associations (from thirteen TFs) are supported by direct genetic 
evidence such as mutations of the TF in the target Mendelian disease, GWAS associations 
between the TF and closely related diseases, or phenotypes closely related to the target disease as 
observed in mouse knockout models of the TF (Table 1).  
 
For example, we identified porphyria as a target disease of GATA1 (odds ratio 170, p-value 9.8 x 
10-9), while direct mutation of GATA1 (R216W) has been reported in a congenital erythropoietic 
porphyria patient (Phillips et al. 2007), and the mutant was suggested to cause the disease by 
regulating UROS, a common causal gene of congenital erythropoietic porphyria. We identified 
hereditary mitochondrial metabolism disease as a target disease of NHF4A, while it has been 
reported that HNF4A is mutated in hereditary noninsulin-dependent diabetes mellitus (NIDDM) 
(Hani et al. 1998), which is a mitochondrial disease. HNF4A is also mutated in maturity-onset 
diabetes of the young (MODY1) (Wang et al. 2000), and the MODY1 mutant form of HNF4A is 
known to cause mitochondrial function defects as well as impairment of nutrient-stimulated 
insulin release. Transcription factor SOX10 is predicted to be associated with Waardenburg's 
syndrome (Table 1) as well as Hirschsprung's disease and megacolon (not shown). Notably, 
SOX10 is a known causal gene of Waardenburg's syndrome type 4C and Hirschsprung’s disease 
(Pingault et al. 1998), while megacolon is a symptom of Hirschsprung’s disease. Another 
example is the association of RFX2 with Bardet-Biedl syndrome (BBS), which is a pleiotropic 
recessive genetic disorder belonging to a group of diseases called ciliopathy (Hildebrandt et al. 
2011). There are at least sixteen known BBS causing genes (or nineteen according to OMIM) 
covering around 80% of the diagnosed cases (Forsythe and Beales 2013). These BBS causing 
genes encode proteins involved in cilia biogenesis and function. Transcription factor RFX2 is not 
known to mutate in BBS patients, however, RFX2 together with RFX3 and RFX4, are key 
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regulators of cilia genesis in mouse and other animal models (Bisgrove et al. 2012; Chung et al. 
2012). 
 
In addition to above examples for GATA1, HNF4A, SOX10 and RFX2, other target Mendelian 
diseases among the top twenty are directly supported by human or mouse phenotypes upon direct 
mutation of the TFs. They are heart septal defect and congenital heart diseases for CTBP2, heart 
septal defect for SUZ12 (Fig. 3C), cancers for ETS1 and TP53, and inherited metabolic disorder 
for USF1. 
 
Complex Phenotypes Targeted by Transcription Factors 
We identified twenty significant complex phenotypes for seven transcription factors (Table S3). 
Transcription factors NFKB1 and RFX5 (Fig. 3D) are each associated with three and six 
autoimmune disorders, while both TFs are known to be involved in autoimmunity (Baeuerle, 
Patrick A. 1997; Masternak et al. 2000, 1998). Especially, NFKB1 is recently identified as a 
causal gene of autosomal dominant variable immunodeficiency-12 (Fliegauf et al. 2015), which 
shows features of autoimmunity. NFKB1 is also genetically associated with autoimmune disease 
Ulcerative colitis (Jostins et al. 2012). RFX5 mutations cause Bare lymphocyte syndrome II 
through impaired MHC II protein expression (DeSandro et al. 1999; Reith and Mach 2001), while 
MHC II is genetically linked to multiple autoimmune diseases (Fernando et al. 2008).  SREBF1 
(sterol regulatory element binding transcription factor 1) is identified to target blood LDL (low 
density lipoprotein) level (p-value 2.2 × 10-6), and not surprisingly, SREBF1 is a known regulator 
of LDL proteins and genes involved in sterol synthesis (Brown and Goldstein 1997; Shimano et 
al. 1997). Consistently, SREBF1 is associated with the statin pharmacodynamics pathway 
(PharmGKB) and multiple biological processes and pathways related to lipid metabolism. The 
SREBF1 LDL association is also directly supported by mouse mutation phenotypes (Hua et al. 
1996; Shimano et al. 1997). 
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Habitual coffee consumption is a significant target phenotype of AHR (Aryl hydrocarbon 
receptor, Fig. 3E), while AHR gene locus itself is also strongly associated with coffee 
consumption and habitual coffee consumption in GWAS studies (Cornelis et al. 2011, 2015; 
Sulem et al. 2011). HNF1A (Fig. 3G) targets three phenotypes, including the serum cell-free 
DNA level as an indicator of cardiovascular disease risk, serum bilirubin levels as a measure of 
cholelithiasis risk, and F-cell levels as an indicator of sickle-cell anemia. The first two phenotypes 
are validated by genetic evidence. HNF1A mutation is associated with elevated risk of 
cardiovascular diseases in diabetes patients (Steele et al. 2010) while SNPs of HNF1A is found to 
be associated with cardiovascular disease risks in young and old European Americans (Reiner et 
al. 2009). The HNF1A-cholelithiasis connection is supported by HNF1A knockout mouse 
(Pontoglio et al. 1996), which showed elevated blood bilirubin levels and jaundice. Consistently, 
HNF1A also targets Reactome pathway synthesis of bile acids and bile salts (Fig. 3G). 
 
Pharmacogenetic Pathways Targeted by Transcription Factors 
We identified 99 TF-target pharmacogenomic pathway relationships, covering 47 unique TFs and 
45 unique pharmacogenetic pathways in PharmGKB. There is no preference towards 
pharmacokinetics (PK) or pharmacodynamics (PD) pathways, with 20 of 40 PK pathways and 26 
of 50 PD pathways identified.  However, different TFs are responsible for the target PK and PD 
pathways. 18 of the 26 target PK pathways are the targets of just 4 TFs (see Table S4), i.e. 
HNF1A, AHR, NR1I3, and FOXA2. Among them, nuclear receptor genes HNF1A, AHR, and 
NR1I3 are well known to regulate xenobiotic-metabolizing enzymes (Pontoglio et al. 1996; 
Sogawa and Fujii-Kuriyama 1997; Lamba et al. 2005; Ma 2008). Unique target PK pathways are 
found for each of the four TFs, suggesting their complementary roles in regulating drug 
metabolism. In addition to these 4 TFs, SP1 and TP53 are each associated with 3 PK pathways 
for cancer drugs. SP1 and TP53 are also associated with other cancer PD pathways, and their 
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associations with cancer are strongly supported by the literature (Li and Davie 2010; Hollstein et 
al. 1991). 
 
We manually examined the full list of identified target PD pathways and confirmed majority of 
the associations (see Table S4). A PD pathway describes the disease pathway that is perturbed by 
a drug. A target PD pathway is considered confirmed if the TF is a member of the PD pathway or 
closely related pathways, or if the TF is known to be genetically linked to the disease or closely 
related phenotypes. For example, ELK1 is identified as a regulator of the EGFR Inhibitor 
Pathway, while the TF itself is a member of the PD pathway. HNF1A is identified as a regulator 
of the PD pathways for cancer, high cholesterol, and diabetes, while mutations of HNF1A is 
known to cause hereditary cancers and diabetes, and variants of HNF1A are strongly associated 
with cholesterol level in GWAS (Teslovich et al. 2010). E2F1 and E2F4 are identified for 
multiple antimetabolite PD pathways. Antimetabolites are a class of drugs for inducing medical 
abortions and treating cancers and autoimmune diseases through halting the cell cycles, while 
E2F1 and E2F4 are well-known regulators of cell cycles (Ren et al. 2002; Gaubatz et al. 2000).  
 
Target Gene Sharing among Transcription Factors 
While the target genes of a transcription factor define its biological functions, the target gene 
sharing between two TFs also reflects the functional relatedness between TFs. We studied the 
relationship between the target gene overlaps and target function sharing between pairs of TFs. 
 
As expected, the target gene sharing, measured by Pearson’s phi coefficient 𝜙!" , is highly 
associated with the target function sharing 𝜙!"#$%&  !"# (Wald T-statistic 126.95, or 109.75 when 
controlling for the number of target genes, both p-values < 2.2 × 10-16). Among 73,536 possible 
TF pairs (Fig. S7), 12,434 (16.9%) show significant target gene sharing at false discovery rate of 
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0.01 based on Fisher’s exact test. We refer to these similar TFs as TF neighbors. Relatedly, there 
are 11,205 pairs of TFs with one or more shared target functions, including 5,866 pairs that also 
show significant target gene sharing (odds ratio 9.3).  
 
Despite the overall consistency between target function overlap and target gene sharing, many 
exceptions occur. Significant target gene sharing was observed for 6568 pairs of TFs that did not 
share any target functions, including 428 pairs that surprisingly showed negative correlations 
between their target function association profiles1. This could be caused by unknown or poorly 
understood functions common to these TF neighbors, and it suggests that the target gene-based 
TF neighbors may provide functional information missed by the target functions, therefore, the 
TF neighbors serve as an additional layer in the TF function annotations. On the other hand, 
significant target function sharing (at FDR < 0.05) is observed for 329 pairs of TFs that have 
lower-than-expected target gene overlaps. The top five TF pairs by target function sharing are 
MXI1 and RFX1, TRIM28 and VDR, LMO2 and ZNF263, ARNTL and BHLHE40, ETV5 and 
MXI1. Among these, two pairs, TRIM28 and VDR, ARNTL and BHLHE40, do not share any 
target genes. However, TRIM28 and VDR (Vitamin D Receptor) share 12 target functions, e.g. 
Reactome Telomere Maintenance, out of 15 and 14 target functions for the two TFs respectively; 
while ARNTL and BHLHE40 share 2 target functions, Reactome Bmal1 Clock Npas2 Activates 
Circadian Expression and Reactome Circadian Clock, out of 4 and 2 target functions for the two 
TFs respectively. Mouse gene knock out confirmed the abnormal circadian rhythm as a 
phenotype for both ARNTL (Bunger et al. 2000; Storch et al. 2007) and BHLHE40 (Rossner et al. 
2008), and the two proteins may be interaction partners (Honma et al. 2002). 
 
                                                
1 The target function association profile of a TF is comprised of the Pearson’s phi coefficients between the TF and all 
3715 functional concepts. A lack of positive correlation between two profiles indicates that the two TFs are likely 
functionally unrelated based on the known functional concepts.  
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Transcription Factors Link Apparently Unrelated Functions: Coffee and Warfarin 
Parallel to the TF target gene sharing and TF target function sharing, we observed extensive 
member gene overlaps and regulator sharing between pairs of functional concepts (see 
Supplemental Material Section 1.3). Majority of TFs (64%) have two or more target functions. 
We observed that apparently unrelated gene functions are frequently linked by transcription 
factors. For example, AHR is found to be associated with coffee consumption, the PK pathways 
for drugs Amodiaquine, Warfarin, Erlotinib, and Phenytoin, as well as the estrogen metabolism 
pathways (Fig. 3E). Based on these observations, we hypothesize that coffee consumption would 
interfere with the metabolism of these drugs and estrogen, either through modifying the activities 
of AHR target enzymes or impacting the expression of the enzyme genes through feedback 
regulation of AHR activity. The interactions of coffee drinking with both Warfarin (Zambon et al. 
2011) and Phenytoin (Wietholtz et al. 1989) have been reported. On the other hand, coffee 
consumption is actually associated with decreased venous thromboembolism (Enga et al. 2011), 
which warfarin can effectively treat. The coffee-estrogen link is even more intriguing. High 
coffee intake is found in multiple studies to be significantly associated with decreased risk of 
estrogen-receptor negative breast cancer (Li et al. 2011; Lowcock et al. 2013) and breast cancer 
risk in BRCA mutant carriers (Nkondjock et al. 2006). In addition, high coffee intake impacts the 
risk of Parkinson’s disease in female in an estrogen dependent manner (Ascherio et al. 2003, 
2004), possibly through modifying blood estrogen levels (Nagata et al. 1998). 
 
Obviously, when two functional concepts are statistically associated, i.e. when they share 
significant number of member genes, they will likely be linked to the same regulators (Fig. 4A 
and Fig. S9A). The inverse is however not true. Two functions can be linked by transcription 
factors even when they do not share significant portion of member genes (Fig. 4B and Fig. S9B).  
In fact, of the 954 function pairs that share identical sets of regulators, 356 (37%) pairs have less 
gene overlap than expected by chance (Table S7), i.e. with odds ratio < 1. Most of such function 
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pairs do not share any member genes. For example, hereditary “lipid storage diseases” do not 
share any genes with Reactome pathways “iron uptake and transport” and “insulin receptor 
recycling”, but the 3 functions are found to share regulators ATF3, NFE2, USF1, and USF2, 
while “iron uptake and transport” is also a target function of ARNT (Fig. 4C). Other examples 
include ventricular septal defect and developmental pattern specification process which are both 
targeted by SUZ12 and CTBP2, PECAM1 Interactions and disease agammaglobulinemia targeted 
by EBF1, intestinal disease and Human immunodeficiency virus infectious disease both targeted 
by NFKB1, prostate cancer and intestinal cancer both targeted by TP53, Metalloendopeptidase 
Activity and cognitive disorder both targeted by ETV4, among many others. 
 
Measuring the Functional Pleiotropy of Transcription Factors 
A transcription factor is functional pleiotropic if it targets multiple unrelated functions. The above 
analyses suggest extensive functional pleiotropy for transcription factors. Here, we quantify the 
functional pleiotropy of TFs in order to further study its causes from the perspective of 
transcriptional regulation. The number of target functions 𝑛!"#$%&  !"# can be a measure of TF 
functional pleiotropy, with the caveat that it double counts closely related or redundant functional 
concepts. We hence define function diversity 𝜋!"#$%&  !"# as the “effective” number of target 
functions by weighting each function by its uniqueness, which is the inverse of the accumulative 
similarity between the function and other functional concepts. Similarly, we define regulator 
diversity 𝜋!"# of a gene as the effective number of regulators. The regulator diversity corrects for 
related or cooperative transcription factors that are counted independently in the number of 
regulators 𝑛!"# targeting a gene (see Methods and Supplemental Material Section 1.4 for details).   
 
The two most functional pleiotropic TFs are BRCA1 and ZNF143. They are annotated with 272 
(45.5 effectively) and 242 (35.4 effectively) target functions, and 101 (14.5) and 22 (2.8) known 
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functions, while regulated by 33 (15.9) and 53 (22.1) upstream TFs respectively. The two TFs of 
the highest upstream regulatory diversity are MYC and TP53. They have 50 (25.1) and 49 (23.0) 
regulators, and are annotated by 159 (24.2) and 175 (26.8) target functions, and 68 (12.4) and 166 
(25.4) known functions respectively. By contrast, TFs with smaller number of target functions 
also tend to have fewer upstream regulators. For example, HNF1A has 9 (3.8) regulators, 30 (6.3) 
target functions, and 58 (11.2) known functions (Fig. 5A); NFKB1 has 26 (11.7) regulators, 143 
(23.7) target functions, and 34 (6.2) known functions (Fig. S11A); SUZ12 has 11 (4.9) regulators, 
48 (8.3) target functions, and 4 (1.0) known functions. Fig. 6 provides the target gene-based 
function annotations for TFs NFKB1 and SUZ12, including the target functions, TF 
neighbors, as well as the function diversity measures. 
 
Upstream Regulation Enables Functional Pleiotropy of Transcription Factors 
Over the set of 384 TFs in the TFTG compendium, we observed a global positive association 
between the target function diversity of TFs with the regulator diversity (Wald test p-value 3.3 × 
10-10 between diversity measures 𝜋!"#$%&  !"# and 𝜋!"#; or p-value 1.6 × 10-9 between raw counts 𝑛!"#$%&  !"# and 𝑛!"#), i.e. TFs with more effectively-unrelated upstream regulators also tend to 
have more effectively-unrelated target functions. This suggests diverse modes of upstream 
regulation as a mechanism for TFs to realize functional pleiotropy. To eliminate technical biases 
due to ChIP-seq experiment quality or uneven research attention for different TFs, we controlled 
for 𝑛!" , the number of target genes per TF, as a confounding factor through linear model. 
Regulator diversity however remained a significant predictor of TF’s function diversity (p-value 
5.3 × 10-6 , Wald test). Further, we examined the known functions of TFs, which, unlike the target 
functions, are independent of the TFTG data compendium. A significant association remained 
between the known function diversity and the regulator diversity of TFs (p-value 6.3 × 10-5 
between diversity measures 𝜋!"#$"  !"# and 𝜋!"#, or p-value 0.00022 between raw counts 
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𝑛!"#$"  !"# and 𝑛!"#). This was true regardless of the number of target genes for the TFs. In fact, 
slightly stronger correlation was observed when TFs with less than 100 target genes were 
removed (Fig. S12). Finally, to completely eliminate the impact of human research biases toward 
popular TFs, which could result in higher number of literature-reported target genes as well as 
literature-reported upstream regulators for the popular TFs, we repeated the above all experiments 
after removing all low-throughput (literature derived) data in the TFTG compendium. We 
observed that regulator diversity and function diversity remain significantly associated (see 
Supplemental Material Section 1.5).  As a control, we evaluated the association between TF’s 
Functional Pleiotropy and its hierarchical location within the gene regulatory network, measure 
by PageRank (Page et al. 1999). Neither the PageRank-function diversity nor the PageRank-target 
function diversity associations are significant after controlling for the number of target genes of 
TFs (see Supplemental Material Section 1.6).  
 
In addition, we observed that the positive association was universal for all six types of function 
annotations. The trends are stronger for biological processes and molecular pathways, and weaker 
for GWAS and disease phenotypes (Fig. 5B). The association between function and regulator 
diversities extends to non-TF genes as well, with p-value 7.9 × 10-5 between diversity measures 𝜋!"# and 𝜋!"# and p-value 3.0 × 10-18 between raw counts 𝑛!"# and 𝑛!"# for 11345 genes that 
have both regulator and function annotations (see Supplemental Material Section 1.7).  
 
If regulator diversity is indeed a cause of TF function diversity, it is likely through driving the 
expression of the TF in diverse conditions. To evaluate this mechanism, we examined the 
expression of transcription factors in a collection of 327 human tissue types and cell lines 
(McCall et al. 2011). As expected, expression diversity of TFs is significantly associated with the 
regulator diversity (Spearman rank correlation 0.22, p-value 2.7 × 10-6, or Spearman rank 
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correlation 0.26, p-value 3.6 × 10-7 for the raw counts). On the other hand, there is a significant 
association between expression diversity of TFs and the target-function diversity (Spearman’s 
rank correlation 0.10, p-value 0.048), and the function diversity (Spearman’s rank correlation 
0.26, p-value 2.2× 10-7). Similarly, we observed strong associations between expression diversity 
of general genes and the function and regulator diversities of genes (see Supplemental Material 
Section 1.7). These support transcriptional regulation diversity as a mechanism for functional 
pleiotropy of transcription factors and other genes. 
 
Discussions 
A major challenge in data-driven TF function annotation is to minimize the impacts from false 
bindings and to reliably extract gene function signals. We combined multiple statistical strategies 
to achieve this. First, we target genes from ChIP-seq experiments are extracted with a stringent 
false discovery rate (FDR), which is calculated using a statistical framework modified from TIP 
(Cheng et al. 2011a) that combines binding locations and intensity information to differentiate 
true TF-DNA binding events from false signals. Second, we define the target functions of TFs as 
the consensus functions among the putative target genes. The statistical enrichment analysis 
hence further filters noises from the remaining false target genes. Third, we choose conservative 
gene universes specific to the types of functions, so as to minimize spurious associations. Finally, 
we apply the Benjamini–Hochberg multi-test correction procedure and require a FDR of 5% for 
all associations we report. With these, around 10K significant TF-target function associations are 
obtained. Meanwhile, the total number of true TF-target function associations is estimated to be 
over 80K, indicating the presence of rich functional signals in the TFTG data (Fig.3). We believe 
there is room for further improvement to retrieve higher number of TF-target function annotations 
at controlled false discovery rate.  
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We globally validate the TF-target function associations by comparing them with known TF-
function relationships, and show that the target functions cover both known and novel TF-
function relationships. Despite the fact that TF-target function and TF-function relationships do 
not always have direct correspondence, we observe a good prediction performance with AUC 
0.80 with 6 types of gene functions combined. In addition, we manually validate the top target 
diseases, phenotypes, and pharmacogenetic pathways based on the literature, and find that 
majority of them are supported by direct genetic evidence, such as direct mutations or GWAS 
implicated associations of a TF in patients with the target disease, or phenotypes of mouse knock-
out models of the TF (Table 1, S3 and S4), even when they are not annotated as known function 
of the TFs. Given that our knowledge is incomplete for even the most well studied TFs, we 
believe the non-validated TF-target functions represent opportunities for future experimental 
studies of the TFs.  
 
The foundation of this study is the hypothesis that genes regulated by a same TF are functionally 
related. We believe this extends to the functional concept level, i.e. multiple concepts targeted by 
the same TF(s) are also functionally related at some higher level. Based on co-regulation, we 
predict the interaction between coffee consumption and the metabolism of multiple drugs 
including warfarin as well as the interaction between coffee consumption and estrogen 
metabolism, both of which are validated by multiple published experimental studies (Wietholtz et 
al. 1989; Zambon et al. 2011; Enga et al. 2011; Li et al. 2011; Lowcock et al. 2013; Nkondjock et 
al. 2006; Ascherio et al. 2003, 2004). Further, we show that TFs link hundreds of functional 
concept pairs that do not share any member genes. This highlights the potential usage of the TF-
target function network to study the high-level organization principles among biological functions 
that is unattainable by solely studying the member genes of functions, e.g. through a member 
gene-based function-function association network.  
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Based on the TF-target function network, we examine the functional pleiotropy of TFs. We 
discover that a TF with more target functions (or known functions) are themselves regulated by 
significantly more TFs, and both function and regulator diversities are associated with the 
expression diversity of the TF in cell lines and tissues. These suggest that regulator diversity may 
be a cause of function diversity of TFs, and it works by driving the expression diversity of genes. 
 
Gene regulation is well known to be cell type specific, and co-expression of TFs is required for 
the co-regulation of TFs on the shared target genes (Ravasi et al. 2010). However current high-
throughput studies for in-vivo TF-DNA binding, including the ENCODE project (Wang et al. 
2013; Gerstein et al. 2012), are generally limited to a small number of tissue/cell types. 
Comprehensive ChIP-seq analysis on a large number of cell types remains unrealistic due to cost 
and resource requirements. We hence compile the transcription factor - target gene relationships 
in a cell type and development stage agnostic manner. Contingent on data availability, this work 
can be easily extended to perform cell type specific TF function annotation. Despite this 
compromise, the resulting TFTG data turns out to partially capture  the cell type specificity of 
TFs, as we observe TFs sharing similar tissue expression patterns also share greater amount of 
target genes (Wald T-test, p-value 1.9 × 10-78). 
 
In an effort to manually annotate TF functions, (Yusuf et al. 2012) teamed up over 100 experts to 
curate and integrate published knowledge and provide mini-reviews on transcription factors. We 
believe automated yet accurate function annotation and manual curation are complementary and 
will together greatly facilitate our understanding of the biological functions of human 
transcription factors.  
 
Despite large consortium efforts such as ENCODE (Bailey et al. 2013; Gerstein et al. 2012), 
existing data for transcription factor-target gene relationships remains scarce. Our TFTG 
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compendium covers 384 unique transcription factors. This is the largest collection to our 
knowledge, as compared to 237 TFs in a recently published study (Griffon et al. 2015), yet this 
only covers 20-25% of the putative 1500-2000 transcription factors in human (Vaquerizas et al. 
2009; Kummerfeld and Teichmann 2006). Relatedly, we notice that the TFTG compendium is 
biased toward the well-known transcription factors, likely due to preferential attachment of 
research efforts to popular TFs. For the same reason, some TFs enjoy higher target gene coverage 
than the other TFs. These biases currently limit the power of target gene based TF function 
annotation. However, with the maturity of ChIP-seq and related high-throughput assays for in-
vivo protein-DNA binding and the availability of the technologies to more labs, we expect a stead 
accumulation of TFTG data with improved accuracy and completeness yet reduced biases. Such 
data will ultimately enable the annotation of all transcription factors in the human genome, and 
serve as the foundation for hypothesis generation and further experimental studies of the roles of 
TFs in normal biological processes and diseases.  
 
 
Methods 
Transcription Factor Target Gene Data Compendium 
We compiled transcription factor-target gene (TFTG) relationships from multiple sources. ChIP-
seq experiments from both large-scale (Bernstein et al. 2012; Gerstein et al. 2012; Yan et al. 2013) 
and small-scale studies were included. Meta-data of 413 ChIP-seq experiments for 235 unique 
transcription factors were curated manually (by October 2013) from GEO (Barrett et al. 2013), in 
addition to around 450 ChIP-seq experiments for 115 unique transcription factors from the 
ENCyclopedia of DNA elements (ENCODE) (Bernstein et al. 2012; Gerstein et al. 2012). 
Manually curated low-throughput target gene annotations were compiled from multiple databases, 
including BIND, HTRI, PAZAR, and TRED (Bader 2003; Bovolenta et al. 2012; Portales-
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Casamar et al. 2009; Jiang et al. 2007). Only TFTG relationships with direct literature evidence 
from low throughput experiments (Yang 1998; Geertz and Maerkl 2010), e.g. as electrophoretic 
mobility shift assays, were included. We did not differentiate sequence specific DNA-binding 
transcription factors from other DNA binding transcriptional regulators. Some cofactors that do 
not directly bind DNA are also included when there are ChIP-seq data available. Despite this, we 
refer to all these transcriptional regulators as transcription factors (TFs) in this study. The binding 
signals from target genes were differentiated from that from non-target genes using a modified 
version of the TIP algorithm (Cheng et al. 2011a), which combines the binding location and 
intensity information for scoring TF target genes (See Supplemental Methods section 2.1).   
 
Gene Function Annotation Data 
Six types of gene annotations were used in this analysis to annotate transcription factors. Gene 
Ontology (GO) (Ashburner et al. 2000) for biological processes (BP) and molecular functions 
(MF), together with the Reactome pathways (Joshi-Tope et al. 2005) were retrieved from the 
MSigDB v4.0 (Liberzon et al. 2011). The Pharmacogenomics pathways for pharmacodynamics 
(PD) and pharmacokinetics (PK) were retrieved on Jan. 20, 2013 from the Pharmacogenomics 
Knowledgebase (PharmGKB) (Hewett 2002). Gene disease association data from genome wide 
association studies (GWAS) were obtained on May 4, 2014 from dbGAP (Mailman et al. 2007) 
and NHGRI (Welter et al. 2014) catalogs with p-value cutoffs at 1E-3 (loose set) or 1E-5 
(stringent set), and the closest gene, or two genes if the SNP is intergenic, to each SNP is retained. 
When not specified, the loose set is used. Note here a large p-value cutoff is used to capture 
majority of the true disease related genes rather than to select for confident ones, as our goal here 
is to associate complex phenotypes and diseases rather than individual genes with transcription 
factors. The gene - Mendelian disease annotations were obtained on July 5, 2014 from the Online 
Mendelian Inheritance in Man (OMIM) (Hamosh et al. 2005), and the disease genes were further 
 24 
grouped in a hierarchical manner to disease classes based on the disease ontology (Schriml et al. 
2012). For all data, only genes uniquely mapped to the Entrez Gene database (Maglott et al. 2005) 
are retained.  
 
Defining Coding Genes and Literature Rich Genes 
Coding genes are defined as all Entrez genes that have associated protein products in Ensembl 
Protein or UniProt databases. Literature Rich genes are defined as coding genes annotated in any 
of the following 7 data sources: GO Biological Processes, GO Molecular Functions, Reactome, 
PharmGKB, Kyoto Encyclopedia of Genes and Genomes pathways(Kanehisa 2000), 
Biocart(Nishimura 2001), and OMIM(Hamosh et al. 2005). There are 19847 Coding and 10931 
Literature Rich genes in total. Interestingly, 333 of the Literature Rich genes are not Coding 
genes, but pseudogenes, discontinued gene records, or gene loci without defined genes. These 
were removed, leaving 10561 Literature Rich genes in total.  
 
Measuring the Associations between Binary Variables 
Fisher’s exact test (Mehta 1986) is used for testing the associations between transcription factors 
and biological functions, by detecting significant enrichment of genes that are target genes of a 
TF and are also annotated with a given function. G-test is used as a fast approximation to Fisher’s 
exact test in preliminary analyses and to demonstrate the presence of functional signals in the TF 
target gene data (Figure 3). To perform multi-test correction, we calculated the Benjamini-
Hochberg false discovery rate (Benjamini and Hochberg 1995) on the p-values for each type of 
annotation separately. 
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Since Fisher’s exact test does not have a test statistic that we can use to measure the similarities 
between two binary variables. We use Pearson’s phi coefficient (𝜙, PPC) to measure association 
strength, 
!! !!!!!!!!!"!!"!!"!!!! !!!!!!" !!"!!!! !!!!!!" , 
where 𝑛!" are the observed number of 𝑖𝑗 value pairs for the two random variables. The strengths 
of TF-Function association, TF-TF target gene sharing, TF-TF target function sharing, TF-TF 
known function sharing, and Function-Function member gene sharing are denoted as 𝜙!"_!"#, 𝜙!" , 𝜙!"#$%&'(), 𝜙!"#, and 𝜙!"#_!!" respectively. PPC is sample size independent, and serves 
as a good measure of the magnitude of associations. The sign of PPC indicates the directionality 
of an association.  
 
Functional and Regulator Diversities of Transcription Factors  
We measure the effective number of transcription factors (i.e. the regulatory diversity) of a 
function or gene and the effective number of target functions (i.e. the function diversity) of a TF 
by down weighting the TFs (or functions) that are correlated with other TFs (or functions). Given 
Pearson’s phi coefficient 𝜙!!! between TFs 𝑡 and 𝑡!, the uniqueness of TF 𝑡 is defined as 𝑢! = 1/ 𝜙!!!!!!∈!"# . Note that 𝑢! is always within 0 to 1, since the association between a TF 
with itself is always 1, i.e. 𝜙!!! = 1.  The regulator diversity 𝜋!"#.! of a function or gene 
(including TF) 𝑔 is then defined as the weighted counts of the transcription factors targeting the 
function or gene, 𝜋!"#.! = 𝑢!!∈!"#  !"#$%&'()#  ! . The regulator diversity measures the effective 
(non-redundant) number of regulators for a gene (or a TF). Similarly we can define the 
uniqueness of each function annotation term, phenotype, or disease, and then define the target 
function diversity 𝜋!"#$%&  !"# (i.e. effective number of target functions) of a transcription factor 
or the function diversity 𝜋!"# (i.e. effective number of known functions) of a gene.  
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Data Access 
The Cytoscape file for the full TF-function network is available at simtk.org under identifier 
TFAnno and the full target function annotations for TFs are available as supplemental Table S7. 
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Figure Legends 
Figure 1:  
An outline of the workflow for regulatory network based annotation of transcription factor 
functions. 
 
Figure 2:  
Presence of gene function signals in the TFTG data. The scatter plot shows the p-values of 
function-TF associations obtained using real TFTG compendium (x-axis) and a fake TFTG 
compendium (y-axis). Each dot corresponds to a pair of p-values for a TF-Function pair. The inlet 
shows the number of significant TF-Target Function relationships at varying p-value cutoffs for 
the real TFTG data (y-axis) against the number for the fake TFTG data (x-axis). P-values are 
obtained by G-tests. 
 
Figure 3:  
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(A) Global view of the transcription factors and their target functions. 311 TFs and 1420 
annotations with one or more significant associations at FDR 0.1 levels are retained. Red 
indicates positive associations, green indicates negative associations, white indicates FDR > 0.1. 
Intensity of the colors corresponds to the significance levels: FDR 0.1, 0.05, and 0.01.The TF and 
target function clustering showed on the left and top was performed based on the TF-target 
function association phi coefficient matrix. We used the literature rich gene universe for the 
association analysis except for the TF-GWAS phenotype association, for which the coding gene 
universe is used.  
(B) The network visualization (Smoot et al. 2011) of TF-target function and TF-known function 
relationships. Edges are colored red or green the same way as in (A). A solid edge links a TF with 
a significant target function that is not a known function. A dashed edge links a TF with a known 
function. A dashed edge with color links a TF with a known function that is also a significant 
target function, while a grey dashed edge links a TF with a known function that is not a 
significant target function. Node colors and shapes correspond to function types: purple circles, 
TFs; grey rectangles, Reactome pathways; blue triangles, GO molecular functions; white 
diamonds, GO biological processes; red rhomboids, PharmGKB PK and PD pathways; yellow 
hexagon, Mendelian diseases; green octagons, GWAS phenotypes.  
 
Figure 4:  
Transcription factor sharing among apparently unrelated functional concepts. (A) Two functional 
concepts with high member gene overlaps always have similar regulators, but (B) two functional 
concepts with nearly identical regulators do not always have high member gene sharing. (C) A 
Venn diagram for 3 functional concepts for which shared transcription factors are identified for 
functions without gene overlaps. The arrows connect the significant regulators for the functions. 
Note that “Iron Uptake and Transport” and “Insulin Receptor Recycling” do share member genes 
significantly, but neither of them shares member genes with “Lipid Storage Disease”. 
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Figure 5:   
The relationship between functional diversity and regulator diversity of transcription factors. 
(A) The target functions of transcription factor HNF1A form 3 major clusters based on 
similarities (member gene sharing) among the functions, while the upstream regulators of 
HNF1A form clusters based on the functional similarities (target gene overlaps) among these 
regulators. The regulator and functional diversities of a gene measures the effective number of 
regulators and effective number of functions for a gene. The coloring schema is same as in Figure 
5 and the clustering of TFs and functions are based on the TF’s target gene overlaps and 
function’s member gene overlaps. 
(B) Significant associations exist between the regulator diversity and target function diversity of 
transcription factors for six types of function annotations separately.  
 
Figure 6:  
Complete target gene-based annotations for two example transcription factors (A) NFKB1 and (B) 
SUZ12. Three types of information are provided: 1) the top TF neighbors obtained by TF distance 
(1- target-gene overlap measured by Pearson’s phi coefficient) < 0.8; 2) the target functions in six 
categories, 3) the functional diversities in six categories and total diversity. See Figure S9 for a 
visualization of the regulator and target function networks surrounding NFKB1.  
 
Figures  
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Figure 3: 
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CATION_CHANNEL_ACTIVITY
GATED_CHANNEL_ACTIVITY
SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY
ION_CHANNEL_ACTIVITY
ION_TRANSPORT
CATION_TRANSPORT
MONOVALENT_INORGANIC_CATION_TRANSPORT
SUBSTRATE_SPECIFIC_TRANSPORTER_ACTIVITY
SUBSTRATE_SPECIFIC_TRANSMEMBRANE_TRANSPORTER_ACTIVITY
TRANSMEMBRANE_TRANSPORTER_ACTIVITY
CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY
ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY
EXCRETION
REACTOME_OLFACTORY_SIGNALING_PATHWAY
REACTOME_DEFENSINS
REACTOME_BETA_DEFENSINS
LIGAND_GATED_CHANNEL_ACTIVITY
NEUROTRANSMITTER_BINDING
NEUROTRANSMITTER_RECEPTOR_ACTIVITY
REACTOME_HS_GAG_DEGRADATION
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM
REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL
REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES
REACTOME_NEURONAL_SYSTEM
CELL_CELL_SIGNALING
SYNAPTIC_TRANSMISSION
TRANSMISSION_OF_NERVE_IMPULSE
NEUROLOGICAL_SYSTEM_PROCESS
SYSTEM_PROCESS
ACTIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY
REACTOME_TRANSPORT_OF_INORGANIC_CATIONS_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES
REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS
LIPASE_ACTIVITY
REACTOME_THE_ACTIVATION_OF_ARYLSULFATASES
PATTERN_SPECIFICATION_PROCESS
EMBRYONIC_MORPHOGENESIS
EMBRYONIC_DEVELOPMENT
HEART_DEVELOPMENT
BRAIN_DEVELOPMENT
CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT
GLAND_DEVELOPMENT
Disease: heart septal defect
Disease: congenital heart disease
Disease: tetralogy of Fallot
Disease: ventricular septal defect
Disease: double outlet right ventricle
Disease: autosomal dominant disease
Disease: genetic disease
Disease: monogenic disease
Disease: autosomal genetic disease
Disease: Waardenburg's syndrome
Disease: colonic disease
Disease: Hirschsprung's disease
Disease: megacolon
SYNAPTOGENESIS
EXTRACELLULAR_STRUCTURE_ORGANIZATION_AND_BIOGENESIS
NERVOUS_SYSTEM_DEVELOPMENT
AXONOGENESIS
MUSCLE_DEVELOPMENT
SKELETAL_DEVELOPMENT
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS
REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS
Pheno_body mass index
Pheno_body height
Pheno_myocardial infarction
Pheno_blood pressure
Pheno_hip
Pheno_echocardiography
Pheno_triglycerides
Pheno_cholesterol, hdl
Pheno_cholesterol, ldl
Pheno_cholesterol
Pheno_exercise test
Disease: disease
Disease: disease of anatomical entity
ORGAN_DEVELOPMENT
ANATOMICAL_STRUCTURE_DEVELOPMENT
SYSTEM_DEVELOPMENT
MULTICELLULAR_ORGANISMAL_DEVELOPMENT
ANATOMICAL_STRUCTURE_MORPHOGENESIS
ORGAN_MORPHOGENESIS
REACTOME_REGULATION_OF_INSULIN_LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS
REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION
REPRODUCTIVE_PROCESS
REPRODUCTION
POSITIVE_REGULATION_OF_CELL_PROLIFERATION
CELL_PROLIFERATION_GO_0008283
REGULATION_OF_CELL_PROLIFERATION
TISSUE_DEVELOPMENT
EPIDERMIS_DEVELOPMENT
ECTODERM_DEVELOPMENT
REACTOME_COLLAGEN_FORMATION
REACTOME_NCAM1_INTERACTIONS
SECOND_MESSENGER_MEDIATED_SIGNALING
G_PROTEIN_SIGNALING_COUPLED_TO_CYCLIC_NUCLEOTIDE_SECOND_MESSENGER
CYCLIC_NUCLEOTIDE_MEDIATED_SIGNALING
G_PROTEIN_SIGNALING_COUPLED_TO_CAMP_NUCLEOTIDE_SECOND_MESSENGER
CAMP_MEDIATED_SIGNALING
AMINE_RECEPTOR_ACTIVITY
REACTOME_AMINE_LIGAND_BINDING_RECEPTORS
PEPTIDE_RECEPTOR_ACTIVITY
RHODOPSIN_LIKE_RECEPTOR_ACTIVITY
G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY
CIRCADIAN_RHYTHM
REACTOME_GABA_SYNTHESIS_RELEASE_REUPTAKE_AND_DEGRADATION
Disease: thyroid gland disease
Disease: congenital hypothyroidism
Disease: hypothyroidism
REACTOME_INTEGRATION_OF_ENERGY_METABOLISM
REACTOME_INCRETIN_SYNTHESIS_SECRETION_AND_INACTIVATION
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS
REACTOME_CELL_CELL_COMMUNICATION
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION
REACTOME_CELL_JUNCTION_ORGANIZATION
STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON
Disease: cardiovascular system disease
Disease: heart disease
Disease: dilated cardiomyopathy
Disease: cardiomyopathy
Disease: intrinsic cardiomyopathy
REACTOME_STRIATED_MUSCLE_CONTRACTION
REACTOME_MUSCLE_CONTRACTION
STRUCTURAL_CONSTITUENT_OF_MUSCLE
REGULATION_OF_HEART_CONTRACTION
PharmGKB_PA153627758_Anti−diabetic_Drug_Potassium_Channel_Inhibitors_Pathway_Pharmacodynamics
Disease: acquired metabolic disease
Disease: type 2 diabetes mellitus
Disease: diabetes mellitus
Disease: carbohydrate metabolism disease
Disease: glucose metabolism disease
Disease: maturity−onset diabetes of the young
REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT
REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS
REACTOME_FACILITATIVE_NA_INDEPENDENT_GLUCOSE_TRANSPORTERS
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES
REACTOME_TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AMINE_COMPOUNDS
PharmGKB_PA165815256_Amodiaquine_Pathway_Pharmacokinetics
REACTOME_ENDOGENOUS_STEROLS
OXYGEN_BINDING
REACTOME_BIOLOGICAL_OXIDATIONS
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE
REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS
NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS
REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS
REACTOME_COMMON_PATHWAY
REGULATION_OF_BODY_FLUID_LEVELS
HEMOSTASIS
WOUND_HEALING
BLOOD_COAGULATION
COAGULATION
PharmGKB_PA154426903_Erlotinib_Pathway_Pharmacokinetics
PharmGKB_PA145011113_Warfarin_Pathway_Pharmacokinetics
PharmGKB_PA154424674_Clopidogrel_Pathway_Pharmacokinetics
PharmGKB_PA145011108_Statin_Pathway_−_Generalized_Pharmacokinetics
PharmGKB_PA146123006_Codeine_and_Morphine_Pathway_Pharmacokinetics
PharmGKB_PA145011109_Atorvastatin/Lovastatin/Simvastatin_Pathway_Pharmacokinetics
PharmGKB_PA152530846_Proton_Pump_Inhibitor_Pathway_Pharmacokinetics
PharmGKB_PA2001_Irinotecan_Pathway_Pharmacokinetics
PharmGKB_PA2029_Irinotecan_Pathway_Pharmacodynamics
PharmGKB_PA165964832_Mycophenolic_acid_Pathway_Pharmacokinetics
PharmGKB_PA164713427_Imatinib_Pathway_Pharmacokinetics/Pharmacodynamics
PharmGKB_PA145011115_Phenytoin_Pathway_Pharmacokinetics
PharmGKB_PA145011118_Estrogen_Metabolism_Pathway
PharmGKB_PA165959537_Sorafenib_Pharmacokinetics
PharmGKB_PA145011111_Fluvastatin_Pathway_Pharmacokinetics
PharmGKB_PA164713428_Losartan_Pathway_Pharmacokinetics
PharmGKB_PA165958541_Theophylline_Pathway_Pharmacokinetics
PharmGKB_PA165817070_Carbamazepine_Pathway_Pharmacokinetics
REACTOME_XENOBIOTICS
PharmGKB_PA145011119_Tamoxifen_Pathway_Pharmacokinetics
PharmGKB_PA165111375_Benzodiazepine_Pathway_Pharmacokinetics
REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS
PharmGKB_PA165964265_Valproic_Acid_Pathway_Pharmacokinetics
PharmGKB_PA2011_Nicotine_Pathway_Pharmacokinetics
PharmGKB_PA165378192_Artemisinin_and_Derivatives_Pathway_Pharmacokinetics
PharmGKB_PA165946349_Tramadol_Pharmacokinetics
REACTOME_GLUCURONIDATION
REACTOME_PHASE_II_CONJUGATION
RESPONSE_TO_XENOBIOTIC_STIMULUS
XENOBIOTIC_METABOLIC_PROCESS
Pheno_anemia, sickle cell
Pheno_dna
PharmGKB_PA145011114_Warfarin_Pathway_Pharmacodynamics
REACTOME_GAMMA_CARBOXYLATION_TRANSPORT_AND_AMINO_TERMINAL_CLEAVAGE_OF_PROTEINS
SERINE_TYPE_ENDOPEPTIDASE_ACTIVITY
REACTOME_FORMATION_OF_FIBRIN_CLOT_CLOTTING_CASCADE
REACTOME_INTRINSIC_PATHWAY
REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES
HORMONE_METABOLIC_PROCESS
STEROID_METABOLIC_PROCESS
LIPID_METABOLIC_PROCESS
CELLULAR_LIPID_METABOLIC_PROCESS
LEARNING_AND_OR_MEMORY
ENDOTHELIAL_CELL_MIGRATION
NEUROPEPTIDE_HORMONE_ACTIVITY
HORMONE_ACTIVITY
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS
PharmGKB_PA2030_Sympathetic_Nerve_Pathway_(Pre−_and_Post−_Ganglionic_Junction)
PharmGKB_PA2042_Sympathetic_Nerve_Pathway_(Neuroeffector_Junction)
REACTOME_AMINE_DERIVED_HORMONES
OXIDOREDUCTASE_ACTIVITY_GO_0016705
MONOOXYGENASE_ACTIVITY
REACTOME_PEPTIDE_HORMONE_BIOSYNTHESIS
REACTOME_HORMONE_LIGAND_BINDING_RECEPTORS
REACTOME_ANDROGEN_BIOSYNTHESIS
REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D
REACTOME_STEROID_HORMONES
RESPONSE_TO_HYPOXIA
ANATOMICAL_STRUCTURE_FORMATION
ANGIOGENESIS
VASCULATURE_DEVELOPMENT
CARBOHYDRATE_BINDING
PharmGKB_PA152241951_Celecoxib_Pathway_Pharmacodynamics
REACTOME_VEGF_LIGAND_RECEPTOR_INTERACTIONS
CELLULAR_DEFENSE_RESPONSE
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL
SIGNAL_TRANSDUCTION
CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166
G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY
REACTOME_SIGNALING_BY_GPCR
REACTOME_GPCR_DOWNSTREAM_SIGNALING
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS
REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS
REACTOME_GPCR_LIGAND_BINDING
RECEPTOR_ACTIVITY
TRANSMEMBRANE_RECEPTOR_ACTIVITY
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS
KERATINOCYTE_DIFFERENTIATION
POSITIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION
RECEPTOR_BINDING
CYTOKINE_ACTIVITY
HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_BINDING
GROWTH_FACTOR_ACTIVITY
RESPIRATORY_GASEOUS_EXCHANGE
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT
REACTOME_REGULATION_OF_COMPLEMENT_CASCADE
REACTOME_COMPLEMENT_CASCADE
DIGESTION
PharmGKB_PA2031_Statin_Pathway_Pharmacodynamics
REACTOME_CHYLOMICRON_MEDIATED_LIPID_TRANSPORT
REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT
REACTOME_LIPOPROTEIN_METABOLISM
REGULATION_OF_PROTEIN_SECRETION
TRIACYLGLYCEROL_METABOLIC_PROCESS
LIPID_TRANSPORTER_ACTIVITY
REACTOME_HDL_MEDIATED_LIPID_TRANSPORT
LIPID_TRANSPORT
LIPID_HOMEOSTASIS
NEGATIVE_REGULATION_OF_HYDROLASE_ACTIVITY
INTERLEUKIN_8_BIOSYNTHETIC_PROCESS
GROWTH_FACTOR_BINDING
CYTOKINE_BINDING
REGULATION_OF_CYTOKINE_PRODUCTION
POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION
POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS
REGULATION_OF_RESPONSE_TO_STIMULUS
POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS
POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS
PRODUCTION_OF_MOLECULAR_MEDIATOR_OF_IMMUNE_RESPONSE
ADAPTIVE_IMMUNE_RESPONSE_GO_0002460
ADAPTIVE_IMMUNE_RESPONSE
T_CELL_DIFFERENTIATION
T_CELL_ACTIVATION
CELL_ACTIVATION
LEUKOCYTE_ACTIVATION
LYMPHOCYTE_ACTIVATION
POSITIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS
POSITIVE_REGULATION_OF_TRANSLATION
REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS
CYTOKINE_METABOLIC_PROCESS
CYTOKINE_BIOSYNTHETIC_PROCESS
HUMORAL_IMMUNE_RESPONSE
IMMUNE_EFFECTOR_PROCESS
CYTOKINE_PRODUCTION
IMMUNE_RESPONSE
IMMUNE_SYSTEM_PROCESS
REACTOME_EXTRINSIC_PATHWAY_FOR_APOPTOSIS
Disease: hypersensitivity reaction type IV disease
Disease: autoimmune lymphoproliferative syndrome
PharmGKB_PA150642262_Platinum_Pathway_Pharmacokinetics/Pharmacodynamics
RESPONSE_TO_DRUG
PharmGKB_PA165816270_Methotrexate_Pathway_(Brain_Cell)_Pharmacokinetics
PharmGKB_PA165816349_Methotrexate_Pathway_Pharmacokinetics
RESPONSE_TO_BIOTIC_STIMULUS
MULTI_ORGANISM_PROCESS
RESPONSE_TO_VIRUS
RESPONSE_TO_OTHER_ORGANISM
CELL_MIGRATION
LEUKOCYTE_CHEMOTAXIS
LEUKOCYTE_MIGRATION
PharmGKB_PA2025_Etoposide_Pathway_Pharmacokinetics/Pharmacodynamics
REGULATION_OF_BLOOD_PRESSURE
NEGATIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS
Disease: inflammatory bowel disease
Disease: intestinal disease
Pheno_bilirubin
REGULATION_OF_BIOLOGICAL_QUALITY
CELLULAR_CATION_HOMEOSTASIS
CATION_HOMEOSTASIS
CELLULAR_HOMEOSTASIS
ION_HOMEOSTASIS
HOMEOSTATIC_PROCESS
CHEMICAL_HOMEOSTASIS
RESPONSE_TO_CHEMICAL_STIMULUS
RESPONSE_TO_EXTERNAL_STIMULUS
DEFENSE_RESPONSE
INFLAMMATORY_RESPONSE
RESPONSE_TO_WOUNDING
BEHAVIOR
LOCOMOTORY_BEHAVIOR
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES
G_PROTEIN_COUPLED_RECEPTOR_BINDING
CHEMOKINE_ACTIVITY
CHEMOKINE_RECEPTOR_BINDING
Disease: syndrome
FOCAL_ADHESION_FORMATION
REACTOME_TCR_SIGNALING
REACTOME_DOWNSTREAM_TCR_SIGNALING
REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK
Disease: reproductive organ cancer
Disease: prostate cancer
Disease: male reproductive organ cancer
REACTOME_L1CAM_INTERACTIONS
REACTOME_SIGNAL_TRANSDUCTION_BY_L1
REACTOME_DEVELOPMENTAL_BIOLOGY
REACTOME_AXON_GUIDANCE
REACTOME_INNATE_IMMUNE_SYSTEM
REACTOME_TOLL_RECEPTOR_CASCADES
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE
REACTOME_TRAF6_MEDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON_TLR7_8_OR_9_ACTIVATION
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING
REACTOME_ACTIVATED_TLR4_SIGNALLING
REACTOME_ACTIVATION_OF_THE_AP1_FAMILY_OF_TRANSCRIPTION_FACTORS
REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES
REACTOME_SIGNALING_BY_NOTCH
REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION
REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING
Disease: disease of cellular proliferation
Disease: organ system cancer
Disease: cancer
PharmGKB_PA162356267_EGFR_Inhibitor_Pathway_Pharmacodynamics
PharmGKB_PA165980050_Vemurafenib_Pathway_Pharmacodynamics
REGULATION_OF_MAP_KINASE_ACTIVITY
ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY
TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY
CELL_CELL_ADHESION
CALCIUM_MEDIATED_SIGNALING
REGULATION_OF_CELL_MIGRATION
POSITIVE_REGULATION_OF_CELL_MIGRATION
POSITIVE_REGULATION_OF_CELL_CYCLE
REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION
REGULATION_OF_PROTEIN_MODIFICATION_PROCESS
REGULATION_OF_PHOSPHORYLATION
POSITIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS
POSITIVE_REGULATION_OF_PHOSPHORYLATION
POSITIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS
POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS
POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS
POSITIVE_REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION
POSITIVE_REGULATION_OF_METABOLIC_PROCESS
POSITIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS
POSITIVE_REGULATION_OF_BIOLOGICAL_PROCESS
POSITIVE_REGULATION_OF_CELLULAR_PROCESS
REGULATION_OF_TRANSFERASE_ACTIVITY
REGULATION_OF_KINASE_ACTIVITY
REGULATION_OF_PROTEIN_KINASE_ACTIVITY
REGULATION_OF_MOLECULAR_FUNCTION
REGULATION_OF_CATALYTIC_ACTIVITY
POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY
POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY
REGULATION_OF_MEMBRANE_POTENTIAL
PharmGKB_PA150981002_Vinka_Alkaloid_Pathway_Pharmacokinetics
RESPONSE_TO_TOXIN
REGULATION_OF_HOMEOSTATIC_PROCESS
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS
REGULATION_OF_PH
REGULATION_OF_CELLULAR_PH
CELLULAR_MONOVALENT_INORGANIC_CATION_HOMEOSTASIS
REACTOME_NUCLEAR_SIGNALING_BY_ERBB4
Disease: migraine
PharmGKB_PA145011120_Aromatase_Inhibitor_Pathway_(Breast_Cell)_Pharmacodynamics
ENDOPEPTIDASE_ACTIVITY
PEPTIDASE_ACTIVITY
METALLOPEPTIDASE_ACTIVITY
METALLOENDOPEPTIDASE_ACTIVITY
PROTEOLYSIS
Disease: cognitive disorder
Disease: tauopathy
Disease: Alzheimer's disease
Disease: dementia
REACTOME_BINDING_AND_ENTRY_OF_HIV_VIRION
POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION
HOMEOSTASIS_OF_NUMBER_OF_CELLS
MYELOID_CELL_DIFFERENTIATION
REGULATION_OF_MYELOID_CELL_DIFFERENTIATION
PEPTIDYL_AMINO_ACID_MODIFICATION
REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION
PEPTIDYL_TYROSINE_PHOSPHORYLATION
PEPTIDYL_TYROSINE_MODIFICATION
POSITIVE_REGULATION_OF_DNA_METABOLIC_PROCESS
B_CELL_DIFFERENTIATION
B_CELL_ACTIVATION
IMMUNE_SYSTEM_DEVELOPMENT
HEMOPOIESIS
HEMOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT
LYMPHOCYTE_DIFFERENTIATION
LEUKOCYTE_DIFFERENTIATION
PROTEIN_HETERODIMERIZATION_ACTIVITY
PROTEIN_DIMERIZATION_ACTIVITY
PROTEIN_HOMODIMERIZATION_ACTIVITY
IDENTICAL_PROTEIN_BINDING
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR
REACTOME_EGFR_DOWNREGULATION
POSITIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION
Disease: respiratory system cancer
Disease: lung cancer
REGULATION_OF_TRANSLATION
REGULATION_OF_PROTEIN_METABOLIC_PROCESS
REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS
NEGATIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS
NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS
NEGATIVE_REGULATION_OF_TRANSLATION
NEGATIVE_REGULATION_OF_CELLULAR_BIOSYNTHETIC_PROCESS
NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS
Disease: essential hypertension
PharmGKB_PA165292177_Doxorubicin_Pathway_Pharmacokinetics
OXYGEN_AND_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS
REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS_VIA_7ALPHA_HYDROXYCHOLESTEROL
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS
REACTOME_ALPHA_LINOLENIC_ACID_ALA_METABOLISM
REACTOME_PEROXISOMAL_LIPID_METABOLISM
PROTEIN_STABILIZATION
REGULATION_OF_PROTEIN_STABILITY
REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS
REACTOME_PPARA_ACTIVATES_GENE_EXPRESSION
REACTOME_FATTY_ACID_TRIACYLGLYCEROL_AND_KETONE_BODY_METABOLISM
CDC42_PROTEIN_SIGNAL_TRANSDUCTION
LIPID_CATABOLIC_PROCESS
CELLULAR_LIPID_CATABOLIC_PROCESS
FATTY_ACID_BETA_OXIDATION
FATTY_ACID_OXIDATION
REACTOME_GENERIC_TRANSCRIPTION_PATHWAY
LIGAND_DEPENDENT_NUCLEAR_RECEPTOR_ACTIVITY
REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY
PharmGKB_PA2027_Glucocorticoid_Pathway_(Peripheral_Tissue)_Pharmacodynamics
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION
REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_EXPRESSION
REACTOME_CIRCADIAN_CLOCK
REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION
REACTOME_RORA_ACTIVATES_CIRCADIAN_EXPRESSION
REACTOME_CIRCADIAN_REPRESSION_OF_EXPRESSION_BY_REV_ERBA
POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS
INDUCTION_OF_APOPTOSIS_BY_INTRACELLULAR_SIGNALS
REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL
REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING
REACTOME_GAB1_SIGNALOSOME
REACTOME_PI_3K_CASCADE
REACTOME_PIP3_ACTIVATES_AKT_SIGNALING
REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING
REACTOME_PI3K_AKT_ACTIVATION
REACTOME_SIGNALLING_BY_NGF
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE
REACTOME_SIGNALING_BY_ERBB4
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR
REACTOME_SIGNALING_BY_FGFR
REACTOME_SIGNALING_BY_ERBB2
REACTOME_SIGNALING_BY_EGFR_IN_CANCER
REACTOME_SIGNALING_BY_SCF_KIT
REACTOME_SIGNALING_BY_PDGF
REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION
RESPONSE_TO_EXTRACELLULAR_STIMULUS
CELLULAR_RESPONSE_TO_STIMULUS
CELLULAR_RESPONSE_TO_EXTRACELLULAR_STIMULUS
ENZYME_REGULATOR_ACTIVITY
ENZYME_INHIBITOR_ACTIVITY
G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE
INTERPHASE
INTERPHASE_OF_MITOTIC_CELL_CYCLE
NEGATIVE_REGULATION_OF_GROWTH
REGULATION_OF_CELL_GROWTH
REGULATION_OF_GROWTH
GROWTH
KINASE_REGULATOR_ACTIVITY
PROTEIN_KINASE_REGULATOR_ACTIVITY
REACTOME_G1_PHASE
G2_M_TRANSITION_OF_MITOTIC_CELL_CYCLE
PROTEIN_KINASE_INHIBITOR_ACTIVITY
KINASE_INHIBITOR_ACTIVITY
NEGATIVE_REGULATION_OF_PHOSPHORYLATION
NEGATIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS
Pheno_caffeine
Pheno_coffee
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_
REACTOME_HEMOSTASIS
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS
REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS_
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING
REACTOME_PLATELET_AGGREGATION_PLUG_FORMATION
REACTOME_CELL_CYCLE_MITOTIC
REACTOME_MITOTIC_G1_G1_S_PHASES
REACTOME_G1_S_TRANSITION
REACTOME_S_PHASE
REACTOME_P53_DEPENDENT_G1_DNA_DAMAGE_RESPONSE
REACTOME_CELL_CYCLE_CHECKPOINTS
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN
REACTOME_SYNTHESIS_OF_DNA
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES
REACTOME_APOPTOSIS
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS
REACTOME_ANTIGEN_PROCESSING_CROSS_PRESENTATION
REACTOME_ER_PHAGOSOME_PATHWAY
REACTOME_SIGNALING_BY_WNT
REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS
REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX
REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_ENDOSOMES
REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1
REACTOME_REGULATION_OF_APOPTOSIS
REACTOME_VIF_MEDIATED_DEGRADATION_OF_APOBEC3G
REACTOME_M_G1_TRANSITION
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1
REACTOME_AUTODEGRADATION_OF_CDH1_BY_CDH1_APC_C
Disease: autosomal recessive disease
Disease: Bardet−Biedl syndrome
Disease: Seckel syndrome
TUBULIN_BINDING
PEROXISOME_ORGANIZATION_AND_BIOGENESIS
REACTOME_MRNA_DECAY_BY_5_TO_3_EXORIBONUCLEASE
CYTOKINESIS
CELL_DIVISION
DNA_PACKAGING
CHROMOSOME_CONDENSATION
CHROMOSOME_SEGREGATION
MITOTIC_SISTER_CHROMATID_SEGREGATION
SISTER_CHROMATID_SEGREGATION
ONE_CARBON_COMPOUND_METABOLIC_PROCESS
METHYLTRANSFERASE_ACTIVITY
TRANSFERASE_ACTIVITY_TRANSFERRING_ONE_CARBON_GROUPS
REACTOME_ASSOCIATION_OF_TRIC_CCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_TRIC
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC
REACTOME_PROTEIN_FOLDING
UNFOLDED_PROTEIN_BINDING
PROTEIN_FOLDING
REACTOME_MITOTIC_G2_G2_M_PHASES
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES
REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES
REACTOME_MITOTIC_PROMETAPHASE
REACTOME_MITOTIC_M_M_G1_PHASES
REACTOME_DNA_REPLICATION
Disease: endocrine gland cancer
Disease: papillary thyroid carcinoma
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANSCRIPTIONAL_ACTIVITY
REACTOME_MEMBRANE_BINDING_AND_TARGETTING_OF_GAG_PROTEINS
REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT
CHROMATIN_REMODELING
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS
CHROMATIN_MODIFICATION
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S
REACTOME_PKB_MEDIATED_EVENTS
REACTOME_MTORC1_MEDIATED_SIGNALLING
TRANSCRIPTION_FROM_RNA_POLYMERASE_III_PROMOTER
UBIQUITIN_CYCLE
PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION
PROTEIN_UBIQUITINATION
RIBOSOME_BIOGENESIS_AND_ASSEMBLY
RRNA_PROCESSING
RRNA_METABOLIC_PROCESS
REACTOME_SLBP_DEPENDENT_PROCESSING_OF_REPLICATION_DEPENDENT_HISTONE_PRE_MRNAS
RNA_3END_PROCESSING
REACTOME_PROCESSING_OF_INTRONLESS_PRE_MRNAS
REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE_MRNA
MRNA_SPLICE_SITE_SELECTION
SPLICEOSOME_ASSEMBLY
RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS
REACTOME_MRNA_SPLICING_MINOR_PATHWAY
REACTOME_RNA_POL_II_TRANSCRIPTION
REACTOME_MRNA_3_END_PROCESSING
REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_REGION_
REACTOME_BASE_EXCISION_REPAIR
REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY
REACTOME_BASE_FREE_SUGAR_PHOSPHATE_REMOVAL_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY
REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY
DAMAGED_DNA_BINDING
DNA_METABOLIC_PROCESS
DNA_REPAIR
RESPONSE_TO_ENDOGENOUS_STIMULUS
RESPONSE_TO_DNA_DAMAGE_STIMULUS
HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS
RIBONUCLEASE_ACTIVITY
ENDORIBONUCLEASE_ACTIVITY
ENDONUCLEASE_ACTIVITY_GO_0016893
3_5_EXONUCLEASE_ACTIVITY
EXONUCLEASE_ACTIVITY
ENDODEOXYRIBONUCLEASE_ACTIVITY
DEOXYRIBONUCLEASE_ACTIVITY
ENDONUCLEASE_ACTIVITY
NUCLEASE_ACTIVITY
MACROMOLECULAR_COMPLEX_DISASSEMBLY
CELLULAR_PROTEIN_COMPLEX_DISASSEMBLY
PROTEIN_COMPLEX_DISASSEMBLY
MANNOSYLTRANSFERASE_ACTIVITY
MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS
CENTROSOME_CYCLE
DOUBLE_STRAND_BREAK_REPAIR
REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICATION_INDEPENDENT_DOUBLE_STRAND_BREAKS
REACTOME_DOUBLE_STRAND_BREAK_REPAIR
DNA_RECOMBINATION
MEIOTIC_CELL_CYCLE
MEIOSIS_I
MEIOTIC_RECOMBINATION
REACTOME_UNWINDING_OF_DNA
REACTOME_DNA_STRAND_ELONGATION
DNA_REPLICATION_INITIATION
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS
REACTOME_G2_M_CHECKPOINTS
DNA_REPLICATION
DNA_DEPENDENT_DNA_REPLICATION
REGULATION_OF_DNA_METABOLIC_PROCESS
REGULATION_OF_DNA_REPLICATION
NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS
NEGATIVE_REGULATION_OF_DNA_REPLICATION
REACTOME_REGULATION_OF_THE_FANCONI_ANEMIA_PATHWAY
REACTOME_FANCONI_ANEMIA_PATHWAY
REACTOME_E2F_ENABLED_INHIBITION_OF_PRE_REPLICATION_COMPLEX_FORMATION
REACTOME_ASSOCIATION_OF_LICENSING_FACTORS_WITH_THE_PRE_REPLICATIVE_COMPLEX
REACTOME_CDC6_ASSOCIATION_WITH_THE_ORC_ORIGIN_COMPLEX
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION
REACTOME_G0_AND_EARLY_G1
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION
REACTOME_REMOVAL_OF_THE_FLAP_INTERMEDIATE_FROM_THE_C_STRAND
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND
REACTOME_LAGGING_STRAND_SYNTHESIS
REACTOME_EXTENSION_OF_TELOMERES
REACTOME_POL_SWITCHING
REACTOME_REPAIR_SYNTHESIS_FOR_GAP_FILLING_BY_DNA_POL_IN_TC_NER
REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES
REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT
CELLULAR_PROTEIN_COMPLEX_ASSEMBLY
PROTEIN_COMPLEX_ASSEMBLY
MACROMOLECULAR_COMPLEX_ASSEMBLY
CELLULAR_COMPONENT_ASSEMBLY
MITOTIC_CELL_CYCLE
CELL_CYCLE_PROCESS
CELL_CYCLE_PHASE
REGULATION_OF_MITOSIS
M_PHASE
MITOSIS
M_PHASE_OF_MITOTIC_CELL_CYCLE
DNA_INTEGRITY_CHECKPOINT
DNA_DAMAGE_CHECKPOINT
MITOTIC_CELL_CYCLE_CHECKPOINT
CELL_CYCLE_CHECKPOINT_GO_0000075
SMALL_CONJUGATING_PROTEIN_SPECIFIC_PROTEASE_ACTIVITY
CYSTEINE_TYPE_PEPTIDASE_ACTIVITY
CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY
REACTOME_LYSOSOME_VESICLE_BIOGENESIS
REACTOME_MEMBRANE_TRAFFICKING
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT
REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLING
PROTEIN_C_TERMINUS_BINDING
REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS
NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS
DNA_HELICASE_ACTIVITY
DNA_DEPENDENT_ATPASE_ACTIVITY
RNA_HELICASE_ACTIVITY
ATP_DEPENDENT_RNA_HELICASE_ACTIVITY
RNA_DEPENDENT_ATPASE_ACTIVITY
ATP_DEPENDENT_HELICASE_ACTIVITY
HELICASE_ACTIVITY
NUCLEOSIDE_TRIPHOSPHATASE_ACTIVITY
HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES
PYROPHOSPHATASE_ACTIVITY
ATPASE_ACTIVITY_COUPLED
ATPASE_ACTIVITY
REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPINDLE_CHECKPOINT_COMPONENTS
REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A
REACTOME_CONVERSION_FROM_APC_C_CDC20_TO_APC_C_CDH1_IN_LATE_ANAPHASE
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B
REACTOME_PHOSPHORYLATION_OF_THE_APC_C
INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT
REACTOME_COPI_MEDIATED_TRANSPORT
GTP_BINDING
GUANYL_NUCLEOTIDE_BINDING
REACTOME_DEADENYLATION_OF_MRNA
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY
MRNA_PROCESSING_GO_0006397
MRNA_METABOLIC_PROCESS
RNA_PROCESSING
RNA_SPLICING
RNA_BINDING
REACTOME_MRNA_SPLICING
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
REACTOME_MRNA_PROCESSING
PROTEIN_METABOLIC_PROCESS
CELLULAR_PROTEIN_METABOLIC_PROCESS
CELLULAR_MACROMOLECULE_METABOLIC_PROCESS
BIOSYNTHETIC_PROCESS
CELLULAR_BIOSYNTHETIC_PROCESS
MACROMOLECULE_BIOSYNTHETIC_PROCESS
TRANSLATION
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE
REACTOME_TRANSLATION
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX
STRUCTURAL_CONSTITUENT_OF_RIBOSOME
REACTOME_PEPTIDE_CHAIN_ELONGATION
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION
REACTOME_METABOLISM_OF_PROTEINS
REACTOME_INFLUENZA_LIFE_CYCLE
REACTOME_METABOLISM_OF_MRNA
REACTOME_METABOLISM_OF_RNA
TRANSLATION_INITIATION_FACTOR_ACTIVITY
TRANSLATION_REGULATOR_ACTIVITY
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY
PROTEIN_RNA_COMPLEX_ASSEMBLY
TRANSLATIONAL_INITIATION
REGULATION_OF_TRANSLATIONAL_INITIATION
REACTOME_RNA_POL_I_TRANSCRIPTION_TERMINATION
REACTOME_RNA_POL_I_TRANSCRIPTION_INITIATION
REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER
REACTOME_DNA_REPAIR
REACTOME_GLOBAL_GENOMIC_NER_GG_NER
REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER
REACTOME_NUCLEOTIDE_EXCISION_REPAIR
REACTOME_RNA_POL_III_TRANSCRIPTION
REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER
REACTOME_RNA_POL_III_TRANSCRIPTION_INITIATION_FROM_TYPE_2_PROMOTER
REACTOME_RNA_POL_III_TRANSCRIPTION_TERMINATION
REACTOME_RNA_POL_III_CHAIN_ELONGATION
REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AND_PROMOTER_OPENING
REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS
REACTOME_MRNA_CAPPING
REACTOME_FORMATION_OF_TRANSCRIPTION_COUPLED_NER_TC_NER_REPAIR_COMPLEX
REACTOME_VIRAL_MESSENGER_RNA_SYNTHESIS
REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX_
REACTOME_FORMATION_OF_THE_HIV1_EARLY_ELONGATION_COMPLEX
REACTOME_ELONGATION_ARREST_AND_RECOVERY
REACTOME_ABORTIVE_ELONGATION_OF_HIV1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT
STRUCTURAL_MOLECULE_ACTIVITY
Disease: aplastic anemia
Disease: bone marrow disease
Disease: Diamond−Blackfan anemia
Disease: congenital hypoplastic anemia
GOLGI_VESICLE_TRANSPORT
ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT
RIBONUCLEOPROTEIN_BINDING
Disease: mitochondrial metabolism disease
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_
REACTOME_MITOCHONDRIAL_TRNA_AMINOACYLATION
TRNA_METABOLIC_PROCESS
LIGASE_ACTIVITY_FORMING_CARBON_OXYGEN_BONDS
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION
REACTOME_TRNA_AMINOACYLATION
REACTOME_PERK_REGULATED_GENE_EXPRESSION
REACTOME_ACTIVATION_OF_GENES_BY_ATF4
REACTOME_DIABETES_PATHWAYS
REACTOME_UNFOLDED_PROTEIN_RESPONSE
REACTOME_DESTABILIZATION_OF_MRNA_BY_KSRP
REACTOME_MRNA_DECAY_BY_3_TO_5_EXORIBONUCLEASE
REACTOME_DESTABILIZATION_OF_MRNA_BY_BRF1
REACTOME_DESTABILIZATION_OF_MRNA_BY_TRISTETRAPROLIN_TTP
STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY
INTRACELLULAR_RECEPTOR_MEDIATED_SIGNALING_PATHWAY
GENERAL_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY
TRANSCRIPTION_INITIATION
TRANSCRIPTION_INITIATION_FROM_RNA_POLYMERASE_II_PROMOTER
RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY
TRANSCRIPTION_COACTIVATOR_ACTIVITY
TRANSCRIPTION_ACTIVATOR_ACTIVITY
REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS
REACTOME_SYNTHESIS_OF_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI
PROTEIN_AMINO_ACID_LIPIDATION
LIPOPROTEIN_METABOLIC_PROCESS
LIPOPROTEIN_BIOSYNTHETIC_PROCESS
TRICARBOXYLIC_ACID_CYCLE_INTERMEDIATE_METABOLIC_PROCESS
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE
ENERGY_DERIVATION_BY_OXIDATION_OF_ORGANIC_COMPOUNDS
AEROBIC_RESPIRATION
CELLULAR_RESPIRATION
COENZYME_BINDING
COFACTOR_BIOSYNTHETIC_PROCESS
HEME_BIOSYNTHETIC_PROCESS
HEME_METABOLIC_PROCESS
REACTOME_METABOLISM_OF_PORPHYRINS
Disease: porphyria
Disease: acute porphyria
PROTEIN_EXPORT_FROM_NUCLEUS
NUCLEAR_EXPORT
REACTOME_GLUCOSE_TRANSPORT
REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN
REACTOME_NEP_NS2_INTERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY
REACTOME_TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_THE_HOST_NUCLEUS
REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT
REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS
REACTOME_HIV_INFECTION
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES
REACTOME_HIV_LIFE_CYCLE
REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE
REACTOME_METABOLISM_OF_NON_CODING_RNA
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM
RNA_CATABOLIC_PROCESS
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_TRANSPORT
RNA_EXPORT_FROM_NUCLEUS
SMALL_GTPASE_BINDING
GTPASE_BINDING
GTPASE_REGULATOR_ACTIVITY
SMALL_GTPASE_REGULATOR_ACTIVITY
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE
REACTOME_SIGNALING_BY_INSULIN_RECEPTOR
REACTOME_REGULATION_OF_RHEB_GTPASE_ACTIVITY_BY_AMPK
REACTOME_REGULATION_OF_AMPK_ACTIVITY_VIA_LKB1
REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK
REGULATION_OF_GENE_EXPRESSION_EPIGENETIC
REACTOME_MICRORNA_MIRNA_BIOGENESIS
REACTOME_REGULATORY_RNA_PATHWAYS
LIGASE_ACTIVITY
SMALL_CONJUGATING_PROTEIN_LIGASE_ACTIVITY
SMALL_PROTEIN_CONJUGATING_ENZYME_ACTIVITY
UBIQUITIN_PROTEIN_LIGASE_ACTIVITY
ACID_AMINO_ACID_LIGASE_ACTIVITY
LIGASE_ACTIVITY_FORMING_CARBON_NITROGEN_BONDS
CELLULAR_CATABOLIC_PROCESS
CATABOLIC_PROCESS
CELLULAR_PROTEIN_CATABOLIC_PROCESS
PROTEIN_CATABOLIC_PROCESS
CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS
BIOPOLYMER_CATABOLIC_PROCESS
MACROMOLECULE_CATABOLIC_PROCESS
ENDOSOME_TRANSPORT
DNA_DIRECTED_DNA_POLYMERASE_ACTIVITY
NUCLEOTIDYLTRANSFERASE_ACTIVITY
DNA_POLYMERASE_ACTIVITY
OXIDOREDUCTASE_ACTIVITY_GO_0016706
LYASE_ACTIVITY
CARBON_CARBON_LYASE_ACTIVITY
REACTOME_GLYCOLYSIS
REACTOME_METABOLISM_OF_CARBOHYDRATES
REACTOME_GLUCONEOGENESIS
REACTOME_GLUCOSE_METABOLISM
CARBOHYDRATE_KINASE_ACTIVITY
GLUCOSE_METABOLIC_PROCESS
ALCOHOL_METABOLIC_PROCESS
ELECTRON_CARRIER_ACTIVITY
OXIDOREDUCTASE_ACTIVITY
GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY
Disease: disease of metabolism
Disease: inherited metabolic disorder
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC
REACTOME_ACTIVATION_OF_CHAPERONES_BY_ATF6_ALPHA
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_ATF6_ALPHA
REACTOME_SYNTHESIS_OF_SUBSTRATES_IN_N_GLYCAN_BIOSYTHESIS
REACTOME_BIOSYNTHESIS_OF_THE_N_GLYCAN_PRECURSOR_DOLICHOL_LIPID_LINKED_OLIGOSACCHARIDE_LLO_AND_TRANSFER_TO_A_NASCENT_PROTEIN
REACTOME_CALNEXIN_CALRETICULIN_CYCLE
REACTOME_N_GLYCAN_TRIMMING_IN_THE_ER_AND_CALNEXIN_CALRETICULIN_CYCLE
REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION
REACTOME_ASPARAGINE_N_LINKED_GLYCOSYLATION
PROTEIN_AMINO_ACID_N_LINKED_GLYCOSYLATION
GLYCOPROTEIN_METABOLIC_PROCESS
GLYCOPROTEIN_BIOSYNTHETIC_PROCESS
VIRAL_REPRODUCTIVE_PROCESS
VIRAL_REPRODUCTION
VIRAL_GENOME_REPLICATION
VIRAL_INFECTIOUS_CYCLE
INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY
ISOMERASE_ACTIVITY
REACTOME_ADVANCED_GLYCOSYLATION_ENDPRODUCT_RECEPTOR_SIGNALING
REACTOME_ERKS_ARE_INACTIVATED
REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION
REACTOME_ERK_MAPK_TARGETS
REACTOME_SPRY_REGULATION_OF_FGF_SIGNALING
REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING
REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING
REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS
REACTOME_CA_DEPENDENT_EVENTS
REACTOME_PLC_BETA_MEDIATED_EVENTS
Disease: immune system cancer
Disease: hematologic cancer
Disease: leukemia
Disease: myeloid leukemia
Disease: acute myeloid leukemia
REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING
REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING
REACTOME_FRS2_MEDIATED_CASCADE
REACTOME_SOS_MEDIATED_SIGNALLING
REACTOME_ARMS_MEDIATED_ACTIVATION
REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS
REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN
REACTOME_RAF_MAP_KINASE_CASCADE
REACTOME_SIGNALLING_TO_RAS
REACTOME_SIGNALLING_TO_ERKS
REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING
REACTOME_SHC_MEDIATED_SIGNALLING
REACTOME_SHC_RELATED_EVENTS
PharmGKB_PA2032_VEGF_Signaling_Pathway
PharmGKB_PA2023_ACE_Inhibitor_Pathway_Pharmacodynamics
PharmGKB_PA165110622_Agents_Acting_on_the_Renin−Angiotensin_System_Pathway_Pharmacodynamics
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Transcrip)on+Factor.Func)on+NetworkB
Pheno_leukocyte count
NR1I2
Pheno_liver cirrhosis, biliaryIRF8
Pheno_alzheimer disease
Pheno_diabetes mellitus, type 2
SOX4
PharmGKB_PA152530846_Proton_Pump_Inhibitor_Pathway_Pharmacokinetics 
PharmGKB_PA154424674_Clopidogrel_Pathway_Pharmacokinetics 
Pheno_amyotrophic lateral sclerosisPheno_calciumPheno_ovarian neoplasms
BARX1EHF
Pheno_lipoproteins
Pheno_stroke
NEUROD1 Pheno_c-reactive proteinPheno_adiponectin Pheno_blood flow velocity Pheno_prostatic neoplasmsPheno_sleep Pheno_smokingPheno_blood pressure determination Pheno_bipolar disorder Pheno_attention deficit and disruptive behavior disorders Pheno_mental competency
REACTOME_HS_GAG_DEGRADATION 
FOXP1
MZF1 TRIM28
GLI3
INSULIN_LIKE_GROWTH_FACTOR_RECEPTOR_BINDING 
REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING 
MECOM
Pheno_alkaline phosphatase
PAX3
Pheno_phosphorus
MAF
HISTONE_MODIFICATION
COVALENT_CHROMATIN_MODIFICATION 
Pheno_factor vii
NFYA
Pheno_diabetic nephropathies
VDR
Pheno_interleukin-6
Pheno_alcoholismPheno_attention deficit disorder with hyperactivity 
REACTOME_SIGNALING_BY_ERBB4 
FOXO1
P OTEOLYSIS
PAX1
ETS2
Pheno_respiratory function tests
PharmGKB_PA165292163_Doxorubicin_Pathway_(Cancer_Cell)_Pharmacodynamics 
KLF6
HOXA5
Pheno_creatininPheno_body weights and measures
PROTEIN_N_TERMINUS_BINDING
Pheno_arteries
REACTOME_CA_DEPENDENT_EVENTS 
NR4A2 SOX9 Pheno_glucosePheno_waist circumference
S_PHASE_OF_MITOTIC_CELL_CYCLE 
GLIS1TFAP2BMITF
GROWTH_FACTOR_ACTIVITY
ARNTL
SETDB1
RBPJ NR1H3HES1 MEF2CHOXB7 HNF1B ZFHX3
Pheno_heart failurePheno_electrocardiography EGR3FOXP2 UBP1 Pheno_platelet cou t P eno_basophils
ZBTB16 Pheno_intuitionZBTB10 NFATC2Pheno_forced expiratory volumePBX3
Pheno_waist-hip ratio Pheno_metabolismPheno_diabetes mellitusPheno_asthmaPheno_frontal lobe TAF7
REACTOME_PURINE_RIBONUCLEOSIDE_MONOPHOSPHATE_BIOSYNTHESIS MAPKKK_CASCADE_GO_0000165 REACT ME_METABOLISM_ F_PROTEINS REACTOME_N GATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK SKELETAL_D VEL PMENT CIRCADIA _RHYTHMPharmGKB_PA165816349_Methotrexate_Pathway_Pharmacokinetics STEROID_METABOLI _PROCESSREACTOME_PLC_BETA_MEDIATED_EVENTS 
Pheno_cardiomegaly Pheno_antidepressive agentsPheno_longevity Pheno_blood proteinsFOXD2Pheno_hypertensionAEBP2Pheno_albumins
Pheno_rhinitis, allergic, seasonal Pheno_goiterPheno_bone densityPheno_carcinoma, basal cell Pheno_insulin resistancePheno_brainPheno_macular degeneration Pheno_diabetic retinopathy Pheno_thyrotropin
Pheno_heart function tests
Pheno_iron
Pheno_body composition
Pheno_coronary artery disease
Pheno_pancreatic neoplasms Pheno_glomerular filtration ratePheno_inflammatory bowel diseases Pheno_lymphocytesPheno_hematocritPheno_endometrial n oplasmsPheno_potassiumPHOX2B Pheno_neutrophilsPheno_erythrocytes Pheno_menopausePheno_monocytesPheno_hypothyroidismPheno_tumor necrosis factor-alpha Pheno_occipital lobePheno_lipoproteins, hdl
SNAI2 Pheno_gamma-glutamyltransfera ePheno_socioeconomic factors Pheno_gamma glutamyltransferasePheno_body weightPOLR3G Pheno_erectile dysfunctionPheno_neuroblastomaPheno_coronary disease Pheno_insulinPheno_schizophrenia Pheno_sarcoma, ewingPheno_lipids
ATF6
BARX2
IRF4
REACTOME_PERK_REGULATED_GENE_EXPRESSION 
MBD2
Pheno_natriuretic peptide, brainPheno_atrial fibrillatio
THRB
Ph no_parkinson disease
REACTOM _ANDROGEN_BIOSYNTHESIS 
KLF3
Pheno_monocyte chemoattractant 
protein 1 (66-77) [supplementary 
concept] 
PRDM1 NKX2-2TBX3NFIL3
LIPID_TRANSPORTER_ACTIVITY Disease: cell type cancerDisease: lymphoma REACTOME_PYRIMIDINE_METABOLIS  CELL_CELL_SIGNALING REACT E_FACILITATIVE_NA_INDEPENDENT_GLUCOSE_TRANSPORTERS 
STAT4 MEF2APAX2RXRB POU3F2 NEUROG3
Disease: migraine SMALL_CONJUGATING_PROTEIN_SPECIFIC_PROTEASE_ACTIVITY RESPONSE_TO_BIOTIC_STIMULUSPOSITIVE_REGULATION_OF_CELL_PROLIFERATION RE CTOME_ACTIVATION_OF_IRF3_IRF7_MEDIATED_BY_TBK1_IKK_ P LON RE PONSE_TO_EXTERNAL_STIMU US REGU ATI _OF_ ELL CY LPHOX2A Pheno_hippocampusREACTOME_TRNA_AMINOACYLATION CREB3L4REGULATION_OF_CELL_PROLIFERATION Pheno_atrial natriuretic factorNITROGEN_COM OUND_BIOSY THETIC PROCESS 
TFCP2
HOXA1
REAC OME_ACTIVATION_OF_THE_AP1_FAMILY_OF_TRANSCRIPTION_FACTORS SYNAPTOGENESISTRNA_METAB LIC_PROCESS
RORA
CREM CTCF
RUNX2Pheno_fibrinogen NR5A2WRNIP1 Pheno_erythrocyte countZEB2
FOSBSTAT5BPharmGKB_PA2042_Sympathetic_Nerve_Pathway_(Neuroeffector_Junction) ATF4 ETV7 DBP RELB
GCPheno_heart ratePheno_elbowSNAI1Pheno_tunica mediaPheno_neoplasmsPheno_hemoglobin a, glycosylatedPheno_hemoglobins
STAG1TRANSCRIPTION_FROM_RNA_POLYMERASE_III_PROMOTER E2F5CCNT2MAZ
Pheno_esophagitis
Pheno_menarche
Disease: atypical teratoid rhabdoid 
tumor 
Pheno_lipid metabolism
LIGASE_ACTIVITY
TRANSFERASE_ACTIVITY_TRANSFERRING_GROUPS_OTHER_THAN_AMINO_ACYL_GROUPS 
Disease: androgen insensitivity 
syndrome 
Disease: corneal disease
Disease: Rubinstein-Taybi syndrome
Pheno_autoimmune diseases
Pheno_fuchs endothelial dystrophy
EZH2
Pheno_albuminuria
Disease: holoprosencephaly
REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT 
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS 
REACTOME_SIGNALING_BY_NODAL 
CEBPZ
NEGATIVE_REGULATION_OF_PHOSPHORYLATION 
CELL_CYCLE_GO_0007049
MAINTENANCE_OF_CELLULAR_LOCALIZATION CELLULAR_PROTEIN_CATABOLIC_PROCESS 
DEVELOPMENTAL_GROWTH
REACTOME_TRANSCRIPTI N
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_ 
MORPHOGENESIS_OF_AN_EPITHELIUM 
PCF11
Pheno_lung neoplasms
ZIC2
Disease: trilateral retinoblastoma
Pheno_esophageal neoplasms
MED1
Pheno_blood coagulation factors
Disease: neuroma
TRANSLATION_INITIA ION_FACTOR_ACTIVITY 
REACTOME_REGULATION_OF_INSULIN SECRE ION 
RESP NSE_T _LIGHT_STIMULUS
REACTOME_INTERACTIONS_OF_VPR_WITH_HOS _CELLULAR PR TEINS 
REACTOME_SIGNALING_BY_WNT
ANDROGEN_ ECEPTOR_SIGNALING_PATHWAY 
CELLULAR_COMPONENT_ASS MBLY REGULATION_OF_ORGANELLE_ORGANIZATION_AND_BIOGENESIS 
REACTOME_HOST_INTERACTION OF HIV_FACT R  
REACTOME_G1_S_TR NSITION
DRUG_BINDING
THYROID_HORMONE_RECEPTOR_BINDING 
CELLULAR_LOCALIZATI N
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX 
CELLULAR_RESPONSE_TO_S RESS 
Pheno_blood urea nitr g n
RNA_POLYMERASE_II_TRANSCRIPTION_MEDIATOR_ACTIVITY 
Disease: dysostosis
Pheno_lipoproteins, vldl
Disease: physical disorder
HYDROLASE_ACT VITY_ACTI G ON_CARBON_ ITROGEN_NO _PEPTIDEBONDSIN_LINEAR_AMID S 
Ph no_immunoglobulin e
Disease: retinal canc r
AC OME_NCAM_SIGNALING_FOR_N URITE_OUT_GROWTH 
REGULA ION_OF_CATABOLIC_PROCESS 
PROTEIN_AMINO_ACID_AUTOPHOSPHORYLATION 
MITOSIS
R ACTOME METABOLISM_OF_NON_CODING_RNA 
EACT ME_APC_C_ DH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C CDH1_TARG TED PROTEINS_I LATE_MITOSIS_EARLY_G1 
HYDROL SE_ACTIVITY_ACTING_ON_CARBON_NITROGEN_NOT_PEPTIDEBONDS 
Disease: nephroblastoma
Disease: stomach cancer
Pheno_pulse
Pheno_prostate-specific antigen
Disease: male reproductive system 
disease 
Pheno_sclerosis
LYL1DNA_BINDING PLAGL1 HORMONE_RECEPTOR_BINDINGCYTOKINE_ACTIVITYZNF395 DNA_METABOLIC_PROCESSREGULATION_OF_BIOLOGICAL_QUALITY 
SEXUAL_REPRODUCTION AMINO_ACID_METABOLIC_PROCESS EPITHELIAL_CELL_DIFFERENTIATION NEGATIVE_REGULATION_OF_ANGIOGENESIS REGULATION_OF_INTERFERON_GAMMA_BIOSYNTHETIC PROCESS TUBE_DEVELOPMENTMUSCLE_CELL_DIFFERENTIATIONRESPON E_TO_STER ID_HORMON _STIMULUS 
P SITIVE_REGULATION_OF_T ANSCRIPTION_FACTOR_ACTIVITY MEMBRANE_ORGANIZATION_AND_BIOGENESIS MAINTENANCE_OF_LOCALIZATIONP OTEIN_CATABOLIC_PROCESSEMBRYO_IMPLANTATIONVITAMIN_ TABOLIC P OCESS REGULATION_OF_ANGIOGENESISDEVELOPME _ F_PRIMARY_SEXUAL_CH R CTERISTICS 
DNA_MODIFICATION NEURON_DEVELOPMENTPOSITIVE_REGULATION_OF_ANGIOGENESIS NEURON_DIFFERE TIATINOTCH_SI NALING_PATHWAYREGULATION_OF_TRANSPOR NEGATIVE_REGULATION_OF_MYELOID_CELL_DIFFERENTIATION PERIPHERAL_NER OUS_SYSTEM_DEVELOPMENT 
REACTOME_IL_7_SIGNALINGREACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT REACTOME_CELL_CYCLEREACTOME_MEIOSISRE CTOM _ANTIGEN_PROCESSI G_CRO S_PRESENTATION REACTOME DAG_AND_IP3_SIGNALING REACTOME_ER_PHAGOSOME_PA HWAY HINFP
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 REACTOME_LIPOPRO EI METABOLISM REACTOME_ ITOTIC_PROMETA HASE REACTOME_IMMUNE_SYSTEMREACTOME_CHYLO ICRON_MEDIATED_LIPID_TRANSPOR  REACTOM _R GULATION_OF_GLUCOKINAS _BY_GLUCOKINASE_ EGULATO Y_PR T IN RE CTOME_APC_C CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_P OTEINS REACTOME AU ODEGRAD I N OF_ DH1_BY_CDH1_AP _C 
REAC OME_SYNTHESIS_SECRETION_AND_DEACYLATION_OF_GHRELIN REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 REACTOME_SEMAPHORIN_INTERACTIONS REACTOME_SYNTHESIS_OF_DNAREACTOME CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_O IGIN_C MPLEX REACTOME_MRNA 3_ ND P OC SSI G CTOME_UNFOLDED_PROT I E PON E REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING 
EGR4CASPASE_REGULATOR_ACTIVITY
ON_MEMBRANE_SPANNING_PROTEIN_TYROSINE_KINASE_ACTIVITY ZBTB33THRAVITAMIN_BINDINGRFX1 TRANSFERASE_ACTIVITY_TRANSFERRING_GLYCOSYL_GROUPS N_ACETYLTRAN FERASE_AC IVITY JUND
Pheno_eosinophils Pheno_varicose veinsPheno_apolipoproteins cPheno_mucocutaneous lymph node syndrome Pheno_sodiumPheno_phospholipidsP eno_body fat distribution
Pheno_maximal midexpiratory flow 
rate 
Pheno_death, sudden, cardiac Pheno_angiographyPheno_follicle stimulating hormonePheno_memory Pheno_marijuana abusePheno_supranuclear palsy, progressive Pheno_alcohol drinkingPheno_survival
Pheno_nonalcoholic fatty liver 
disease Pheno_crohn diseasePheno_antipsychotic agentsPheno_audiometry, pure-tone Pheno_cardiovascular diseasesP eno_tissue plasminogen a tivatorPheno_inflammation
Pheno_cystatinsPheno_subcutaneous fatPh no_lupus vulgaris Pheno_corneaPheno_leukemia, lymphocytic, chronic, b-cell Pheno_glucose tolerance test Pheno_adiposity
Pheno_sex hormone-binding 
globulin 
Disease: MHC class II deficiency
Pheno_polysaccharides
Dis ase: leukopenia
HOXA4
Disease: Cornelia de Lange 
syndrome 
HISTONE_DEACETYLASE_BINDING
Disease: papilloma
Disease: synostosis
Disease: corneal dystrophy
Disease: bone marrow cancerDisease: myxoid liposarcoma
Disease: gonadal disease
Disease: pancreatic carcinoma
Dise se: ocular cancerDiseas : osteochondrodysplasia Disease: iris disease
Disease: premature ovarian failureDisease: kidney disease
Disease: spinocerebellar 
degeneration Disease: motor neuron disease
D sease: lung small cell carcino Disease: eye disease
Disease: female reproductive 
system disease 
Pheno_insulin-like growth factor iPheno_retinal vein Pheno_melanosis
Disease: Chandler syndrome
Pheno_stevens-johnson syndrome
Disease: polydactylyDisease: ovarian diseaseDisease: urinary bladder cancerDisease: microphthalmiaDisease: Charcot-Marie-Tooth disease 
Pheno_eye color Pheno_suntanPheno_hair color
Disease: hypospadias
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 
Dis ase: congenital nervous system 
abnormality 
Disease: Fuchs' endothelial 
dystrophy 
Pheno_tyrosine
Disease: thyroid hormone resistance 
syndrome 
Disease: retinal disease
Disease: testicular d
Disease: hereditary breast ovarian 
cancer 
Pheno_citalopram
REACTOME_PHOSPHOLIPASE_C_MEDIATED_CASCADE REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE RE CTOME_POST_NMDA_RECEPTOR_ACTIVATION_EVENTS REACTOME_MYOGENESISREACTOME_MITOTIC M_M_G1_PHASES REACTOME_ACTIVA I N_OF_NMDA_RECEPTOR_UPON_GLUTAMATE_BINDING AN _POSTSYNAPTIC_E ENTS REACTOME_C E _PHOSPHORYLATI N_THROUGH_TH _AC IVATION_OF_RAS R ACT M _RNA_POL_I RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION RE ME_MIT TIC_G1_G1_S_PHASES 
REGULATION_OF_ACTION_POTENTIAL MACROMOLECULE_BIOSYNTHETIC_PROCESS M NO ACID_AND_DERIVATIVE_METABOLIC_PROCESS G1_PHASE_OF_MITOTIC_CELL_CY LE MRNA_PRO ESSING_GO_0006397MACROMOLECULE_CATABOLIC_PROCESS CELLULAR_PR T IN_METABOLIC_PROCESS BILE_ACID_METABOLI _PROCESS NEGATIVE_REGU ATION_OF_CELL_DIF ERENTIATION 
RESPONSE_TO_WOUNDINGNEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY TISSUE_REMODELINGCELLULAR_MACROMOLECULE_METABOLIC_PR CESS INNATE_IMMUNE_MRNA_METABOLIC_PROCESSNEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY ACUTE_INF AMMATORY_RESPONS  NEGATIVE REGULATION_OF_DEVELOPMENTAL_PROCESS 
VITAMIN_TRANSPORT REGULATION_OF_DEVELOPMENTAL_PROCESS PR TEIN_DNA_COMPLEX_ASSEMBLY C LL_CYCLE_PROCESS REGULATION_OF_GENE_SPECIFIC_TRANSCRIPTION POSITIVE_ EGULATION_OF_IMMUN _RESP E NEGATIVE_REGULATION_OF_CELLULAR_PR C SS POSITIVE_REGULATION_OF_TRANSPORT PHAGOCYTOSIS
REACTOME_SIGNALING_BY_EGFR_IN_CANCER REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR EACTOME_PPARA_ACTIVATES GENE_EXPR SSION REACTOM _ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_ ENES REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR REACTO E_SRP_DEPENDENT_COTRANSLATIONAL_P TEIN_TARGETING_TO_MEMBRA E REACTO E_P OLAC IN_REC PTOR_SIG ALING REACTO _ACTIV TION_OF_NF_KAPPA _IN_B_CELLS REACTOM _ORC1_REMOVAL_FROM_CHR ATIN 
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION REACTOME_IN GRATION_OF_PROVIRUS REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTAT O  REACTOME_NONSENSE_MEDIA ED_DECAY NHANCED_BY_THE_EXON_JUNCTI N_COMPLEX REACTOME_ MYLOIDSREAC O E_PACKA ING_OF_TELOMERE_ENDS RE CTOME_ADAPT VE_IMMUNE_SYSTEM REACTOME_ EIOTIC_SYN PSISRE CT ME_CYTOKINE_SIGNALING IN_IMMUNE_SYSTEM 
Pheno_colony-forming units assay
Disease: Li-Fraumeni syndrome
Disease: nonpapillary renal cell 
carcinoma 
Disease: spinal muscular atrophyDi ease: neurodegenerative disease
Pheno_leukemia, lymphoid
Disease: Frasier syndrome
Pheno_colorectal neoplasms
Disease: malignant glioma
Pheno_personality
RNA_POLYMERASE_ACTIVITYRNA_BINDING
ZNF384HOXB13
Disease: adrenal cortex cancerDis ase: mature B-cell neoplasm
BIOPOLYMER_CATABOLIC_PROCESS DNA_REPAIR
SMAD_BINDING
Di ease: coloboma of optic nerve
Disease: choroid plexus papilloma
Pheno_paralysis, hyperkalemic 
periodic 
Dise se: aortic valve disease
CDX1
MED12
Disease: overnutrition
Disease: aniridi
Disease: hyperimmunoglobulin 
syndrome 
SMARCC1
AXON_GUIDANCE
RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITYENHANCER_BINDING 
Disease: severe combined 
immunodeficiency 
Disease: kidney cancer
Disease: neutropenia
Pheno_alopecia
PROTEIN_AUTOPROCESSING
Dise se: sensory system disease
Disease: endocrine system disease
SPECIFIC_TRANSCRIP ONAL_REPRESSOR_A TIVITY 
Disease: coloboma
Disease: combined T cell and B cell 
immunodeficiency 
FOSL1 TRANSFERASE_ACTIVITY_TRANSFERRING_PENTOSYL_GROUPS SMC1APROTEIN_KINASE_BINDINGSTEROID_BINDINGHOXA7 SMC3AUXILIARY_TRANSPORT_PROTEIN_ACTIVITY LIGAND_GATED_CHANNEL_ACTIVITY 
ORGANELLE_ORGANIZATION_AND_BIOGENESIS REGIONALIZATION HOXA11GAMETE_GENERATIONPOSITIVE_REGULATION_OF_BINDING TRANSLATIONAL_INITIATI N ESTABLISHME T OF_C LLULAR_LOCALIZ TION HOXA10INDUCTION_OF_APOPTOSIS_BY_EXTRACELLULAR_SIGNALS 
REGULATION_OF_CELL_DIFFERENTIATION INTERLEUKIN_8_PRODUCTIONNEGATIVE_REGULATION_OF_DNA_BINDING PROTEIN_RNA_COMPLEX_ASSEMBLY POSITIVE_REGULATION OF_DEV LOPMENTAL_ ROCESS RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY MYELOID_LEUKOCYTE_DIFFERENTIATION ACTIVATION_OF_IMMUNE_RESPONSE NEGATIVE_REGULATION_OF_IN CELLU AR_TRA SPORT INTERLEUKIN_2_PRODUCTIONREGULATION_OF_CHROMOSOME_ RGANIZ IO AND_BIOGE ESIS REGULATION_OF_TRANSCRIPT ON_FACTOR_ACTIVITY 
STRIATED_MUSCLE_DEVELOPMENT BIOSYNTHETIC_PROCESSMACROMOLECULAR_COMPLEX_ASSEMBLY RESPONSE_TO_NUTRIERESPONSE_TO_ENDOGENOUS_STIMULUS PROGRAMMED_CELL_DEATHM_PHASEMYOBLAST_DIFFERENTIATIONINTRACELLULAR_T ANSPORT
BCLAF1 PROTEIN_DEACETYLASE_ACTIVITYNUCLEAR_HORMONE_RECEPTOR_BINDING NPATRECEPTOR_SIGNALING_PROTEIN_ACTIVITY STRUCTURAL_MOLECULE_ACTIVITY ZBTB7 DEACETYLASE_ACTIVITYI BINDING_BRIDGING
POSITIVE_REGULATION_OF_MAP_KINASE_ACTIVITY RHYTHMIC_PROCESSNITROGEN_ OMPOUND_METABOLIC_PROCESS HOXA9RESPONSE_TO_NUTRIENT_LEVELSCELLU AR C RBOHYDRATE_METABOLIC_P CESS 
REACTOME_LIPID_DIGESTION_MOBILIZATION_AND_TRANSPORT REACTOME_APOPTO IS REACTOME_HEMOSTASISREACTOME_E2F_MEDIATED_REGULATION_ F_DNA_RE LICA I  REACTOME_NEP_NS2_IN ERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY RE CTO _TR N PORT_OF_RIBONUCLEOPR TEINS_INTO_THE_HOST_NUCLEUS REACTOME_CLEAVAGE_OF_GROWING_TRANSCR P _IN THE_TERMI ATI N_REGI N_ REACTOME_EARLY P ASE_OF_ IV_LIFE_CYCLE REACTOME_DNA_ PLICATIONREACTOME_INTERFERON_GAMMA_SIGNALING REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET PRODUCTIO  REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 RE CTOME_INTERFER _ALPH _BETA_SIGNALING REACTOME MEIOTIC_ ECOMBINATI N AFG REACTOME_INTERFERO _SIGNALING REACTO E_SYNTHESIS_SECRETION_AND_INACTIVA ION_OF_GL 1 REACTOME_SYNTHESIS_S CRETI N_AND_INACTIVATIO _OF_GIP 
REACTOME_TRANSLATIONPOLR3DMAINTENANCE_OF_PROTEIN_LOCALIZATION POLR3GLM_PHASE_OF_MITOTIC_CELL_CYCLE CELLULAR_RESPONSE_T _NUTRIENT_LEVELS R SPONSE_TO_ORGANIC_SUBSTANCE ELL_FATE_ OMMITMENT
REACTOME_CELL_CYCLE_CHECKPOINTS 
APOPTOSIS_GONEGATIVE_REGULATION_OF_PHOSPHATE_METABOLIC PROCES  
REACTOME_DIABETES_PATHWAYS 
REGULATION_OF_IMMUNE_RESPONSE 
REACTOME_LOSS_OF_NLP_FROM_ ITOTIC_CENTROS S 
PROTEIN_METABOLIC_PROCESS IMMUNE_SYSTEM_PROCESSSKELETAL_MUSCLE_DEVELOPMENT PROTEIN_AMINO_ACID_ADP_RIBOSYLATION REGULATION_OF_ENDOCYTOSICELL_PROLIFERATION_GO_0008283 R GULATION_OF_INTRACELLULAR_TRANSPORT CELLUL R_MACROMOLECULE_CATABOLIC_PROCESS BONE_REM DELING
RESPONSE_TO_DNA_DAMAGE_STIMULUS REGULATION_OF_APOPTOSISINTERFERON_GAMMA_PRODUCTION REGULATION_OF_PROGRAMM D_CELL_DE TH YROSIN _P OSPHORYLATION_OF_STAT_PROTEIN NEG IVE REGULATION_OF_PROGRAMMED_CELL_D A H REGULATION_OF_IMMUNE_SYSTEM_PROCESS 
REACTOME_CELL_CYCLE_MITOTIC REACTO E_OPIOID_SIGNALLINGREACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY REACTOME_REGULATED_PROTEOLYSIS_ F_P75N R REACTOME_RNA_POL_I_TRANSCRIPTION R ACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES REACTOME_REGULATI N_OF RNITHINE_DECARBOXYLASE_ODC REACTOME_PROCESSING_OF_CAPPED_INTRONLESS_PRE_MRNA REACTOME_M_G1_TRANSITIONREACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_TRANSITION_ REACTOME_3_UTR_MEDIATED_TRAN LATI NAL_REGULATION REACTOME_P53 DEPENDENT_G1_DNA_DAMAGE_ SPONS  REACTOME_PKA_MEDIATED_PHOSPH RYLATION_OF_CREB REACTOME_G1_PHASEEAC OME_DOWNSTREAM SIGN L_TRANSD CTIO  
PROTEIN_HOMOOLIGOMERIZATION CARBOHYDRATE_METABOLIC_PROCESS G1_PHASEPO ITIVE_REGULATION_OF_BIOLOGICAL_P OCESS AMINE_METABOLI _PROCESS RE PONSE_TO_IONIZING_RADIATION NEUR GENESISCYTOKINE_AND_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY NEGATIVE_REGULATION_OF_BINDING 
ZNF250Pheno_depressive disorder, majorPheno_cytomegalovirus vaccinesPheno_breast neoplasms HOXD9Pheno_magnesium
NR5A1
Disease: sex differentiation disease
Disease: chromosomal disease
Disease: atrial heart septal d fect
Pheno_peroxidasePheno_intercellular adhesion molecule-1 Pheno_face
Pheno_carcinoma, non-small-cell 
lung 
Disease: bone development diseaseDisease: bone disease
Disease: malignant mesothelioma Disease: urinary system diseaseDisease: p ncreatic cancer
Pheno_urinary bladder neoplasms
Disease: myeloma
Disease: reproductive system 
disease Disease: eye and adnexa diseaseDisease: renal ag nesis
Disease: cell type benign neoplasmDisease: benign neoplasm Disease: organ system benign neoplasm 
Pheno_keratoconusPheno_clozapine Pheno_von willebrand factor Pheno_odontogenesisPheno_precursor cell lymphoblastic leukemia-lymphoma Pheno_bleomycin NCOA3
Disease: cancerDisease: integumentary system disease 
Disease: alveolar 
rhabdomyosarcoma 
Disease: aortic valv  st nosis
Disease: Kennedy's disea
Disease: musculoskeletal system 
disease 
Disease: nervous system benign 
neoplasm Disease: sensory system cancer
Disease: musculoskelet l syst m 
cancer 
PharmGKB_PA154426155_Taxane_Pathway_Pharmacokinetics PharmGKB_PA165948566_Metformin_Pathway_Ph rmacodynamic 
Disease: lipomatous cancerDisease: ad enocortical carcinoma
PharmGKB_PA2031_Statin_Pathway_Pharmacodynamics 
Dise se: adrenal gland cancer
KINASE_BINDINGLIPID_BINDING
Disease: skeletal muscle cancerDisease: urinary system cancer Diseas : muscle cancer
COPPER_ION_BINDINGTRANSFERASE_ACTIVITY_TRANSFERRING_ACYL_GROUPS SPECIFIC_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY 
Disease: heart valve disease Disease: renal cell carcinoma
CATION_BINDING ZNF148SIRT6 NR2F1
Disease: renal carcinomaDisease: hereditary renal cell carcinoma Disea : n uromuscular disease
Pheno_hair Pheno_graves diseasePheno_blood cellsPheno_obesityPheno_conduct disorderPheno_dermatitis, atopicPheno_cell adhesion molecules Pheno_hypertrophy, left ventricularPheno_resistinPheno_e-selectin Pheno_forced vital capacityPheno_kidney diseasesPheno_vitamin dPheno_ rythrocyte indices
Pheno_fibromyoma Pheno_restless legs syndromePheno_tuberculosisPheno_arthritis, psoriaticPheno_fetal hemoglobinPheno_carcinoma, renal c llPheno_depression Pheno_nevirapine
Disease: skin diseaseDis ase: nutrition diseaseDisease: central nervous system cancer Disease: uveal diseaseDisease: liposarcoma
Disease: X-linked disease
Disease: lung carcinomaDisease: Denys-Drash syndrome
Disease: Weaver syndrome
Disease: juvenile polyposis 
syndrome 
Disease: Greig 
cephalopolysyndactyly syndrome 
Disease: hermaphroditism
Disease: phaeochromocytoma
Disease: FG syndrome
Disease: leukocyte disease Disease: type 1 diabetes mellitus ELF2Disease: obesityDi : multiple myeloma PharmGKB_PA2024_Beta- gonist/Beta-blocker_Pathway_Pharmacodynamics Disease: brain diseaseDisease: Pallister-Hall syndrome
Disease: disease of cellular 
proliferation 
SMARCB1
Disease: branchiootorenal syndrome
Disease: organ system cancer
Disease: gonadal dysgenesisDisease: spinocerebellar ataxia Disease: 46 XY gonadal dysgenesis
ERBB2 Disease: branchiooculofacial syndrome 
Disease: Athabaskan brainstem 
dysgenesis syndrome 
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE 
REACTOME_S_PHASE REACTOME_APOPTOTIC_EXECUTION_PHASE 
REACTOME_ASSEMBLY_OF THE_PRE_REPLIC TIVE_COMPLEX R ACTOME_ SPIRATORY_ELECTRON_TRANSPORT 
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_P21 
REACTOME_SIGNALING_BY_ILS
REACTOME_VIF_MEDIATED_DEGRAD TI N_ F_APOBEC3G 
REACTOME_RNA_POL_I_PROMO ER_ PENING 
REACTOM _DNA_STRAND_ELONGATION 
REAC OME_FATTY ACID_TRIACYLGLY EROL_AND_K NE_B DY_METABOL S
NEGATIVE_REGULATION_OF_BIOLOGICAL_PROCESS POSITIVE_REGULATION_OF_DNA_BINDING 
ANTI_APOPTOSISDIGESTION
CARBOHYDRATE_BIOSYNTHETIC_PROCESS 
MAI ENANCE_OF_CELLULAR_PROTEIN_LOCALIZA IO  
INTERFERON_GAMMA_BIOSYNTHETIC_PROCESS REGULATION_OF_PROTEI _IMPORT_INTO_NUCLEUS 
PROTEIN_PROCESS GGENERATION_OF_A_SIGNAL_INVOLVED_IN_CELL_CELL_SIGNALING 
MITOTIC_CELL_CYCLE
EACTOME_APOPTOSIS_INDUCED_DNA_FRAGMENTATION 
DNA_REPLICATION
TELOMERIC_DNA_BINDING
REACT ME_CHR MOSOME_MAINTENANC  
REACTOME_G2_M_CH CKPOINT
MALE_GONAD_DEVELOPMENT
NEGATIVE_REGULATION_OF_APOPTOSIS 
REA TOME_CDK_MEDIATED_PHOSPHORYLATION_AND_REMOVAL_OF_CDC6 REACTOME_SIGNALING_BY_FGFR_MUTANTS REACTOME_TRANSPORT_OF_MATURE_TRANSCRI T_TO_CYTOPLASM REACTOME_ACTIVATI N OF_THE_MRNA UP BINDI G_OF_THE_CAP_BINDING COMPL X_AND_ IFS_AND_SUBSEQUENT_BINDING_TO 43S ACTOME_RESPONSE_TO_ELEVATED_PLATELET_CY SOLIC_CA2_ ZNF266
R GULATION_OF_PHOSPHORYLATION 
TRANSLATION
POSITIVE_REGULATION_OF_ LLULAR_COMPONENT_ORGANIZATION_AN _BIOGENESIS 
PROTEIN_TYROSINE_KINASE_ACTIVITY 
NEURITE_DEVELOPMENT
ACTIN_BINDINGACETYLTRANSFERASE_ACTIVITYZNF274 ION_BINDINGGLI1
N_ ERMINAL_PROTEIN_AMINO_ACID_MODIFICATION 
CELL_CYCLE_PHASEACTIVATION_OF_NF_KAPPAB_TRANSCRIPTION_FACTOR 
TUBE_MORPH GEN SISHORMONE_SECRETION NEGATIVE_REGULATION_OF_TRANSPORT FEMALE_PREGNA CY
CELLULAR_BIOSYNTHETIC_PROCESS MES DERM_DEVELOPMENTLIPID_METABOLIC_PROCES
Disease: neuropathy
Pheno_risperidone
Disease: Parkinson'  di a e
Disease: central nervous system 
disease 
Disease: ADULT syndrome
Pheno_aortaPheno_uric acid
Disease: Charcot-Marie-Tooth 
disease type 4 
Disease: Job's syndrome
Pheno_carotid arteries
Disease: cleidocranial dysplasia
Disease: Burkitt's lymphoma
Disease: Down syndrome
Pheno_life expectancy
Disease: piebaldism
Ph no_central nervous syst m
Disease: nervous system d
D sease: severe congenital 
neutropenia 
Pheno_alanine transaminas
Disease: Charcot-Marie-Tooth 
disease type 3 
Disease: rhabdomyosarcoma
Disease: lipodystrophy
Disease: visual pathway disease
Pheno_receptors, tumor necrosis 
factor, type ii 
CELL_DEVELOPMENT
Disease: campomelic dysplasia
Disease: neurilemmoma
Disease: agranulocytosis
Pheno_neurobehavioral 
manifestations 
N_ACYLTRANSFERAS _ACTIVITY
Disease: retinoblastoma
Pheno_respiration disorders
Disease: Charcot-Marie-Tooth 
disease type 1 
Disease: neurilemmom tosis
Disease: retinal cell cancer
Di ease: brain cancer
Ph no_perphenazi e
Pheno_cd40 ligand
REACT ME_TELOMERE_MAINTENANCE 
REACTOME_MITOTIC_G2_G2_M_PHAS S 
REACTOME_SIGNALING_BY_B P
POSITIVE_R GULATION_OF_CELLULAR_PROCESS 
CELLULA _ ORPHOGENESIS_DURING_DIFFERENTIATION 
EGULATION OF_MITOTIC_CELL_CYCLE 
DNA_D PENDENT_DNA_R PLICATION 
P53_INDEP NDENT_G1_S_DNA_DAM GE_CHECKPOINT 
HOMEOSTATIC_PROCESS
REAC OME_PLAT L T_ CTIVATION_SIGNALING_AND AGG GA ION 
RE CTOME_DNA_REPAI
GE ERATION_OF_NEUR NS
STEROID_HORMONE_RECEPTO _ACTIVITY 
P eno_temporal lobe
Pheno_ etabolic syndrome x
Disease: familial partial lipodystrophy
Disease: acroc phalosyndactyli
Disease: nervous system cancer
Disease: B-cell lymphocytic 
neoplasm 
TISSUE_MORPHOGEN SIS
REACTOME_GRB2_SOS_PROVIDES_LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS_ 
RXRA
BLOOD_COAGULATION
REACTOME_CELL_CELL_COMMUNICATION TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY 
NFIC
LIGAND_DEPENDENT_NUCLEAR_RECEPTOR_ACTIVITY REACTOME_TRANSPORT_OF_INORGANIC_CATIONS_ANIONS_AND_AMINO_ACIDS_OLIGOPEPTIDES 
REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS ANTIOXIDANT_ACTIVITY RESPONSE_TO_OXIDATIVE_STRES  
CEBPE
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PEROXIDE AS_ACCEPTOR 
LMO1
REA TOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS 
REACTO E_BILE_ACID_AND_BILE_SALT_METABOLISM 
NR1H4
REACTOME_DOWNREGULATION_OF_TGF_BETA_RECEPTOR_SIGNALING REAC ME_PI3K_EVENTS_IN_ERBB4_SIGNALING 
NEGATIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS REACTOME_SMAD2_SMAD3_SMAD4_HETEROTRIMER_REGULATES_TRANSCRIPTION 
CH PERONE_BINDING
REACTOME_CELL_CELL_JUNCTION_ORGANIZATION 
ZZZ3
REACTOME_TRANSCRIPTIONAL_ACTIVITY_OF_SMAD2_SMAD3_SMAD4_HETEROTRIMER 
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS REACTOME_G0_AND_EARLY_G1
ESP RATORY_GASEOUS_EXCHANGE 
MYBL2
REACTOME_CELL_JUNCTION_ORGANIZATION 
OXYGEN_AND_REACTIVE_OXYGEN_SPECIES_METABOLIC_P OCESS 
CEBPD
TFAP2C
REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY 
ZNF84
INTRAMOLECULAR_OXIDOREDUCTASE_ACTIVITY 
TCF4ZNF706
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING ISOMERASE_ACTIVITY
Disease: liver carcinoma
CHROMATIN_MODIFICATION
PAX5
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING 
SMAD7
Disease: liver cancer
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS 
REACTOME_REGULATION_OF_IFNG_SIGNALING 
REACTOME_SEMA3A_PAK_DEPENDENT_AXON_REPULSION REACTOME_ION_CHANNEL_T ANSP RT 
PPARGC1ASMAD3
RE CTOM _TGF_BE A_RECEPTOR_S G ALING_ACTIVATES_SMADS 
SP4
PROTEIN_AMINO_ACID_DEPHOSPHORYLATION Disease: hepatocellular carcinoma NTRACELLULAR_RECEPTOR_MEDIATED_SIGNALING_PATHWAY ENDOPEPTIDASE_ACTIVITY REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSI  
MONOVALENT_INORGANIC_CATION_HOMEOSTASIS REGULATION_OF_CELLULAR_PHNUCLEOTIDYLTRANSFERASE_ACTIVITY Disease: papillary thyroid carcinoma
Disease: Alzheimer's disease
PharmGKB_PA164713427_Imatinib_Pathway_Pharmacokinetics/Pharmacodynamics 
ATF2
XRCC4
REACTOME_STEROID_HORMONES
RDBP
REACTOME_REGULATION_O _INSULI _LIKE_GROWTH_FACTOR_IGF_ACTIVITY_BY_INSULIN_LIKE_GROWTH_FACTOR_BINDING_PROTEINS_IGFBPS 
STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY DEPHOSPHORYLATION
CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY 
AR
CATABOLIC_PROCESS
REACTOME_TETRAHYDROBIOPTERIN_BH4_SYNTHESIS_RECYCLING_SALVAGE_AND_REGULATION 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING 
BRF2
Disease: dementia
REACTOME_CREB_PHOSPHORYLATION_THROUGH_THE_ACTIVATION_OF_CAMKII 
TISSUE_DEVELOPMENT BRF1
EPIDERMIS_DEVELOPMENT Disease: tauopathy
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE 
REACTOME_SIGNALING_BY_SCF_KIT 
ZEB1
REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE 
Disease: Bardet-Biedl syndrome TRANSCRIPTION_COFACTOR_ACTIVITY 
ZBTB7B
Disease: autosomal recessive 
disease 
RFX2
REACTOME_NUCLEAR_SIGNALING_BY_ERBB4 LYMPHOCYTE_DIFFERENTIATION
NFAT5
CELLULAR_RESPONSE_TO_EXTRACELLULAR_STIMULUS 
RESPONSE_TO_HYPOXIA
CELLULAR_CATABOLIC_PROCESS
ZNF236
ECTODERM_DEVELOPMENTREACTOME_IONOTROPIC_ACTIVITY_OF_KAINATE_RECEPTORS 
TRANSCRIPTION_COREPRESSOR_ACTIVITY 
TFAP2A
PROTEIN_OLIGOMERIZATIONFOCAL_ADHESION_FORMATION
SMAD4
REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION 
REACTOME_ RANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION 
ESR2IRF2
CYSTEINE_TYPE_PEPTIDASE_ACTIVITY EPITHELIAL_TO_MESENCHYMAL_TRANSITION 
TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY 
Disease: diabetes mellitus
Disease: carbohydrate metabolism 
disease 
GFI1
REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_BETA_CELLS 
PharmGKB_PA153627758_Anti-diabetic_Drug_Potassium_Channel_Inhibitors_Pathway_Pharmacodynamics 
PROTEIN_EXPORT_FROM_NUCLEUS 
HEME_BIOSYNTHETIC_PROCESS
Disease: porphyria
GATA1
Disease: hematopoietic system 
disease REACTOME_METABOLISM_OF_PORPHYRINS 
REACTOME_REGULATION_OF_AMPK_ACTIVITY_VIA_LKB1 Disease: acute porphyria
HEME_METABOLIC_PROCESS
CELLULAR_HOMEOSTASIS
ION_HOMEOSTASIS
REACTOME_MRNA_PROCESSING
REACTOME_HIV_INFECTION
REACTOME_INFLUENZA_LIFE_CYCLE 
REACTOME_PEPTIDE_CHAIN_ELONGATION 
POLR2A
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION 
REACTOME_MRNA_SPLICING_MINOR_PATHWAY 
REACTOME_HIV_LIFE_CYCLE
REACTOME_MRNA_SPLICING
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA REACTOME_L TE_PHASE_OF_HIV_LIFE_CYCLE 
REACTOME_RNA_POL_II_TRANSCRIPTION 
DAMAGED_DNA_BINDING
PURINE_RIBONUCLEOTIDE_BINDING 
NUCLEOTIDE_BIOSYNTHETIC_PROCESS 
ADENYL_RIBONUCLEOTIDE_BINDING 
NUCLEOTIDE_METABOLIC_PROCESS 
E2F1
PharmGKB_PA165291575_Antimetabolite_Pathway_-_Folate_Cycle_Pharmacodynamics 
REACTOME_DCC_MEDIATED_ATTRACTIVE_SIGNALING 
PharmGKB_PA145011118_Estrogen_Metabolism_Pathway 
GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY 
KLF11
REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT 
PDX1
Disease: maturity-onset diabetes of 
the young Disease: glucose metabolism 
disease 
Disease: type 2 diabetes mellitusNUCLEOTIDE_BINDING
PURINE_NUCLEOTIDE_BINDING
REACTOME_METABOLISM_OF_NUCLEOTIDES 
PharmGKB_PA2040_Thiopurine_Pathway_Pharmacokinetics/Pharmacodynamics 
ADENYL_NUCLEOTIDE_BINDING
REACTOME_INHIBITION_OF_REPLICATION_INITIATION_OF_DAMAGED_DNA_BY_RB1_E2F1 
REACTOME_REGULATION_OF_COMPLEMENT_CASCADE 
REACTOME_COMPLEMENT_CASCADE 
REACTOME_COMMON_PATHWAY
PharmGKB_PA165817070_Carbamazepine_Pathway_Pharmacokinetics 
FOXA1
FOXA2
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_TRIC 
PharmGKB_PA2027_Glucocorticoid_Pathway_(Peripheral_Tissue)_Pharmacodynamics 
REACTOME_PROTEIN_FOLDING
UNFOLDED_PROTEIN_BINDING
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC 
HSF1
PROTEIN_FOLDING
CELLULAR_CATION_HOMEOSTASIS 
CELLULAR_MONOVALENT_INORGANIC_CATION_HOMEOSTASIS ACTIN_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 
MYBL1
CHROMATIN_REMODELINGREGULATION_OF_PH
CBFB
REGULATION_OF_TRANSLATION
COFACTOR_METABOLIC_PROCESS 
NFE2L2
COENZYME_BIOSYNTHETIC_PROCESS 
COFACTOR_BIOSYNTHETIC_PROCESS 
B_CELL_ACTIVATION
ELECTRON_CARRIER_ACTIVITY
REACTOME_SYNTHESIS_AND_INTER ONVERSION_OF_NUCLEOTIDE_DI_AND_TRIPHOSPHATES 
REGULATION_OF_DNA_METABOLIC_PROCESS CEBPG
COENZYME_BINDING REGULATION_OF_RESPONSE_TO_STIMULUS 
REACTOME_GLUTATHIONE_CONJUGATION 
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES 
PREB
B_CELL_DIFFERENTIATION
POSITIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 
GLUCOSE_METABOLIC_PROCESS
DAND5
HIF1A
REACTOME_GLUCONEOGENESIS
REACTOME_CHOLESTEROL_BIOSYNTHESIS 
REACTOME_REGULATION_OF_HYPOXIA_INDUCIBLE_FACTOR_HIF_BY_OXYGEN 
NFIARESPONSE_TO_EXTRACELLULAR_STIMULUS 
GLI2
REACTOME_CYTOSOLIC_SULFONATION_OF_SMALL_MOLECULES 
MAFFMAFK
REACTOME_PHASE_II_CONJUGATION 
PROTEIN_POLYMERIZATION
TCF12
MAGNESIUM_ION_BINDING
TRANSCRIPTION_REPRESSOR_ACTIVI Y 
PharmGKB_PA145011114_Warfarin_Pathway_Pharmacodynamics REACTOME ASSOCIATION_OF TRIC_CCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS 
SMARCC2CARBON_CARBON_LYASE_ACTIVITY 
HORMONE_METAB LIC_PR CESS
CARBOHYDRATE_KINASE_ACTIVITY 
HOXA6
INDUCTION_OF_APOPTOSIS_BY_INTRACELLULAR_SIGNALS NFYC
CELLULAR_RESPONSE_TO_STIMULUS 
REACTOME_RECYCLING_PATHWAY_OF_L1 REACTOME_METABOLISM_OF_CARBOHYDRATES 
REACTOME_GLYCOLYSIS
FATTY_ACID_METABOLIC_PROCESS 
LIPID_CATABOLIC_PROCESS
CELLULAR_LIPID_CATABOLIC_PROCESS 
NR2F2
LIPID_TRANSPORT
PPARD
MONOCARBOXYLIC_ACID_METABOLIC_PROCESS 
FATTY_ACID_BETA_OXIDATION
PPARA
SYSTEM_PROCESS
REST
SYNAPTIC_TRANSMISSIONPharmGKB_PA2030_Sympathetic_Nerve_Pathway_(Pre-_and_Post-_Ganglionic_Junction) 
PharmGKB_PA162355621_Nicotine_Pathway_(Dopaminergic_Neuron)_Pharmacodynamics 
REACTOME_LIGAND_GATED_ION_CHANNEL_TRANSPORT 
REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS 
REACTOME_CLASS_C_3_METABOTROPIC_GLUTAMATE_PHEROMONE_RECEPTORS G_PROT IN_C UPLED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 
NEUROLOGICAL_SYSTEM_PROCESS 
REACTOME_NEURONAL_SYSTEM
TRANSMISSION_OF_NERVE_IMPULSE 
REACTOME_VOLTAGE_GATED_POTASSIUM_CHANNELS 
SREBF2REACTOME_POTASSIUM_CHANNELS NEUROPEPTIDE_HORMONE_ACTIVITY 
REACTOME_TRIGLYCERIDE_BIOSYNTHESIS 
PharmGKB_PA154423660_Bisphosphonate_Pathway_Pharmacodynamics 
REACTOME_FATTY_ACYL_COA_BIOSYNTHESIS 
LIPID_BIOSYNTHETIC_PROCESS
LIPOPROTEIN_METABOLIC_PROCESS 
CELLULAR_LIPID_METABOLIC_PROCESS 
SREBF1
LIPID_HOMEOSTASIS
STEROID_BIOSYNTHETIC_PROCESS 
Pheno_lipoproteins, ldl
ALCOHOL_METABOLIC_PROCESS
HNF4G
REGULATION_OF_PROTEIN_SECRETION 
FATTY_ACID_OXIDATIONTRIACYLGLYCEROL_METABOLIC_PROCESS REACTOME_ALPHA_LINOLENIC_ACID_ALA_METABOLISM 
CDC42_PROTEIN_SIGNAL_TRANSDUCTION 
POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 
REACTOME_HDL_MEDIATED_LIPID_TRANSPORT 
SP1
PROTEIN_IMPORT_INTO_NUCLEUS
REACTOME_GAMMA_CARBOXYLATION_TRANSPORT_AND_AMINO_TERMINAL_CLEAVAGE_OF_PROTEINS 
MONOOXYGENASE_ACTIVITY
PharmGKB_PA150981002_Vinka_Alkaloid_Pathway_Pharmacokinetics 
PROTEIN_IMPORT_INTO_NUCLEUS_TRANSLOCATION 
SP3
REACTOME_ENDOGENOUS_STEROLS 
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL 
VIRAL_REPRODUCTION
YBX1
REACTOME_BASE_EXCISION_REPAIR 
RESPONSE_TO_DRUG
SATB1
PharmGKB_PA154426903_Erlotinib_Pathway_Pharmacokinetics 
GTPASE_BINDING
REACTOME_VITAMIN_B5_PANTOTHENATE_METABOLISM 
REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS 
INSULIN_RECEPTOR_SIGNALING_PATHWAY 
SECRETION
ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 
REACTOME_PEPTIDE_HORMONE_BIOSYNTHESIS 
REACTOME_CIRCADIAN_REPRESSION_OF_EXPRESSION_BY_REV_ERBA 
GATA3
REACTOME_SIGNALING_BY_NOTCH 
REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION 
RESPONSE_TO_HORMONE_STIMULUS 
RARB
OXIDOREDUCTASE_ACTIVITY_GO_0016705 OXIDOREDUCTASE_ACTIVITY_GO_0016706 
REACTOME_GAB1_SIGNALOSOME
REACTOME_RORA_ACTIVATES_CIRCADIAN_EXPRESSION 
REACT ME_VEGF_LIGAND_RECEPTOR_INTERACTIONS 
EPAS1
RARGREACTOME_GLUCOSE_METABOLISM 
REACTOME_RETROGRADE_NEUROTROPHIN_SIGNALLING 
SIX5
NEGATIVE_REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS 
BCOR
NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 
FEV
REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY 
REACTOME_N_GLYCAN_ANTENNAE_ELONGATION_IN_THE_ DIAL_TRANS_GOLGI 
REACTOME_NEPHRIN_INTERACTIONS 
Disease: genetic disease
Disease: colonic disease
Disease: autosomal dominant 
disease 
Disease: autosomal genetic disease
Disease: Waardenburg's syndrome
SOX10
Disease: megacolon
Disease: monogenic disease
Disease: Hirschsprung's disease
FOS
VIRAL_REPRODUCTIVE_PROCESS
SMALL_GTPASE_BINDING
PharmGKB_PA150642262_Platinum_Pathway_Pharmacokinetics/Pharmacodynamics 
STRUCTURE_SPECIFIC_DNA_BINDING 
UBTF
REGULATION_OF_NUCLEOCYTOPLASMIC_TRANSPORT 
CYTOSKELETAL_PROTEIN_BINDING 
REACTOME_SYNTHESIS_OF_PIPS_AT_THE_PLASMA_MEMBRANE 
REACTOME_TGF_BETA_RECEPTOR_SIGNALING_IN_EMT_EPITHELIAL_TO_MESENCHYMAL_TRANSITION 
POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION 
REACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS 
FLI1
PROTEIN_HOMODIMERIZATION_ACTIVITY 
PEPTIDYL_AMINO_ACID_MODIFICATION 
REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE 
REACTOME_R GULATION_OF_RHEB_GTPASE_ACTIVITY_BY_AMPK 
G1_S_TRANSITION_OF_MITOTIC_CELL_CYCLE PROTEIN_KINASE_REGULATOR_ACTIVITY 
KINASE_INHIBITOR_ACTIVITY
REGULATION_OF_GROWTH
Disease: MHC class I deficiency ENZYME_INHIBITOR_ACTIVITY
IRF1
PHOSPHOTRANSFERASE_ACTIVITY_ALCOHOL_GROUP_AS_ACCEPTOR 
PROTEIN_AMINO_ACID_PHOSPHORYLATION 
PHOSPHORYLATION
REACTOME_SIGNALING_BY_HIPPO 
REACTOME_PHOSPHOLIPID_METAB LISM 
REGULATION_OF_SIGNAL_TRANSDUCTION 
PROTEIN_KINASE_CASCADE
POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 
PROTEIN_SERINE_THREONINE_KINASE_ACTIVITY REACTOME_PI_METABOLISM
PROTEIN_KINASE_ACTIVITY
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE 
REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 
REACTOME_CD28_DEPENDENT_VAV1_PATHWAY 
I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 
NUCLEOBASENUCLEOSIDE_AND_NUCLEOTIDE_METABOLIC_PROCESS 
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 
REACTOME_IL1_SIGNALING
PURINE_NUCLEOTIDE_METABOLIC_PROCESS 
REACTOME_ACTIVATED_NOTCH1_TRANSMITS_SIGNAL_TO_THE_NUCLEUS 
REACTOME_THE_ROLE_OF_NEF_IN_HIV1_REPLICATION_AND_DISEASE_PATHOGENESIS 
INTERPHASE_OF_MITOTIC_CELL_CYCLE 
INTERPHASE
KLF4
POSITIVE_REGULATION_OF_CELL_CYCLE 
G2_M_TRANSITION_OF_MITOTIC_CELL_CYCLE 
NF_KAPPAB_BINDING
PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS 
TAL1
Disease: myeloid leukemia
Disease: hematologic cancer
ERG
GATA2
MRNA_BINDING
Disease: acute myeloid leukemia
REACTOME_SIGNALING_BY_FGFR1_MUTANTS 
PROTEIN_UBIQUITINATION
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR 
REACTOME_SULFUR_AMINO_ACID_METABOLISM 
PROTEIN_METHYLTRANSFERASE_ACTIVITY 
REACTOME_NFKB_IS_ACTIVATED_AND_SIGNALS_SURVIVAL 
RIBONUCLEOTIDE_METABOLIC_PROCESS 
KINASE_ACTIVITY
REACTOME_TRAF6_ EDIATED_INDUCTION_OF_NFKB_AND_MAP_KINASES_UPON_TLR7_8_OR_9_ACTIVATION 
REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS 
SMALL_GTPASE_REGULATOR_ACTIVITY 
GTPASE_REGULATOR_ACTIVITY
SPI1
REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1 
REACTOME_MYD88_MAL_CASCADE_INITIATED_ON_PLASMA_MEMBRANE 
REGULATION_OF_CELL_GROWTH
KINASE_REGULATOR_ACTIVITY
FOXO4
MEOX2
GROWTH
PROTEIN_KINASE_INHIBITOR_ACTIVITY 
NEGATIVE_REGULATION_OF_GROWTH 
Disease: leukemia
PROTEIN_MODIFICATION_PROCESS 
LIGASE_ACTIVITY_FORMING_CARBON_NITR G N_BONDS 
BIOPOLYMER_MODIFICATION
ACID_AMINO_ACID_LIGASE_ACTIVITY 
SMALL_CONJUGATING_PROTEIN_LIGASE_ACTIVITY 
REACTOME_SIGNALLING_BY_NGF
POST_TRANSLATIONAL_PROTEIN_MODIFICATION 
UBIQUITIN_PROTEIN_LIGASE_ACTIVITY 
REACTOME_MEMBRANE_BINDING_AND_TARGETTING_OF_GAG_PROTEINS 
FOSL2
REACTOME_CIRCADIAN_CLOCK
BHLHE40
REACTOME_COPI_MEDIATED_TRANSPORT 
CLOCKPOSITIVE_REGULATION_OF_CELL_MIGRATION 
REGULATION_OF_CELL_MIGRATION CALCIUM_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_EXPRESSION 
MYOD1
Disease: cardiovascular system 
disease 
Disease: intrinsic cardiomyopathy
Disease: dilated cardiomyopathy
Disease: heart disease
STRUCTURAL_CONSTITUENT_OF_MUSCLE 
Disease: cardiomyopathy
STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON 
REACTOME_STRIATED_MUSCLE_CONTRACTION 
REGULATION_OF_HEART_CONTRACTION 
HMGN3
ESTABLISHMENT_OF_VESICLE_LOCALIZATION REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS 
TRANSITION_METAL_ION_BINDING
HDAC2
BDP1
VESICLE_LOCALIZATION
REACTOME_METABOLISM_OF_MRNA 
ZNF281
REACTOME_METABOLISM_OF_RNA 
INTERACTION_WITH_HOST
ACTIN_FILAMENT_BASED_MOVEMENT 
RARA
ANATOMICAL_STRUCTURE_FORMATION 
PharmGKB_PA145011120_Aromatase_Inhibitor_Pathway_(Breast_Cell)_Pharmacodynamics 
CYT KELETON_DEPENDENT_INTRACELLULAR_TRANSPORT 
HEART_DEVELOPMENT
ACTIN_FILAMENT_BASED_PROCESS 
TEF
POSITIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS 
REACTOME_PECAM1_INTERACTIONS 
ANGIOGENESIS
Disease: agammaglobulinemia
POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 
HUMORAL_IMMUNE_RESPONSE
Disease: cognitive disorder
CELLULAR_DEFENSE_RESPONSE
Disease: blood protein disease
REGULATION_OF_MAP_KINASE_ACTIVITY 
Disease: B cell deficiency
EBF1
VASCULATURE_DEVELOPMENT
ATP_BINDING
REACTOME_FORMATION_OF_ATP_BY_CHEMIOSMOTIC_COUPLING REACTOME_ACTIVATION_OF_GENES_BY_ATF4 
CTCFL
GATA6
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE 
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 
JNK_CASCADE
STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_PATHWAY 
DDIT3
REACTOME_MUSCLE_CONTRACTION 
PEROXISOME_ORGANIZATION_AND_BIOGENESIS 
SRF
NEGATIVE_REGULATION_OF_TRANSCRIPTION_FACTOR_ACTIVITY 
REACTOME_RAF_MAP_KINASE_CASCADE REACTOME_OXYG N_DEPENDENT_PROLINE_HYDROXYLATION_OF_HYPOXIA_INDUCIBLE_FACTOR_ALPHA 
REACTOME_SMOOTH_MUSCLE_CONTRACTION 
ARNT
Pheno_multiple sclerosis
REACTOME_PD1_SIGNALING
REACTOME_TCR_SIGNALING
Pheno_hepatitis b, chronic
Pheno_lupus erythematosus, 
systemic 
Pheno_scleroderma, systemic
PharmGKB_PA146123006_Codeine_and_Morphine_Pathway_Pharmacokinetics 
Pheno_anemia, sickle cell
PharmGKB_PA165959537_Sorafenib_Pharmacokinetics PharmGKB_PA165946349_Tramadol_Pharmacokinetics 
PharmGKB_PA2011_Nicotine_Pathw y_Pharmacokinetics 
PharmGKB_PA164713428_Losartan_Pathway_Pharmacokinetics 
Disease: acquired metabolic disease
PharmGKB_PA165111375_Benzodiazepine_Pathway_Pharmacokinetics 
Pheno_dna
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS 
PharmGKB_PA165964832_Mycophenolic_acid_Pathway_Pharmacokinetics 
PharmGKB_PA2001_Irinotecan_Pathway_Pharmacokinetics 
HNF1A
PharmGKB_PA145011119_Tamoxifen_Pathway_Pharmacokinetics 
RESPONSE_TO_XENOBIOTIC_STIMULUS 
PharmGKB_PA165378192_Artemisinin_and_Derivatives_Pathway_Pharmacokinetics 
PharmGKB_PA165964265_Valproic_Acid_Pathway_Pharmacokinetics 
XENOBIOTIC_METABOLIC_PROCESS PharmGKB_PA2029_Irinotecan_Pathway_Pharmacodynamic  
REACTOME_GLUCURONIDATION
Pheno_bilirubin
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS 
TRANSCRIPTION
REGULATION_OF_TRANSCRIPTIONREGULATION_OF_RNA_METABOLIC_PROCESS 
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT 
RNA_BIOSYNTHETIC_PROCESS
NEGATIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS 
HOXA2
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT 
TRANSCRIPTION_COACTIVATOR_ACTIVITY 
LMO2
REACTOME_PLATELET_CALCIUM_HOMEOSTASIS 
ELF5
TRANSCRIPTION_ACTIVATOR_ACTIVITY ATOH1
REGULATION_OF_GENE_EXP SSION 
NEGATIVE_REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 
BIOPOLYMER_METABOLIC_PROCESS 
REGULATION_OF_METABOLIC_PROCESS 
GFI1B
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER 
TRANSCRIPTION_DNA_DEPENDENT 
RNA_METABOLIC_PROCESS
REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 
PharmGKB_PA165110622_Agents_Acting_on_the_Renin-Angiotensin_System_Pathway_Pharmacodynamics 
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION 
MYELOID_CELL_DIFFERENTIATION
RNA_SPLICING
GMEB1
RNA_PROCESSING
AEROBIC_RESPIRATION
CELLULAR_RESPIRATION
REACTOME_PEROXISOMAL_LIPID_METABOLISM 
ENERGY_DERIVATION_BY_OXIDATION_OF_ORGANIC_COMPOUNDS 
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE 
ESRRA
PharmGKB_PA2023_ACE_Inhibitor_Pathway_Pharmacodynamics 
REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX 
PharmGKB_PA152241951_Celecoxib_Pathway_Pharmacodynamics 
ETV4
METALLOPEPTIDASE_ACTIVITY
Disease: essential hypertension
METALLOENDOPEPTIDASE_ACTIVITY 
REACTOME_SIGNALING_BY_RHO_GTPASES 
PharmGKB_PA145011111_Fluvastatin_Pathway_Pharmacokinetics 
CUX1
PharmGKB_PA145011115_Phenytoin_Pathway_Pharmacokinetics 
PharmGKB_PA145011108_Statin_Pathway_-_Generalized_Pharmacokinetics 
PharmGKB_PA145011109_Atorvastatin/Lovastatin/Simvastatin_Pathway_Pharmacokinetics 
NR1I3
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION 
REACTOME_KINESINS
CARBOXYLIC_ACID_METABOLIC_PROCESS 
TRICARBOXYLIC_ACID_CYCLE_INTERMEDIATE_METABOLIC_PROCESS 
ORGANIC_ACID_METABOLIC_PROCESS 
COENZYME_METABOLIC_PROCESS 
PPARG
REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS 
NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION_AND_BIOGENESIS 
REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS 
REACTOME_XENOBIOTICS
OXYGEN_BINDING
REACTOME_BIOLOGICAL_OXIDATIONS 
PharmGKB_PA165815256_Amodiaquine_Pathway_Pharmacokinetics 
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE 
Pheno_coffee
AHR
Pheno_caffeine
PharmGKB_PA145011113_Warfarin_Pathway_Pharmacokinetics 
RELA
SMAD2
ENZYME_ACTIVATOR_ACTIVITY
REACTOME_TAK1_ACTIVATES_NFKB_BY_PHOSPHORYLATION_AND_ACTIV TION_OF_IKKS_COMPLEX 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_ATF6_ALPHA 
ZNF12
HISTONE_ACETYLTRANSFERASE_ACTIVITY 
REACTOME_ACTIVATION_OF_CHAPERONES_BY_ATF6_ALPHA 
RBCK1
REACTOME_TRANSLOCATION_OF_ZAP_70_TO_IMMUNOLOGICAL_SYNAPSE 
CHEMICAL_HOMEOSTASIS
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY 
POLR3A
ATPASE_ACTIVITY_COUPLED
ATF1
NEGATIVE_REGULATION_OF_CELLULAR_BIOSYNTHETIC_PROCESS 
CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 
NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PR CESS 
RESPONSE_TO_VIRUS
MUSCLE_DEVELOPMENT
REGULATION_OF_BLOOD_PRESSURE 
REACTOME_ENDOSOMAL_VACUOLAR_PATHWAY 
RFX5
REACTOME_DOWNSTREAM_TCR_SIGNALING 
REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS 
REACTOME_DEVELOPMENTAL_BIOLOGY 
Pheno_behcet syndrome
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS 
Pheno_leprosy
REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL 
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC 
HOXD3
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 
Pheno_nasopharyngeal neoplasms
Pheno_diabetes mellitus, type 1
REACTOME_AXON_GUIDANCE
REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES 
REACTOME_L1CAM_INTERACTIONS 
REACTOME_BASIGIN_INTERACTIONS 
PAX6
JUNB
ENDOTHELIAL_CELL_MIGRATION
ZINC_ION_BINDING
RAD21
TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 
LYASE_ACTIVITY
REACTOME_GLYCEROPHOSPH LIPID_BIOSYNTHESIS 
KLF5
CELL_SURFACE_RECEPTOR_LINKED_SIGNAL_TRANSDUCTION_GO_0007166 
NEGATIVE_REGULATION_ F_TRANSLATION 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION 
REGULATION_OF_MITOSIS
DNA_DIRECTED_DNA_POLYMERASE_ACTIVITY 
CELL_DIVISION
MITOTIC_SISTER_CHROMATID_SEGREGATION 
REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 
TUBULIN_BINDING
REACTOME_REMOVAL_OF_THE_FLAP_INTERMEDIATE_FROM_THE_C_STRAND 
E2F4
MITOTIC_SPINDLE_ORGANIZATION_AND_BIOGENESIS 
NUCLEOCYTOPLASMIC_TRANSPORT 
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE 
MICROTUBULE_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 
DNA_REPLICATION_INITIATION
CELL_CYCLE_CHECKPOINT_GO_0000075 
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND 
S_PHASE
MEIOTIC_RECOMBINATION
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS NEGAT VE_REGULATION_OF_DNA_METABOLIC_PROCESS 
DNA_RECOMBINATION
TFDP1
SOX2
ZNF263
NEGATIVE_REGULATION_OF_TRANSCRIPTION 
NEGATIVE_REGULATION_OF_TRANSCRIPTION_DNA_DEPENDENT 
Disease: immune system cancer
NEGATIVE_REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER 
CERAMIDE_METABOLIC_PROCESS
SPHINGOID_METABOLIC_PROCESS 
PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION 
GTPASE_ACTIVITY
ELF1
Disease: endocrine gland cancer
ENDOSOME_TRANSPORT
PROTEIN_POLYUBIQUITINATION
UBIQUITIN_CYCLE
REACTOME_DOWNREGULATION_OF_SMAD2_3_SMAD4_TRANSCRIPTIONAL_ACTIVITY 
REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT 
TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS 
NEGATIVE_REGULATION_OF_RNA_METABOLIC_PROCESS 
REACTOME_P75NTR_SIGNALS_VIA_NFKB 
REACTOME_SIGNALING_BY_FGFR1_FUSION_MUTANTS 
REACTOME_REGULATION_OF_SIGNALING_BY_CBL 
RUNX1
SMALL_PROTEIN_CONJUGATING_ENZYME_AC IVITY 
REACTOME_PKB_MEDIATED_EVENTS 
REACTOME_PHOSPHORYLATION_OF_THE_APC_C 
REACTOME_FANCONI_ANEMIA_PATHWAY 
REACTOME_POL_SWITCHING
DNA_DEPENDENT_ATPASE_ACTIVITY 
MEIOTIC_CELL_CYCLE
RESPONSE_TO_ABIOTIC_STIMULUS 
NIPBL
E2F3
SPINDLE_ORGANIZATION_AND_BIOGENESIS 
MEIOSIS_I
MICROTUBULE_BASED_PROCESS
CHROMOSOME_SEGREGATIONCHROMOSOME_CONDENSATION
FOXM1
MITOTIC_CELL_CYCLE_CHECKPOINT 
CYTOKINESIS
GROWTH_FACTOR_BINDING
Disease: hypersensitivity reaction 
type IV disease 
EGR2
WT1
MITOCHONDRIAL_MEMBRANE_ORGANIZATION_AND_BIOGENESIS 
REACTOME_EXTRINSIC_PATHWAY_FOR_APOPTOSIS 
POSITIVE_REGULATION_OF_CASPASE_ACTIVITY 
PharmGKB_PA165292177_Doxorubicin_Pathway_Pharmacokinetics 
RESPONSE_TO_TOXIN
Disease: osteosarcoma
PharmGKB_PA165980050_Vemurafenib_Pathway_Pharmacodynamics REACTOME_ACTIVATION_OF_BH3_ONLY_PROTEINS 
Disease: lung cancer
PROTEIN_TETRAMERIZATIONDisease: respiratory system cancerDisease: male reproductive organ 
cancer 
PAX8
Disease: colon cancer
Disease: large intestine cancerPOSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY 
CASPASE_ACTIVATION
REACTOME_AMINE_DERIVED_HORMONES 
REGULATION_OF_TRANSFERASE_ACTIVITY 
REGULATION_OF_MOLECULAR_FUNCTION REGULATION_OF_PROTEIN_KINASE_ACTIVITY 
Disease: connective tissue cancer
MITOCHONDRIAL_TRANSPORT
Disease: gastrointestinal system 
cancer 
PGR
Disease: autoimmune 
lymphoproliferative syndrome 
PharmGKB_PA165374494_Busulfan_Pathway_Pharmacodynamics 
REACTOME_INFLAMMASOMES
Disease: intestinal cancer
Disease: prostate cancer
REGULATION_OF_MEMBRANE_POTENTIAL 
REGULATION_OF_DNA_BINDINGPROTEIN_DIMERIZATION_ACTIVITY
DNA_DAMAGE_RESPONSESIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR 
PharmGKB_PA2039_Methotrexate_Pathway_(Cancer_Cell)_Pharmacodynamics 
INTERLEUKIN_8_BIO YNTHETIC_PROCESS REACTOME_BASE_FREE_SUGAR_PHOSPHATE_REMOVAL_VIA_THE_SINGLE_NUCLEOTIDE_REPLACEMENT_PATHWAY 
CELL_MIGRATION
REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION 
REGULATION_OF_TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY 
REGULATION_OF_MYELOID_CELL_DIFFERENTIATION 
POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 
LEUKOCYTE_MIGRATION
STAT2
CYTOKINE_BINDING
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELLULAR_PROTEINS 
REACTOME_REGULATION_OF_IFNA_SIGNALING REACTOME_NEGATIVE_REGULATORS_OF_RIG_I_MDA5_SIGNALING 
IRF3
REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT 
CELLULAR_PROTEIN_COMPLEX_ASSEMBLY 
IMMUNE_RESPONSEPOU2F1
G_PROTEIN_COUPLED_RECEPTOR_BINDING 
CEBPBPOSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 
REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 
REGULATION_OF_CELLULAR_PROTEIN_METABOLIC_PROCESS 
STAT5A
INFLAMMATORY_RESPONSE
DEFENSE_RESPONSEBEHAVIO
REACTOME_IL_3_5_AND_GM_CSF_SIGNALING NFKB1
REACTOME_IL_2_SIGNALI G
RECEPTOR_BINDING
POSITIVE_REGULATION_OF_PROTEIN_AMINO_ACID_PHOSPHORYLATION 
LEUKOCYTE_CHEMOTAXIS
POSITIVE_REGULATION_OF_PHOSPHATE_METABOLIC_PROCESS 
LOCOMOTORY_BEHAVIOR
POSITIVE_REGULATION_OF_CELLULAR_ R TEIN_METABOLIC_PROCESS 
CYTOKINE_PRODUCTIONREACTOME_CHEMOKINE_RECE TORS_BIND_CHEMOKINES 
REACTOME_ACTIVATED_TLR4_SIGNALLING 
REACTOME_INNATE_IMMUNE_SYSTEM 
STAT3
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING REACTOME_TRAF3_DEPENDENT_IRF_ACTIVATION_PATHWAY 
REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_PROTEINS Disease: primary immunodeficiency disease REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS 
STAT1
REACTOME_TOLL_RECEPTOR_CASCADES 
RESPONSE_TO_CHEMICAL_STIMULUS 
IMMUNE_SYSTEM_DEVELOPMENT
POSITIVE_REGULATION_OF_PHOSPHORYLATION 
KERATINOCYTE_DIFFERENTIATION
JAK_STAT_CASCADE
REPRODUCTIVE_PROCESS
REACTOME_CTLA4_INHIBITORY_SIGNALING 
REACTOME_PLATEL T_ADHESION_TO_EXPOSED_COLLAGEN 
REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS 
NEGATIVE_REGULATION_OF_CELL_CYCLE 
HOMEOSTASIS_OF_NUMBER_OF_CELLS 
POSITIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION 
PROTEIN_COMPLEX_ASSEMBLY
ICOSANOID_METABOLIC_PROCESS 
CELL_CYCLE_ARREST_GO_0007050 
REGULATION_OF_PROTEIN_METABOLIC_PROCESS 
LEUKOCYTE_DIFFERENTIATIONREACTOME_IL_RECEPTOR_SHC_SIGNALING 
REGULATION_OF_CYTOKINE_PRODUCTION 
HEMATOPOIETIN_INTERFERON_CLASSD200_DOMAIN_CYTOKINE_RECEPTOR_BINDING INTRACELLULAR_SIGNALING_CASCADE 
JUPOSITIVE_R GULATION_OF_RESPONSE_TO STIMULUS 
REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK 
REACTOME_G_ALPHA_Q_SIGNALLING_EVENTS 
REGULATION_OF_NEURON_APOPTOSIS 
POU3F1
EXTRACELLULAR_STRUCTURE_ORGANIZATION_AND_BIOGENESIS 
REACTOME_AMINE_LIGAND_BINDING_RECEPTORS 
CATION_HOMEOSTASIS
REGULATION_OF_HOMEOSTATIC_PROC SS 
AMINE_RECEPTOR_ACTIVITY
HEMOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT 
RESPONSE_TO_OTHER_ORGANISM 
REGULATION_OF_LIPID_METABOLIC_PROCESS 
REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D 
REACTOME_HORMONE_LIGAND_BINDING_RECEPTORS 
POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 
NEURON_APOPTOSIS
CREB1
REACTOME_BINDING_AND_ENTRY_OF_HIV_VIRION 
MULTI_ORGANISM_PROCESSREACTOME_GPCR_LIGAND_BINDING 
SIGNAL_TRANSDUCTION
HORMONE_ACTIVITY
REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS 
ESR1
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS 
RHODOPSIN_LIKE_RECEPTOR_ACTIVITY 
LEARNING_AND_OR_MEMORY
KAT2A
REACTOME_MAP_KINASE_ACTIVATION_IN_TLR_CASCADE 
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS_MEDIATED_BY_MAP_KINASES 
REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING 
REACTOME_THROMBIN_SIGNALLING_THROUGH_PROTEINASE_ACTIVATED_RECEPTORS_PARS 
REACTOME_ADVANCED_GLYCOSYLATION_ENDPRODUCT_RECEPTOR_SIGNALING 
REACTOME_GRB2_EVENTS_IN_ERBB2_SIGNALING 
REACTOME_GROWTH_HORMONE_RECEPTOR_SIGNALING 
REACTOME_ERKS_ARE_INACTIVATED 
REACTOME_ERK_MAPK_TARGETS
REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS 
INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT 
REACTOME_BIOSYNTHESIS_OF_THE_N_GLYCAN_PRECURSOR_DOLICHOL_LIPID_LINKED_OLIGOSACCHARIDE_LLO_AND_TRANSFER_TO_A_NASCENT_PROTEIN 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 
ER_NUCLEAR_SIGNALING_PATHWAY 
REACTOME_CALNEXIN_CALRETICULIN_CYCLE 
REGULATION_OF_CELLULAR_METABOLIC_PROCESS 
REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER 
ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 
REACTOME_SIGNALLING_TO_RAS
REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING 
REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING 
REACTOME_ I LLING_TO_P38_VIA_RIT_AND_RIN 
REACTOME_SHC_MEDIATED_SIGNALLING 
REACTOME_SHC_RELATED_EVENTS 
RE CTOME_SOS_MEDIATED_SIGNALLING 
REACTOME_SIGNALING_BY_PDGF
REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION 
REACTOME_SPRY_REGULATION_OF_FGF_SIGNALING 
REACTOME_SIGNALLING_TO_ERKS 
REACTOME_FRS2_MEDIATED_CASCADE 
ELK1
REACTOME_ARMS_MEDIATED_ACTIVATION 
PharmGKB_PA162356267_EGFR_Inhibitor_Pathway_Pharmacodynamics 
MXI1
REACTOME_PRE_NOTCH_PROCESSING_IN_GOLGI 
SECRETORY_PATHWAY
REACTOME_TRANSPORT_TO_THE_GOLGI_AND_SUBSEQUENT_MODIFICATION 
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Figure 5: 
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Figure 6: 
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Tables 
Table 1. Top twenty TF – target disease associations. The “Literature Rich” gene universe is used 
for the association detection. Log2(OR), log2 transformed odds ratio; P-value: p-value from 
single-tailed Fisher’s exact test for odds ratio > 1; Evidence: lists published genetic evidence 
directly support the association of the TF with the disease;  Mutation: mutations of the TF are 
observed in the disease or closely related diseases. Association: The TF gene locus is genetically 
associated with the disease or related diseases. Mouse: mouse model shows phenotypes directly 
related to the disease. Non-genetic evidence in the literature is not considered. MODY1: 
maturity-onset diabetes of the young. FCHL: familial combined hyperlipidemia.  
 
TF Target Disease log2(OR) P-value Evidence 
ATF3 Lysosomal storage disease 4.5  3.9E-09 - 
BRCA1 Mitochondrial metabolism disease 3.1  3.7E-09 - 
CTBP2 Heart septal defect 
Congenital heart disease 
6.9  
6.5  
4.4E-10 
1.6E-09 
Mouse 
(Hildebrand 
and Soriano 
2002) 
Mouse 
(Hildebrand 
and Soriano 
2002) 
ETS1 Organ system cancer 2.6  1.2E-08 Mutation 
(Seth and 
Watson 2005) 
GATA1 Acute porphyria 7.4  9.8E-09 Mutation(Philli
ps et al. 2007) 
HNF4A Mitochondrial metabolism disease 3.0  5.3E-09 Mutation in 
MODY1 
(Wang et al. 
2000) 
NFE2 Lysosomal storage disease 
Lipid storage disease 
5.7  
6.0  
4.8E-12 
5.8E-09 
- 
- 
RFX2 Bardet-Biedl syndrome 5.5  1.1E-12 Mouse 
(Bisgrove et 
al. 2012; 
Chung et al. 
2012) 
SOX10 Waardenburg's syndrome 11.4  2.0E-09 Mutation 
(Pingault et 
al. 1998) 
SUZ12 Heart septal defect 6.2  7.4E-09 Mouse (He et 
al. 2012) 
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TP53 Organ system cancer 
Cancer 
Disease of cellular proliferation 
Reproductive organ cancer 
3.5  
3.5  
3.4  
4.8  
1.5E-19 
3.6E-19 
1.7E-18 
1.2E-08 
Mutations in 
multiple 
cancer  
Types (Malkin 
et al. 1990) 
USF1 Disease of metabolism 
Inherited metabolic disorder 
2.2  
2.2  
1.3E-10 
7.5E-09 
Association 
with FCHL 
(Coon et al. 
2005; 
Pajukanta et 
al. 2004) 
USF2 Lysosomal storage disease 
Disease of metabolism 
4.1  
2.3  
1.3E-09 
2.8E-09 
- 
- 
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1. Supplemental Results 
1.1. Negative Associations between Transcription Factors and Functions 
Overall, 279 (73%) transcription factors are annotated by at least one functional term, while 
around 27% (103) transcription factors are annotated at least once by negatively associated gene 
functions or phenotypes. Percentage of negative TF association is lowest for pharmacogenomic 
pathways (2%) and Mendelian diseases (5%), and highest for GWAS phenotypes (51%) and gene 
molecular functions (40%). Many of the negative associations may simply indicate that the TFs 
and the function are irrelevant, although some of the negative TF-phenotype associations appear 
to be biologically meaningful. For example, NOTCH1 is negatively associated with myocardial 
infarction (OR = 0.47, Hypergeometric test p-value = 3.8 × 10-7), while NOTCH1 is known to 
mediate cardiac repair following myocardial infarction (Gude et al. 2008; Li et al. 2011). 
 
1.2. Transcription Factors have Preferences on the Type of Function Annotations 
We observed extensive TF sharing among the 6 types of gene functions (Fig. S5A).  
Meanwhile, we observed systematic preference of different types of TFs to different sources of 
gene functions. For example, HNF1A target functions are 53 fold enriched for PK/PD pathways, 
23 fold enriched for GWAS phenotypes, and 4 fold enriched for Mendelian diseases, while 
TCF12 target functions are 16 fold enriched for GO molecular functions, and 4 fold enriched for 
Reactome pathways. In total, there are 62 TFs with significant biases toward specific types of 
functions (Fig. S5B). We note that different types of gene annotations are focused on different 
levels or different aspects of functions in living organisms. The biases of TFs toward specific 
types of functions suggest some high-level architecture of the TF-target function network. 
Specifically, different TFs may be in charge of functions of different levels from molecular to 
phenotype. 
 
1.3. Transcription Factors Sharing Reveals Redundant or Related Functions 
From the TF-target function relationships, we observed extensive regulator sharing among the 
functional concepts (e.g. Cor pulmonale and primary pulmonary hypertension) as well as target 
function overlaps among transcription factors (e.g. CTBP2 and SUZ12 in Fig. 3B top left). 
Redundancies or associations among functional concepts from both same sources and different 
annotation sources are observed (Fig. 3B). One cause of the concept similarities is the built-in 
redundancy of functional concepts within sources such as Gene Ontology, which defines concepts 
hierarchically, and between sources such as the GO biological processes and Reactome pathways, 
both of which covers signaling pathways. Another cause is the inherent biological relatedness of 
apparently different concepts, such as beta-cell development and diabetes, both of which are 
identified as targets of KLF11 and PDX1 (Fig. 3B bottom left). 
 
We quantified the redundancy between functional concepts by their member gene overlap using 
Pearson’s 𝜙 coefficient, and estimated the total effective number of functional concepts to be 
1316 compared to the total of 3715. Relatedly, 954 pairs of functional concepts are regulated by 
identical set of TFs, and 141 pairs of concepts have identical member genes. GO biological 
processes have the highest redundancy of 3.7 fold, while the GWAS phenotypes have the lowest 
redundancies of 1.2 fold (Table S2). 
 
To further reveal the overall concept relatedness/redundancy between different sources of 
functional concepts, we calculated the average number of shared TFs per pairs of functional 
concepts from the 6 different sources (Fig. S5B). We find molecular functions, biological 
processes, and Reactome pathways cluster closely with >0.5 TFs shared per pair of functions 
from different sources, compared to 0.6-1.3 TFs shared per pair of functions from same sources). 
Pharmacogenomic pathways and Mendelian diseases form another cluster with 0.08 TFs shared 
per pair of functions from different sources, compared to 0.16 or 0.22 TFs shared per pair of 
functions from same sources.   
 
1.4. Basic Statistics of Functional Diversity and Regulator Diversity of TFs 
Overall, the average uniqueness of all functional concepts is only 0.4 (i.e. average degeneracy 
2.8). There are on average 23.9 target functions per TF, while the target function diversity is only 
3.7 with a degeneracy of around 6.1 fold, higher than the average degeneracy of all functions. On 
the other hand, the transcription factors are also highly related to each other, with an average 
uniqueness of 0.6, and effectively 226.0 functionally unique TFs out of 384. For each TF, there 
are 11.8 upstream regulators, while the regulator diversity is 5.2 and regulator degeneracy 2.2. 
Fig. 6A give an example of TF HNF1A, which have 6.3 effective target functions and 3.8 
effective regulators (see Fig. S11 for more transcription factors RXF5 and NFKB1; and also 
examples of non-TF gene MTHFR). 
 
1.5. Removing the impact of human research biases on the association between TF regulator 
diversity and function diversity 
The TFTG compendium contains TF-target gene relationships from the literature of low 
throughput studies. Such data are prone to human biases toward the perceived important TFs. 
These popular TFs can have more target genes as well as upstream regulators reported due to 
higher research efforts, hence creating an artificial association between the number of regulators 
and number of identified target functions. We corrected such biases by including the number of 
target genes of TF as a confounding variable (see main text). As a stricter validation, we 
completely removed the low-throughput data in the TFTG data, retained only the target genes for 
262 TFs from ChIP-seq studies, and redid all analyses. The selection of TFs in ChIP-seq 
experiment remains biased toward the well-known TFs. Popular TFs however should no longer 
have more upstream TFs due to preferred study of the regulators of these TFs. Despite a smaller 
number of TFs and a loss of the most reliable target genes for the remaining TFs, regulator 
diversity and function diversity remain significantly  associated (p-value 0.015, or 0.0086 when 
controlling for the number of target genes).  
 
1.6. Hierarchical location of a TF in the regulatory network is not associated with 
multifunctionality of the TF 
Aside from regulation diversity, we discover that the hierarchical seniority of a TF, as measured 
by the PageRank of a TF in the core TRTG network, is also associated with the (known) function 
diversity (p-value 0.0023, PCC 0.15) and the regulator diversity of a TF (p-value 0.025, PCC 
0.12). There is an even stronger association between PageRank and the target function diversity 
of a TF (p-value 1.2e-42 and PCC 0.62). These indicate that a transcription factor at the top of the 
regulatory hierarchy tends to have more diverse functions. This correlation however may be 
caused by the shared association of PageRank and the target-function diversity with the number 
of target genes of a TF, as they are both defined on the target genes.  Indeed, after controlling for 
the target gene size through a linear model, neither the PageRank-function diversity or PageRank-
target function diversity associations are significant (p-values 0.94 and 0.051 respectively). 
Similar behavior is observed for other TF hierarchical rank measures defined based on breadth 
first search (BFS) and percentage of regulatory target genes (Yu and Gerstein 2006; Bhardwaj et 
al. 2010). 
 
1.7. Gene’s Regulator Diversity and Multifunctionality 
Significant associations between function and regulator diversities of genes are observed for 
specific types of functional annotations (Supplemental Fig. S10), including signaling/metabolic 
pathways (p-value 1.5 × 10-6), biological processes (p-value 1.5 × 10-6), and GWAS phenotypes 
(p-value 1.1 × 10-10), while the diversity of GWAS phenotype of a gene is inversely correlated 
with its regulator diversity. Genes regulated by 10 or more other TFs are 14% less likely to be 
associated with any GWAS phenotypes, and 46% less likely to be associated with 5 or more 
phenotypes. Note that we used the Coding gene universe when analyzing GWAS phenotype 
associations, and the Literature Rich gene universe when analyzing other annotations. Both of 
these are conservative choices of gene universes. Using Literature Rich gene universe will lead to 
more significant negative association between TF regulation and phenotypes, while using Coding 
gene universe will lead to more significant positive associations between TF regulation and 
signaling & metabolic pathways, biological processes, and molecular functions.  
 
We removed the low-throughput data in the TFTG data, and only retained the target genes for 
262 TFs from ChIP-seq studies. The associations of TFs’ regulator diversity with specific types 
of functions are PCC 0.17, p-value 0.007 for GWAS phenotypes; PCC -0.0063, p-value 0.92 for 
Mendelian disease; PCC 0.11 p-value 0.093 for PK & PD pathways; PCC 0.086, p-value 0.17 for 
molecular functions, PCC 0.14, p-value 0.032 for biological processes; PCC 0.15, p-value 0.015 
for signaling & metabolic pathways. Meanwhile, for general genes (TFs and non-TFs), there is 
still a significant positive association between regulator diversity and signaling/metabolic 
pathway diversity (PCC 0.072, p-value 1.3e-6), and a significant negative association for GWAS 
phenotypes (PCC -0.11, p-value 6.8 e-19). 
 
For the 10792 general genes that have regulators, function annotations as well as expression data, 
genes’ regulator diversity and expression diversity are correlated (Spearman rank correlation 0.22, 
p-value 3.7 × 10-120 for diversities, or correlation 0.26, p-value 1.0 × 10-165 for the raw counts), 
and genes’ regulator diversity and function diversity are also correlated (Spearman rank 
correlation 0.12, p-value 1.0 × 10-33). 
 
 2. Supplemental Methods 
2.1. Modified TIP algorithm for Exacting Target Genes from ChIP-Seq Data 
The binding signals from target genes were differentiated from that from non-target genes using a 
modified version of the TIP algorithm (Cheng et al. 2011). Specifically, the modified 
implementation accepts both fixed step and variable step wiggle formatted files as well as other 
commonly used genome feature formats, such as bed and bigWig. It properly handles the 0-based 
start and 1-based end coordinates of transcript annotations and the 1-based coordinates in wig 
files. Genomic regions with read density less than 1 read per million total reads are ignored. In 
addition, it only evaluates the unambiguously mapped transcripts, and removes redundant 
promoter regions (i.e. transcripts with identical TSS are merged). RefSeq gene annotations on 
human genome hg18 and hg19 were obtained from the UCSC genome browser 
(https://genome.ucsc.edu) (Karolchik 2003). Instead of the dot product scoring functions used in 
TIP, we used log likelihood ratio to achieve a Gaussian like distribution of the scores,  
𝑆! = 𝑥!" ∙ log 𝑚!.!"#"𝑚!.!"##!"""!!!!""" , 
where 𝑥!" is the read counts at location 𝑙 within the promoter region, and score 𝑆! for 
promoter/gene 𝑔 is calculated as the read-counts weighted sum of the log likelihood ratio 
between the average signal distribution 𝑚!.!"#" and the even distribution  𝑚!.!"##. A 6k window 
is used spanning ±3K base pairs 5’ and 3’ to the TSS. P-values are then computed by assuming a 
Gaussian distribution of 𝑆!. The target genes of each TF in each experiment are then obtained at 
q-value cutoff of 0.01 (Storey 2003; Storey and Tibshirani 2003). Multiple experiments or data 
sources for the same TF are then merged, resulting in target gene sets for 384 unique transcription 
factors. 
 
 3. Supplemental Figures 
Figure S1:  
A. Transcription factor coverage by three sources of TF-target gene data. LTP: low throughput 
experiments; ENCODE: TF ChIP-seq experiments in ENCODE study; Other ChIP-seq: non-
ENCODE ChIP-seq experiments compiled from GEO. 
B-E. Transcription factor (TF) and target gene (TG) degree distributions in the TFTG data 
compendium and the subset of TF-target TF core network. (B) TG degree (i.e. node in-degree) 
and (C) TF degree (i.e. node out-degree) distributions in the full TFTG data compendium. (D) TG 
degree (i.e. node in-degree) and (E) TF degree (i.e. node out-degree) distributions in the core 
TRTG data compendium for which the TGs are restricted to be only the 384 TFs. 
 
Figure S2:  
Venn diagram showing the overlaps among five types of gene function annotations. Mendelian 
diseases are not included in the Venn diagram due to limitation of the visualization technique. 
 
Figure S3:  
The significance of TF-target function association depends on the choice of gene universe. Shown 
here is the impact of gene universe on the association between TF SP1 and Reactome pathway 
Immune System. Three gene universes are evaluated, while the literature rich gene universe is the 
one used in this study. 
 
Figure S4:  
A. The in-degree and out-degree distributions of the TF-Target Function network follow a power 
law distribution with exponents 1.2 approximately. Left: distribution of the out-degrees of TFs 
(#Functions per TF). Right: distribution of the in-degrees of functions (#TFs per function).  
B. The TFs that are not annotated with any target functions (blue curve) have less target genes 
than TFs that are annotated with one or more target functions. 
 
Figure S5:  
A. Average number of transcription factors shared per pair of function annotations. FDR cutoff 
0.05 was applied to select significant target functions. The clustering is based on 1 – diagonal-
normalized TF sharing, which is 1-average(cosine similarity) of regulator vectors of functional 
concepts. 
B. Shown are heatmap of 62 TFs with significant annotation type biases at q-value cutoff 0.01. 
Clustering are based on cosine similarity of the counts of significant TF-Target function 
associations. The color in the heatmap correspond to log(Cij*C++/Ci+*C+j), where Cij is the 
counts for TF i and function type j, C++ is the total count, Ci+ is the total number of significant 
target functions for TF i, and C+j is the total number of significant TFs for a function type j. 
Positive values (red) indicate favored function types, and negative values (all set to -1, green 
color) indicate disfavored function types.  
 
 
Figure S6:  
Receiver Operator Characteristics (ROC) curves measuring the predictive performances of TF-
Target function associations (phi) against known TF-function annotations. AUC, area under the 
ROC curve; FET, Fisher’s Exact Test; Centered p-value, 2 times the min of the two single tailed 
FET p-values. 
 
Figure S7:  
Clustering of TFs by target gene-based TF-TF similarity (measured by Pearson’s phi). In the 
heatmap, colors green to red correspond to negative to positive TF-TF target gene associations. 
Hierarchical clustering of TFs is performed using 1-phi as distance measure. Six selected sub-
trees in the clustering dendrogram are shown (see Figure S8 for a larger version of the full 
dendrogram). 
 
Figure S8: 
Evolutionary and functional trees of 384 TFs covered by the TFTG data compendium.  
(A) Protein sequence based phylogenetic trees of TFs. Sequence similarity based clustering of 
transcription factors using UPGMA.  
(B) Target-gene similarity (phi) based functional clustering of transcription factors, same as the 
clustering shown in Figure 6.  
 
 
Figure S9: 
Functional concepts that share TFs do not necessarily share member genes significantly.  
(A) Two target functional concepts with 100% member gene overlaps always have identical 
regulators, but (B) two functional concepts with 100% identical regulators do not always have 
high member gene sharing.  
 
Figure S10: 
Significant association exists between the regulator diversity and functional diversity of 11345 
genes that have both regulators and function annotations.  
(A) Six types of function annotations are analyzed separately and significant positive association 
is observed for biological processes and signaling/metabolic pathways.  
(B) Estimated odds ratio for tightly regulated genes (number of TF >= 10) versus annotated genes 
(number of annotation > 0). 
 
Figure S11: 
The upstream regulators and downstream (target) functions of TFs (A) NFKB1 and (B) RFX5, 
and non-TF gene MTHFR. The coloring schema is same as in Figure 5 and the clustering of TFs 
and functions are based on the target gene and member gene overlaps. 
 
Figure S12:  
Transcription factor’s regulator diversity is associated with target function diversity. Pearson 
correlation is 0.32, p-value 3.3e-10; and for the TF with over 100 target genes, correlation is 0.35, 
p-value 6.0e-06. HNF1A is highlighted in red. 
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4. Supplemental Tables 
 
Table S1: A summary of the total number and effective number of concepts in each of the 
6 function annotation databases. Phenotype: complex phenotypes studied in GWAS; 
Diseases: Mendelian Diseases; PharmGKB: PK & PD pathways from PharmGKB; MF: 
Molecular Functions from GO; BP: Biological processes from GO; Pathways: Signaling & 
Metabolic Pathways from Reactome. 
 
Phenotype Disease PharmGKB MF BP Reactome 
Functional Concept 
Counts 573 1156 91 396 825 674 
Within DB 
Redundancy-
Adjusted Counts 467.7 551 44.9 176.8 225.2 217.3 
Between DB 
Redundancy-
Adjusted Counts 368.4 465.3 24.8 115.3 178.7 163.3 
 
Table S2. Average number of significant functional concept enrichments per transcription factors 
at FDR 0.05. Coding gene universe is used for phenotypes and literature rich gene universe for 
the rest. 
 
Phenotype Disease PharmGKB MF BP Reactome 
# Enrichment  0.052  0.471 0.263  1.383  7.992  11.216  
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Table S3: TFs and their target complex phenotypes at FDR 0.05. The Coding gene universe is 
used for the association analysis. Only enrichment (positive associations) and the corresponding 
single tailed p-values are shown. log2(OR): log2 transformed odds ratio. Evidence: lists published 
genetic evidence directly supports the association of the TF with the disease; Mutation: mutations 
of the TF are observed in the disease or closely related diseases. Association: The TF gene locus 
is genetically associated with the disease or related diseases. Mouse: mouse model shows 
phenotypes directly related to the disease. Non-genetic evidence in the literature is not considered. 
# MHC II: RFX5 is mutated in Bare lymphocyte syndrome II (DeSandro et al. 1999; Reith and 
Mach 2001), and RFX5 knock out mouse shows abnormality in the immune system (Masternak et 
al. 1998; Clausen et al. 1998) 
TF Phenotype log2(OR) P-value Evidence 
AHR Coffee consumption 12.5 2.3E-07 Association (Sulem et al. 2011; 
Cornelis et al. 2011, 2015) 
Habitual caffeine 
consumption 
10.1 5.0E-06 Association (Sulem et al. 2011; 
Cornelis et al. 2011, 2015) 
HNF1A Serum cell-free DNA 
(Cardiovascular 
Risk) 
8.9 1.3E-09 Association (Reiner et al. 2009), 
Mutation (Steele et al. 2010) 
Sickle-cell anemia 
(F-cell levels) 
Serum bilirubin 
levels (bilirubin and 
cholelithiasis risk) 
7.6 
5.7 
5.6E-10 
3.8E-06 
- 
 
Mouse (Pontoglio et al. 1996) 
NFKB1 Psoriasis 3.6 1.1E-07 - 
Ulcerative colitis  3.3 5.1E-07 Association (Jostins et al. 2012) 
Rheumatoid arthritis     3.2 4.0E-09 - 
POU2F2 Celiac disease 4.2 4.7E-06 - 
RFX5 Chronic hepatitis b 7.1 8.2E-06 - 
Nasopharyngeal 
neoplasms 
6.5 9.5E-07 - 
Systemic 
scleroderma  
6.1 2.8E-10 MHC II # 
Leprosy 4.7 7.5E-10 - 
Psoriasis 3.7 4.9E-06 MHC II # 
Type 1 diabetes 
mellitus 
3.7 1.9E-09 MHC II # 
Multiple sclerosis 3.3 2.4E-08 MHC II # 
Behcet syndrome 3.3 8.8E-06 MHC II # 
Systemic lupus 
erythematosus 
3.2 1.0E-06 MHC II # 
SREBF1 Low density 
lipoproteins (LDL) 
3.9 2.2E-06 Mouse (Shimano et al. 1997) 
TBP Systemic 
scleroderma  
4.8 5.9E-06 - 
 
 
Table S4: TF and their target pharmacogenomic pathways at FDR 0.05. The Literature Rich gene 
universe is used for the association detection. Log2(OR), log2 transformed odds ratio; P-value: p-
value from single-tailed Fisher’s exact test for odds ratio > 1; Evidence: For the PD pathways, we 
listed direct evidence supporting the TF-PD pathway relationship if, 1) Member: the TF is 
annotated as a member gene in same or closely related PharmGKB/Reactome pathways or GO 
biological processes; 2) Census or Mutation: the TF is a known causal gene of the diseases based 
on Cancer Gene Census (Futreal et al. 2004) or OMIM (Hamosh et al. 2005); 3) GWAS: the TF 
gene locus is strongly associated with related phenotypes in GWAS. 4) Mouse: mouse model 
shows phenotypes directly related to the disease. Other forms of evidence in the literature are not 
considered. * PD pathways containing 50% or more PK genes. & neural normal: this is not disease 
related, but a normal pathway in neurological processes. N/A: not applicable. 
TF 
Pharmacogenomics 
pathways log2(OR) 
P-
value Diseases Evidence 
AHR Amodiaquine Pathway (PK) 11.6  8.4E-07 N/A N/A 
 Warfarin Pathway (PK) 9.8  7.9E-06 N/A N/A 
 Estrogen Metabolism 
Pathway 
9.6  4.9E-08 N/A N/A 
 Erlotinib Pathway (PK) 9.6  1.0E-05 N/A N/A 
 Phenytoin Pathway (PK) 8.3  5.3E-05 N/A N/A 
ATF1 Busulfan Pathway (PD) 4.0  6.9E-05 Cancer Mutation: melanoma 
(Futreal et al. 2004) 
ATF2 ACE Inhibitor Pathway (PD) 6.3  3.0E-05 
Hypertension -  Agents Acting on the Renin-
Angiotensin System Pathway 
(PD) 
6.3  3.0E-05 
BRF1 Imatinib Pathway (PK & PD) 8.0  8.0E-05 Cancer - 
BRF2 Imatinib Pathway (PK & PD) 7.7  1.2E-04 Cancer - 
CREB1 Sympathetic Nerve Pathway 
(Neuroeffector Junction) 
4.2  5.4E-06 Neural 
normal& 
Member: Reactome 
REACT_18334.1, 
REACT_15370.2 
E2F1 Antimetabolite Pathway - 
Folate Cycle (PD) 
 
4.8  2.5E-07 Cancer & 
autoimmune 
diseases 
Cancer & 
autoimmune 
diseases 
Cancer & 
autoimmune 
diseases 
Member: multiple GO 
terms for Cell cycle control 
 
Member: multiple GO 
terms for Cell cycle control 
 
Member: multiple GO 
terms for Cell cycle control 
 Thiopurine Pathway (PK & 
PD) 
 
3.1  3.2E-05 
 Methotrexate Pathway 
(Cancer Cell) (PD) 
3.1  1.3E-04 
E2F4 Antimetabolite Pathway - 
Folate Cycle (PD) 
3.5  2.7E-05 Cancer & 
autoimmune 
diseases 
Member: multiple GO 
terms for Cell cycle control 
EGR1 EGFR Inhibitor Pathway 
(PD) 
2.6  4.5E-05 Cancer - 
ELK1 EGFR Inhibitor Pathway 
(PD) 
5.6  5.8E-06 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
ETS1 Vinka Alkaloid Pathway 
(PK) 
4.9  6.2E-05 N/A N/A 
 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.1  5.2E-05 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
Member: PharmGKB 
(EGFR Inhibitor Pathway) 
 Vemurafenib Pathway (PD) 3.9  2.2E-05 Cancer 
(melanoma) 
 Platelet Aggregation 
Inhibitor Pathway (PD) 
3.2  2.0E-05 thrombosis - 
ETV4 ACE Inhibitor Pathway (PD) 5.6  1.1E-04 hypertension 
 
- 
 Agents Acting on the Renin-
Angiotensin System Pathway 
(PD) 
5.6  1.1E-04  
 Celecoxib Pathway (PD) 4.6  8.2E-06 pain - 
FOS Platinum Pathway (PK & 
PD) 
4.4  3.2E-05 Cancer 
 
Member: PharmGKB 
(EGFR Inhibitor Pathway) 
 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.1  1.3E-05 Cancer Member: PharmGKB 
(EGFR Inhibitor Pathway) 
FOXA1 Benzodiazepine Pathway 
(PK) 
4.6  1.1E-04 N/A N/A 
FOXA2 Carbamazepine Pathway 
(PK) 
4.4  2.1E-05 N/A N/A 
 Phenytoin Pathway (PK) 4.0  7.0E-05 N/A N/A 
HIF1A Glucocorticoid Pathway 
(Peripheral Tissue) (PD) 
6.0  6.3E-05 Inflammation Member: GO cytokine 
production 
HNF1A Artemisinin and Derivatives 
Pathway (PK) 
8.4  5.4E-07 N/A N/A 
 Tramadol (PK) 8.1  9.4E-07 N/A N/A 
 Losartan Pathway (PK) 8.0  9.2E-05 N/A N/A 
 Sorafenib(PK) 7.6  1.4E-04 N/A N/A 
 Mycophenolic acid Pathway 
(PK) 
7.4  1.2E-09 N/A N/A 
 Irinotecan Pathway (PD*) 7.3  7.4E-08 Cancer Mutation: renal cell 
carcinoma (Rebouissou et 
al. 2005)  
 Benzodiazepine Pathway 
(PK) 
7.3  4.4E-06 N/A N/A 
 Valproic Acid Pathway (PK) 7.0  4.0E-09 N/A N/A 
 Irinotecan Pathway (PK) 7.0  7.6E-06 N/A N/A 
 Tamoxifen Pathway (PK) 6.9  2.3E-07 N/A N/A 
 Estrogen Metabolism 
Pathway 
6.7  1.2E-05 N/A N/A 
 Phenytoin Pathway (PK) 6.3  3.0E-05 N/A N/A 
 Statin Pathway (PD) 5.9  5.9E-05 High 
cholesterol  
Association (Teslovich et 
al. 2010) 
 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
5.7  8.4E-05 Diabetes Mutation: diabetes, type 1 
(Yamada et al. 1997) and 
type 2 (Hegele et al. 1999)  
HNF1B Methotrexate Pathway (PK) 9.3  1.5E-05 N/A N/A 
HNF4G Statin Pathway (PD) 4.7  6.5E-05 High 
cholesterol  
Weak Association 
(Kathiresan et al. 2007) 
HOXA5 Doxorubicin Pathway 
(Cancer Cell) (PD) 
8.2  6.0E-05 Cancer Mouse: abnormal cell 
migration (Mandeville et al. 
2006) 
HSF1 Glucocorticoid Pathway 
(Peripheral Tissue) (PD) 
7.1  6.4E-06 Inflammation Mouse (Xiao et al. 1999) 
KLF11 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
9.2  2.1E-05 Diabetes Mutation (Neve et al. 2005) 
MYC Antimetabolite Pathway - 
Folate Cycle (PD) 
3.9  4.5E-06 Cancer & 
autoimmune 
diseases 
Member: GO cell cycle 
control;  
Census (Collins and 
Groudine 1982; Yokota et 
al. 1986);  
 Thiopurine Pathway (PK & 
PD) 
2.4  8.6E-05 Cancer & 
autoimmune 
diseases 
Member: GO cell cycle 
control;  
Census (Collins and 
Groudine 1982; Yokota et 
al. 1986); 
NFKB1 Doxorubicin Pathway 
(Cancer Cell) (PD) 
4.4  3.8E-06 Cancer 
 
Cancer 
- (Strong literature evidence 
but no mutation) 
-  EGFR Inhibitor Pathway 
(PD) 
3.1  8.9E-07 
NR1I2 Clopidogrel Pathway (PK) 6.1  4.7E-05 N/A N/A 
NR1I3 Fluvastatin Pathway (PK) 11.3  1.5E-06 N/A N/A 
 Atorvastatin/Lovastatin/Simv
astatin Pathway (PK) 
11.2  1.7E-06 N/A N/A 
 Statin Pathway - 
Generalized(PK) 
10.7  3.6E-06 N/A N/A 
 Phenytoin Pathway (PK) 10.7  3.6E-06 N/A N/A 
NR2C2 Imatinib Pathway (PK & PD) 7.7  1.2E-04 Cancer - 
PDX1 Anti-diabetic Drug Potassium 
Channel Inhibitors Pathway 
(PD) 
9.2  2.1E-05 Diabetes Mutation (Macfarlane et al. 
1999; Hani et al. 1999) 
PHOX2
A 
Sympathetic Nerve Pathway 
(Neuroeffector Junction) 
9.9  9.9E-06 Neural 
normal& 
Mouse (Coppola et al. 
2010) 
PPARA Statin Pathway (PD) 6.3  3.8E-08 High 
cholesterol  
Mutation (Vohl et al. 2000) 
 Celecoxib Pathway (PD) 4.6  7.8E-05 Pain - 
PPARD Statin Pathway (PD) 6.4  2.1E-05 High 
cholesterol  
Mouse (Gross et al. 2011) 
RARA Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 
8.1  1.6E-06 Cancer 
 
Cancer 
Census 
 
Census  EGFR Inhibitor Pathway 
(PD) 
4.0  1.1E-05 
RARB Vemurafenib Pathway (PD) 5.6  1.0E-04 Cancer 
Cancer 
- 
-  EGFR Inhibitor Pathway 
(PD) 
4.5  1.0E-04 
RDBP Imatinib Pathway (PK & PD) 8.0  8.0E-05 Cancer - (Involved in cancer, not 
through genetic mutation) 
REST Sympathetic Nerve Pathway 
(Pre- and Post- Ganglionic 
Junction) 
4.9  6.9E-05 Neural 
normal& 
Mouse: thick retinal 
ganglion layer (Mao et al. 
2011) 
RXRA Statin Pathway (PD) 5.4  6.1E-08 High 
cholesterol  
- 
SP1 Vinka Alkaloid Pathway 
(PK) 
4.6  5.2E-06 N/A N/A 
 Erlotinib Pathway (PK) 4.3  5.7E-05 N/A N/A 
 Etoposide Pathway (PK & 
PD) 
3.9  7.3E-06 Cancer - 
 Statin Pathway (PD) 3.8  3.4E-08 High 
cholesterol  
- 
 EGFR Inhibitor Pathway 
(PD) 
2.1  7.3E-05 Cancer - 
SREBF1 Bisphosphonate Pathway 
(PD) 
5.7  3.0E-07 Osteoporosis - 
 Statin Pathway (PD) 5.3  7.0E-08 High 
cholesterol  
Mouse Knockout (Liang et 
al. 2002) 
SREBF2 Bisphosphonate Pathway 
(PD) 
6.8  9.3E-09 Osteoporosis - 
 Statin Pathway (PD) 6.4  1.1E-09 High 
cholesterol  
Mouse Knockout (Liang et 
al. 2002) 
STAT1 EGFR Inhibitor Pathway 
(PD) 
3.1  1.9E-05 Cancer - 
STAT5A Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 
8.9  2.8E-05 Breast & 
ovarian cancer 
- 
STAT5B Aromatase Inhibitor Pathway 
(Breast Cell) (PD) 
8.9  2.6E-05 Breast & 
ovarian cancer 
Cancer Gene Census 
TFAP2A Sympathetic Nerve Pathway 
(Neuroeffector Junction) 
3.6  2.4E-06 Neural 
normal& 
 
 
Mutation: Branchio-oculo-
facial syndrome (Lin et al. 
2000; Milunsky et al. 2008; 
Gestri et al. 2009) 
  Celecoxib Pathway (PD) 3.2  4.3E-07 Pain 
 EGFR Inhibitor Pathway 
(PD) 
2.6  8.8E-05 Cancer  
- 
TP53 Doxorubicin Pathway 
(Cancer Cell) (PD) 
5.2  2.0E-09 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990) 
 Vinka Alkaloid Pathway 
(PK) 
5.0  4.6E-05 - - 
 Etoposide Pathway (PK & 
PD) 
4.6  1.3E-05 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Busulfan Pathway (PD) 4.2  3.9E-09 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Vemurafenib Pathway (PD) 4.0  1.5E-05 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
 Methotrexate Pathway 
(Cancer Cell) (PD) 
4.0  2.6E-06 Cancer & 
autoimmune 
diseases 
Census (Chen et al. 1990; 
Halevy et al. 1990); Normal 
immune response (Chiang 
et al. 2012) 
 Doxorubicin Pathway (PK) 3.9  1.0E-04 - - 
 EGFR Inhibitor Pathway 
(PD) 
3.4  2.4E-08 Cancer Census (Chen et al. 1990; 
Halevy et al. 1990)  
USF1 Theophylline Pathway (PK) 6.0  1.2E-04 - - 
WT1 Doxorubicin Pathway 
(Cancer Cell) (PD) 
6.6  4.6E-07 Cancer Census (Pelletier et al. 
1991) 
 Doxorubicin Pathway (PK) 5.8  6.7E-05 - - 
 Vemurafenib Pathway (PD) 5.6  1.0E-04 Cancer Census (Pelletier et al. 
1991) 
YBX1 Erlotinib Pathway (PK) 9.9  6.7E-06 - - 
 
 
Table S5. The tables list the functional concepts with the highest and lowest unique 
scores from 6 sources of gene function annotations. The uniqueness score are computed 
with all data sources merged. 
GWAS Phenotypes Uniqueness Mendelian Diseases Uniqueness 
oligospermia 1 anauxetic dysplasia 1 
cd8-positive t-lymphocytes 1 polycystic ovary syndrome 1 
t-lymphocytes 1 intracranial arterial disease 1 
serotonin 1 Moyamoya disease 1 
transforming growth factor 
beta1 
1 Mobius syndrome 1 
lymphoma, follicular 0.24 papilloma 0.1 
hepatitis b, chronic 0.24 choroid plexus papilloma 0.1 
myeloproliferative disorders 0.23 adrenocortical carcinoma 0.1 
alopecia 0.22 adrenal gland cancer 0.1 
papillomaviridae 0.18 adrenal cortex cancer 0.1 
 
PharmGKB PK/PD 
pathways 
Uniqueness GO MF Uniqueness 
PA165947317_Leukotriene_
modifiers_pathway_PD 
0.75 DRUG_BINDING 0.76 
PA2026_Glucocorticoid_Pat
hway_(HPA_Axis)_PD 
0.73 PROTEIN_TRANSPORTER_A
CTIVITY 
0.74 
PA165111376_Benzodiazepi
ne_Pathway_PD 
0.66 OXIDOREDUCTASE_ACTIVI
TY_ACTING_ON_SULFUR_G
ROUP_OF_DONORS 
0.72 
PA2027_Glucocorticoid_Pat
hway_(Peripheral_Tissue)_P
0.65 OXIDOREDUCTASE_ACTIVI
TY_ACTING_ON_THE_CH_N
0.7 
D H_GROUP_OF_DONORS 
PA2036_Gemcitabine_Pathw
ay_PD 
0.59 NUCLEOBASENUCLEOSIDE
NUCLEOTIDE_AND_NUCLEI
C_ACID_TRANSMEMBRANE
_TRANSPORTER_ACTIVITY 
0.68 
PA145011111_Fluvastatin_P
athway_PK 
0.11 METAL_ION_TRANSMEMBR
ANE_TRANSPORTER_ACTIV
ITY 
0.08 
PA152325160_Gefitinib_Pat
hway_PK 
0.1 ION_CHANNEL_ACTIVITY 0.08 
PA2034_Cyclophosphamide_
Pathway_PK 
0.1 TRANSMEMBRANE_TRANS
PORTER_ACTIVITY 
0.08 
PA145011108_Statin_Pathw
ay_-_Generalized_PK 
0.1 ION_TRANSMEMBRANE_TR
ANSPORTER_ACTIVITY 
0.07 
PA145011109_Atorvastatin/
Lovastatin/Simvastatin_Path
way_PK 
0.09 SUBSTRATE_SPECIFIC_TRA
NSMEMBRANE_TRANSPOR
TER_ACTIVITY 
0.07 
 
GO BP Uniqueness Signaling/Metabolic Pathways Uniqueness 
ESTABLISHMENT_AND_
OR_MAINTENANCE_OF_
CELL_POLARITY 
0.63 TRYPTOPHAN_CATABOLIS
M 
0.86 
KERATINOCYTE_DIFFER
ENTIATION 
0.58 DIGESTION_OF_DIETARY_C
ARBOHYDRATE 
0.76 
RESPIRATORY_GASEOUS
_EXCHANGE 
0.58 VITAMIN_B5_PANTOTHENA
TE_METABOLISM 
0.72 
PEPTIDE_METABOLIC_P
ROCESS 
0.58 METABOLISM_OF_POLYAM
INES 
0.72 
MEMBRANE_FUSION 0.58 CELL_EXTRACELLULAR_M
ATRIX_INTERACTIONS 
0.7 
REGULATION_OF_TRANS
CRIPTION 
0.06 CDT1_ASSOCIATION_WITH_
THE_CDC6_ORC_ORIGIN_C
OMPLEX 
0.04 
REGULATION_OF_NUCL
EOBASENUCLEOSIDENU
CLEOTIDE_AND_NUCLEI
C_ACID_METABOLIC_PR
OCESS 
0.06 P53_INDEPENDENT_G1_S_D
NA_DAMAGE_CHECKPOINT 
0.04 
REGULATION_OF_GENE_
EXPRESSION 
0.06 SCF_BETA_TRCP_MEDIATE
D_DEGRADATION_OF_EMI1 
0.04 
REGULATION_OF_META
BOLIC_PROCESS 
0.06 AUTODEGRADATION_OF_T
HE_E3_UBIQUITIN_LIGASE_
COP1 
0.04 
REGULATION_OF_CELLU
LAR_METABOLIC_PROC
ESS 
0.06 CDK_MEDIATED_PHOSPHO
RYLATION_AND_REMOVAL
_OF_CDC6 
0.04 
 
Table S6: A list of negatively associated functional concepts linked by transcription 
factors. 
File: TableS6.xlsx 
 
Table S7: The complete TF annotation results. -Log10 (p-value) are provided in 
parentheses following the target functions.  
File: TableS7.xlsx 
 
 
Reference 
Bhardwaj N, Yan K-K, Gerstein MB. 2010. Analysis of diverse regulatory networks in a hierarchical context shows 
consistent tendencies for collaboration in the middle levels. Proc Natl Acad Sci U S A 107: 6841–6. 
Chen PL, Chen YM, Bookstein R, Lee WH. 1990. Genetic mechanisms of tumor suppression by the human p53 gene. 
Science 250: 1576–80. 
Cheng C, Min R, Gerstein M. 2011. TIP: a probabilistic method for identifying transcription factor target genes from 
ChIP-seq binding profiles. Bioinformatics 27: 3221–7. 
Chiang YJ, Difilippantonio MJ, Tessarollo L, Morse HC, Hodes RJ. 2012. Exon 1 disruption alters tissue-specific 
expression of mouse p53 and results in selective development of B cell lymphomas. PLoS One 7: e49305. 
Clausen BE, Waldburger JM, Schwenk F, Barras E, Mach B, Rajewsky K, Förster I, Reith W. 1998. Residual MHC 
class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity 8: 143–55. 
Collins S, Groudine M. 1982. Amplification of endogenous myc-related DNA sequences in a human myeloid 
leukaemia cell line. Nature 298: 679–681. 
Coppola E, Rallu M, Richard J, Dufour S, Riethmacher D, Guillemot F, Goridis C, Brunet J-F. 2010. Epibranchial 
ganglia orchestrate the development of the cranial neurogenic crest. Proc Natl Acad Sci U S A 107: 2066–71. 
Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, Fischer K, Renstrom F, et al. 
2015. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol 
Psychiatry 20: 647–56. 
Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, Berndt SI, Boerwinkle E, Chanock S, Chatterjee 
N, et al. 2011. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as 
determinants of habitual caffeine consumption. PLoS Genet 7: e1002033. 
DeSandro A, Nagarajan UM, Boss JM. 1999. The bare lymphocyte syndrome: molecular clues to the transcriptional 
regulation of major histocompatibility complex class II genes. Am J Hum Genet 65: 279–86. 
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. 2004. A census of human 
cancer genes. Nat Rev Cancer 4: 177–83. 
Gestri G, Osborne RJ, Wyatt AW, Gerrelli D, Gribble S, Stewart H, Fryer A, Bunyan DJ, Prescott K, Collin JRO, et al. 
2009. Reduced TFAP2A function causes variable optic fissure closure and retinal defects and sensitizes eye 
development to mutations in other morphogenetic regulators. Hum Genet 126: 791–803. 
Gross B, Hennuyer N, Bouchaert E, Rommens C, Grillot D, Mezdour H, Staels B. 2011. Generation and 
characterization of a humanized PPARδ mouse model. Br J Pharmacol 164: 192–208. 
Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, Muraski JA, Alvarez R, Rubio M, Schaefer E, et al. 
2008. Activation of Notch-mediated protective signaling in the myocardium. Circ Res 102: 1025–35. 
Halevy O, Michalovitz D, Oren M. 1990. Different tumor-derived p53 mutants exhibit distinct biological activities. 
Science 250: 113–6. 
Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. 2005. Online Mendelian Inheritance in Man 
(OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33: D514–7. 
Hani EH, Stoffers DA, Chèvre JC, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. 1999. Defective mutations 
in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 104: R41–8. 
Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. 1999. The hepatic nuclear factor-1alpha G319S variant is 
associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 84: 1077–82. 
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, 
et al. 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. 
Nature 491: 119–24. 
Karolchik D. 2003. The UCSC Genome Browser Database. Nucleic Acids Res 31: 51–54. 
Kathiresan S, Manning AK, Demissie S, D’Agostino RB, Surti A, Guiducci C, Gianniny L, Burtt NP, Melander O, 
Orho-Melander M, et al. 2007. A genome-wide association study for blood lipid phenotypes in the Framingham 
Heart Study. BMC Med Genet 8 Suppl 1: S17. 
Li Y, Hiroi Y, Ngoy S, Okamoto R, Noma K, Wang C-Y, Wang H-W, Zhou Q, Radtke F, Liao R, et al. 2011. Notch1 
in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation 123: 866–76. 
Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. 2002. Diminished hepatic response to 
fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-
binding protein-1c. J Biol Chem 277: 9520–8. 
Lin AE, Semina E V, Daack-Hirsch S, Roeder ER, Curry CJ, Rosenbaum K, Weaver DD, Murray JC. 2000. Exclusion 
of the branchio-oto-renal syndrome locus (EYA1) from patients with branchio-oculo-facial syndrome. Am J Med 
Genet 91: 387–90. 
Macfarlane WM, Frayling TM, Ellard S, Evans JC, Allen LI, Bulman MP, Ayres S, Shepherd M, Clark P, Millward A, 
et al. 1999. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 
104: R33–9. 
Mandeville I, Aubin J, LeBlanc M, Lalancette-Hébert M, Janelle M-F, Tremblay GM, Jeannotte L. 2006. Impact of the 
loss of Hoxa5 function on lung alveogenesis. Am J Pathol 169: 1312–27. 
Mao C-A, Tsai W-W, Cho J-H, Pan P, Barton MC, Klein WH. 2011. Neuronal transcriptional repressor REST 
suppresses an Atoh7-independent program for initiating retinal ganglion cell development. Dev Biol 349: 90–9. 
Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith 
W. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II 
deficiency patients. Nat Genet 20: 273–7. 
Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT, Burch MN, Clemens M, Mulliken JB, Smith R, et 
al. 2008. TFAP2A mutations result in branchio-oculo-facial syndrome. Am J Hum Genet 82: 1171–7. 
Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, Vaillant E, Benmezroua Y, Durand 
E, Bakaher N, et al. 2005. Role of transcription factor KLF11 and its diabetes-associated gene variants in 
pancreatic beta cell function. Proc Natl Acad Sci U S A 102: 4807–12. 
Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE. 1991. WT1 mutations contribute to abnormal 
genital system development and hereditary Wilms’ tumour. Nature 353: 431–4. 
Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. 1996. Hepatocyte nuclear factor 
1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575–85. 
Rebouissou S, Vasiliu V, Thomas C, Bellanné-Chantelot C, Bui H, Chrétien Y, Timsit J, Rosty C, Laurent-Puig P, 
Chauveau D, et al. 2005. Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 
Hum Mol Genet 14: 603–14. 
Reiner AP, Gross MD, Carlson CS, Bielinski SJ, Lange LA, Fornage M, Jenny NS, Walston J, Tracy RP, Williams OD, 
et al. 2009. Common coding variants of the HNF1A gene are associated with multiple cardiovascular risk 
phenotypes in community-based samples of younger and older European-American adults: the Coronary Artery 
Risk Development in Young Adults Study and The Cardiovascula. Circ Cardiovasc Genet 2: 244–54. 
Reith W, Mach B. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 19: 
331–73. 
Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. 1997. Elevated levels of SREBP-
2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin 
Invest 100: 2115–24. 
Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. 2010. Increased all-cause and 
cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 27: 
157–61. 
Storey JD. 2003. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 31: 2013–2035. 
Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440–5. 
Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KKH, Franke B, den Heijer M, Kovacs P, 
Stumvoll M, et al. 2011. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. 
Hum Mol Genet 20: 2071–7. 
Teslovich TM, Musunuru K, Smith A V, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman 
DI, Willer CJ, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 
707–13. 
Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, Houde G, Cellier C, Faith JM, Després JP, et al. 2000. 
Molecular scanning of the human PPARa gene: association of the L162v mutation with 
hyperapobetalipoproteinemia. J Lipid Res 41: 945–52. 
Xiao X, Zuo X, Davis AA, McMillan DR, Curry BB, Richardson JA, Benjamin IJ. 1999. HSF1 is required for extra-
embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J 18: 
5943–52. 
Yamada S, Nishigori H, Onda H, Utsugi T, Yanagawa T, Maruyama T, Onigata K, Nagashima K, Nagai R, Morikawa 
A, et al. 1997. Identification of mutations in the hepatocyte nuclear factor (HNF)-1 alpha gene in Japanese 
subjects with IDDM. Diabetes 46: 1643–7. 
Yokota J, Tsunetsugu-Yokota Y, Battifora H, Le Fevre C, Cline M. 1986. Alterations of myc, myb, and rasHa proto-
oncogenes in cancers are frequent and show clinical correlation. Science (80- ) 231: 261–265. 
Yu H, Gerstein M. 2006. Genomic analysis of the hierarchical structure of regulatory networks. Proc Natl Acad Sci U S 
A 103: 14724–31. 
 
 
